var title_f0_25_400="Insertion track";
var content_f0_25_400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Location of insertion site for implanon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure above reflects the manufacturer's recommendations. The author finds the procedure is easier when the arm is extended. This allows full exposure of the insertion site at the crease between the biceps and triceps muscles. We identify an insertion site approximately three fingerbreadths (6 to 8 cm) superior and lateral to the medial epicondyle of the humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_400=[""].join("\n");
var outline_f0_25_400=null;
var title_f0_25_401="Hanging bronchoscopes";
var content_f0_25_401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopes hung upright to prevent the accumulation of moisture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_401=[""].join("\n");
var outline_f0_25_401=null;
var title_f0_25_402="Intraoperative cholangiogram of possible bile duct injury";
var content_f0_25_402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraoperative cholangiogram of possible bile duct injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraoperative cholangiogram shows filling of distal bile duct with flow into the duodenum. The lack of retrograde&nbsp;flow into the proximal biliary tree is concerning.&nbsp;A clip may be present occluding the bile duct proximally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_402=[""].join("\n");
var outline_f0_25_402=null;
var title_f0_25_403="Grade V liver laceration";
var content_f0_25_403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Grade V liver laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 237px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADtAlkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3r4neP9L+HOg2+ra1b31xbz3K2qrZojOGKO+SGZRjCHv6V5j/AMNT+Cv+gT4k/wDAeD/49Tv2zv8AkmGlf9hmP/0nuK8p+BXwh8MeOPAWq+IfEuparZmxvJYWNrLGsaxJFHIWIaNjn5279AOKAPVP+Gp/BX/QJ8Sf+A8H/wAepf8AhqfwV/0CfEn/AIDwf/Hq4r4XfCD4X/EnTLy80HU/GEItJhFLDdy2ySDKgq2FjYbTzjn+E8V8zKcqM9x1oA+zv+Gp/BX/AECfEn/gPB/8eoH7U3gr/oE+JP8AwHg/+PV8ZelW7W0MiebKdkI6t6/SgD7Jtv2m/CNznydG8StjqfItwB+Jmpj/ALT/AIOQ4OkeI8+0Nuf5TV8fzXrGPyIQI4R2Hf61WjUnnPFAH2OP2o/Bh/5hHiT/AL8W/wD8eo/4aj8Gf9AjxJ/34g/+PV8dMOTyKUow52k5oA+xR+1F4NPTSPEn/fi3/wDj1H/DUPg3/oEeJP8Avxb/APx6vkCC1nmbCQux9hWhBoGoyoWS1lYf7poA+rx+1D4NP/MI8Sf9+Lf/AOPUp/ag8HDro/iT/vxb/wDx6vkxNEvnkMccEjMOwHSraeF9YkBxYzE9vloA+pv+Go/Bg/5hHiT/AL8W/wD8epR+1D4NPTR/En/fi3/+PV8vjwfrXA+xS4x3WhvB+sjB+xuB34oA+of+GofBv/QI8Sf9+Lf/AOPU3/hqLwZ/0CPEn/fi3/8Aj1fLg8M6og+a2YD6Uw+HLssPkwTxQB9Tf8NReDP+gR4k/wC/Fv8A/HqX/hqLwaf+YR4k/wC/Fv8A/Hq+Y4PBuoTAlAMe9ST+BdVgi8woCp545oA+mP8AhqLwb/0CPEn/AH4t/wD49Sf8NR+DP+gR4k/78W//AMer5Xfw/cgnA+YfmKlPhLUdu5Y8gjPFAH1J/wANQ+Df+gR4k/78W/8A8eoH7UXg0jjSPEn/AH4t/wD49XykfDuoqufszkeuKqjSr0ylPJO4dsUAfW5/ah8GjrpHiT/vxb//AB6j/hqHwb/0CPEn/fi3/wDj1fKS+HtSYc27bfXFTp4Z1Q4RbVz74oA+pv8AhqHwbnH9keJM/wDXC3/+PUf8NQ+Df+gR4k/78W//AMer5Vl8MarGTvtpM/SqdxpV3F9+Ig+/agD61P7UfgwddI8Sf9+Lf/49R/w1H4M/6BHiT/vxB/8AHq+PzbTMT+7PA9KidXHBQg+mKAPsT/hqTwZ/0CPEn/fiD/49S/8ADUfgz/oEeJP+/Fv/APHq+N9pz0P5UYyVPFAH2P8A8NSeC/8AoE+JP+/Fv/8AHqX/AIak8Gf9AnxJ/wB+Lf8A+PV8c7RjNOUBu4HrQB9if8NR+DP+gR4k/wC/Fv8A/HqB+1H4MPTSPEn/AH4t/wD49Xx2yDINJg560AfYo/aj8GE4/sjxJn/rhb//AB6nJ+1B4Odtq6R4jJ/642//AMer43PBI4A/nSDK8g0AfZU37T3g+H/WaN4lX/thb/8Ax6oj+1N4LH/MJ8Sf+A8H/wAer5Ct7p4yyuBIh6huafJZR3Cl7TAbGTGev4UAfXX/AA1N4K/6BPiT/vxB/wDHqP8AhqbwV/0CfEn/AH4g/wDj1fGroysQwwR1B7U3HFAH2Z/w1N4L/wCgT4k/8B4P/j1H/DU3gr/oE+JP/AeD/wCPV8Zijv1HFAH6Ma58QNK0b4aR+OLq3vn0mS1t7sRRohn2TFAgwWC5HmDPzeuM15h/w1V4I/6BXiT/AMB4P/j1HxL/AOTNrP8A7A2k/wDodvXhPwK+Hfh7xro3jHU/E9xq0MGhW8VyF0541Z1KzM4w6kE4iGOR159gD3b/AIaq8Ef9ArxJ/wCA8H/x6j/hqrwR/wBArxJ/4Dwf/Hq4Dwf8Jvhp4m1fTdOjPjuwm1OxOo2bXctkVmhBxnMauVPswFeC+N9Kg0Lxpr+kWbyvbafqFxaRNKQXKRyMoLEADOAM4AoA+uf+GqvBH/QK8Sf+A8H/AMeo/wCGqvBH/QK8Sf8AgPB/8er4sooA+0/+GqvBH/QK8Sf+A8H/AMeo/wCGqvBH/QK8Sf8AgPB/8er4sooA+0/+GqvBH/QK8Sf+A8H/AMeo/wCGqvBH/QK8Sf8AgPB/8er47sNJu75wIYmwe5Fdr4f+GGo6lh5yYo89fWgD6P8A+GqvBH/QK8Sf+A8H/wAeo/4aq8Ef9ArxJ/4Dwf8Ax6vPfCXwJttQuWMzuIY1yWI6msDxh8KoYdReDS0YxxnDOBxmgD2H/hqrwR/0CvEv/gPB/wDHqX/hqnwT/wBAnxL/AOA0H/x6vFdL8AtGFWSzViO7L1qxJ4PmhkPl2CYXts60Aexj9qfwUemkeJv/AAGg/wDj1L/w1L4M/wCgP4n/APAaD/49Xh02kXCuVTSjkHB+WsTWoLu2iZDprKcfe20AfRn/AA1N4L/6BHib/wABoP8A49Sf8NT+Cv8AoEeJf/AaD/49Xy94f0vVdcvGtrOwllk9FXOK2B4QuEvHt7m3eKVT91lxQB9Gx/tQ+DpDhNG8TE/9e8H/AMeqdP2l/CjgldD8TkD/AKd7f/49Xz+Ph3qU8W60JUeuOK5HXNA8Q+HZi08cpjBzuUZFAH1NL+1H4NibEmj+JlPvbQf/AB6kT9qXwY5wukeJSf8Ar3g/+PV8k/2pFexiO6iAcDqKqWLRNdldxRc8UAfYjftP+D1GW0bxMB/17wf/AB6kb9qLwcoy2jeJgP8Ar2g/+PV8mXV3BBnzCGA6AdTWRfanLc/KoEcfoKAPsUftU+CCcDSvEuf+veD/AOPVKv7UPg5hldG8TEf9e8H/AMer4mqWK4kjPyscelAH2yn7TPhN8bdE8THP/Tvb/wDx6pj+0j4YCgnQfE+D38i3/wDj1fHml6yuds+FzwDitmfXVt4CUUPgcDFAH1BP+1B4OgP73R/Eqn3gt/8A49UP/DVPgj/oFeJf/AeD/wCPV8d6hevezmR0A9hTf3MaEupL9hQB+gvwp+KuifE3+1P7CtNSt/7O8rzftsaJu8zft27XbP8AqznOO1d/Xyz+w829vGpxjix/9uK+pqAPBP2zv+SYaV/2GY//AEnuK434EaDrPij9nLxRofh25tLW7v8AWHgkmuWZVWEw2/mY2qSSVyuPc812X7Z//JMNK/7DMf8A6Tz18X7QT0H5UAfe3gT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa+CkwVUd8UBV7gflWrpVgskbXV1hLZOgP8AGfSgBljZKYvtN1kW69B3am310blwEASIfdUdBUl9ctcv2Ea8Ko6AVXKYX5VBNADI15wRnNXILN5j5ccbE9wKs6Fpkl7dxrjAz83HavYvD2gQW4VokQr3J60AebaV4Lv7uRP3LLGedx7V6l4V+Gdky7rh12/xM/GPpW69kYdggY467R3rSttQlgVVxCSOzjOKAN3wx4S8OW2Et7czTDjzGTIr0WTwvpen6HItvZQvM4+/sGcmvM7DxRqFnGyw3CrnoixDFdba+NdWuNMMX9nh5sY8xAf5UAYJ+G1rHdedC6eaTklavXHgmXyFRHYEfrVi31fV3YmSwlQHjp1NW/7f1OIZNm7BRnp0oA5q68H6uuFtp1K/7QrD1rwr4kgtmaExSjHPHNdtfeN5YQv2izkK56heaba/EPR5pFW682BwerLwKAPKPB/gvxHr+qXFo7JCIxuZpeOPYVuL8O9QhvXt7y2ZWVuHUZB9816ede0a9ulvbS9h8xcfd+U8Vjar8TJYb9bZ7VJIc8SJQByN/wDCi9mtWa1vJIXIyBnivNtUt/E/gm6KanHJPaseGIyK+irHxhbXyDyW2E8bT2q9nTNX8y11pYriCRSPn6D3oA+V9R1G0uIoriKLbI5+bb2raF7a2tlE5uF2kZO88/SrHxR8KW3hDU/M0ueKeym+ZY1b7ntXkWoX801wWk3FQenoKAOx1nxsqRPBpkACjje3P5Vw0uq3ZnEwkKyE5PvSTT71GIx+VVfKZ8MRx6UAdTo3jO5iZUugHTPNej+H/EVnexq6SJvByRXhjRFXG0Vc025ms51aFipB5oA9p8ReJrVIjCkGZWH3gK423SG7YvOWVSed1T6H4gtrl1j1K3QDpv8Aau//ALC0nWFij0ZWeIgbyy4OaAPMJtQ063laKKEzkcDinhbWeMtLZMCefudq+hvDfgDQdOtFluLNXnPqmTW3qHhzRri2IFiqADk7cGgD5fbR9Oubf/UbGPQnjNYmraFa267UkG/sAa9n8W+EbdG22bkbuy9q5XRfhJrHiS5cWNx5bZ/5bcUAeSyWBzhTk571E9nIpwB9a9Y8d/BnXPCNjHdT3EU4Y4yh71xNtod4ctMQnsaAOYIaPhgfypCVJ967Z9KuTabJIkl442isRdElklaPyyjj1WgDAbg4wKQrnpzWpNpF3HJt8osT6CqstnLCcPE6/VeKAKg6nNPjcowZSQwPanCLPfn0oUY68H0oAvrHFqabZCEuQPlf+99ayZ4nglaKRcOvWpy5XAGc5zmtEbdTi8qYgXCj9257+1AGGKT1J+lPlieFyki4ZTgg0w9zjNAH2T8S/wDkzaz/AOwNpP8A6Hb15/8Asi6dNrHhb4n6ZbNGs97ZQW0bSEhQzpcqCSATjJ9K9A+Jf/Jm1n/2BtJ/9Dt6+LKAPub4b/CnWPDviDwrfTxaFpUejWUtteNpUrvJqzsu0NNmKMAKfmGd5z37j5D+LH/JU/GX/Yavf/R71ytFABR1PFFXtKh8ycEjOO1ABY6ZNdN/dH610Wn6HaxOjS7jJnoa2NItYcgop3Dqe1bUlosj5IwMfeoAu6BFDbqjKYvM6Df0FddpF5ZfawdQ1RkGeFhHFcTDbtnakZcDoTW5pWhahdkfZ4doPGSuKAPoHwJ4g0iSzltYtQjYAZwxwwrnteu9JP221juFkiclZOcZB68iuP0bwJe58y5kCN329a6EfDq0YLJNczEE84NAFuz1DTY4lQKvlKoUdyABxVpNR0mTO90JB6jtVc+CLSGI4nfaOh3c1Wm8C2z24kjnKNQBPNfaSZQkbw46mo7jT7C/QGVYpIV64x0rhPE/g+5tXVxJJg5GQ1cubXUrU7rS/lBHG0saAPXtL0iDw/rRvdBQRJJjKkZyO9X/ABN4v8Ml9l9bKuonGX2/1ryK31LxPAuHnMqnoTVe90y6vwZb1jvJzkUAeu2utadKifZpUKnnC4qDUWt7+CSKW3jeF+DuHUV5jY6Pc27ebFc/KAMgGtqG6uo4tplPXjNAHO/E74QQwWw1Tw427KGR4l5x614TPmB2RlKyqcHPavo3VNX1L7G8MFyyhlK9eK8X13w5cm5kmZwSxyaAOQJJOScmipZoGicq3UUwIxOADQA2inGNx1U0mw+lACVZtrxoeGAdfQ1XwaTFAHceG20S7Vzf/u5MfIoHU1v6T4Qh1K8VjFmIngAdq43whZrLdbpAp9N1e7+H7wafDGbdI2IGcEZFAHpP7PujWuh+I/E9rZIEQ2OnSMB/eMl2P6Cvba8b+B1++o+MPFk0kaxt9i09dq9Pv3f+NeyUAeCftnf8kw0r/sMx/wDpPcV8YjrX2d+2d/yTHSs/9BmP/wBJ7ivjvTbN764WNDgdWY9FFAE+kaf9qLSzkraxcu3r7VY1C7NwQkYCQJwiDjA9adqF0oVLW1G23j4H+0e5NUk98c0ARkZJArR02ya4lVQhZycBRVe3haWVY41DOxAGK+tPgF8J7Ox0yDXddhSa4kG6GNxwo9TQB5P4S8Fakqm4ntzDCBkkiu50PTtkbSykoF456Gvb/HENjZaJOwhUyynCKoA/KuJ0Dw/9uRZrwbIFPyxE4/OgDnrWwur+UpaRYz0c9/eup0vwUoAbUNpJAPyGunht47aOOOGEEDptFW1fdjYHGOqjpQBTtNG06zIVIASO7DNasAhiA8qNOehA/SmBnjhdwVcduKhhv3MgxGo/CgDRXe6uVizjkrjNRoWSR3dPlPQMtXYJmSBiigs3cdax9SvJoGXeVP8AtMcUAZniP7D5JaeEZJ6rwfyrz+9isLl/KhWKbnhW4Irq/GYW60dpYmPmgZyteD3Woy219FdRzurB8Mh780AenDwzbJhzYyxMSPuHINWLm0t7WMZt38tecMvWu+8KX0GoaRayH5ZGQNkHitO4t4JT+8ijc9CCOtAHk8d1pmV8tDE55IxgVYe7tsAiZMY6huRXos2lWM0RL2cJ+bgYwayrrwVpVy5PkGN/7oPBzQB494mGjXOWu5yzexzXl3iKHSVl/wBFbIPGMV9Iar8JdIuVI3Sxv67q5/8A4UTpszmRbt2x1UHNAHzzDp0EvKSjHoe1Om0eBc/6Qu32r6Sg+C2kQoNzugPcirCfB3RVySWk+nOaAPll9OtkBJuCcD0psdrbgF/MyR+tfUcnwl0Eg5hk3elUL74Q6PJhUVlYe1AHz3oUEUl2nmSAKD0NfQfgd7eC0XyNhfA5zWTJ8HNMiYyC9eMg8AL0rmpreTQr2SOC+zHFkZI9KAPZr/XboQLkxHaDtwMVwuq6z4iuDMqTxIp6Beorih43hlsZGm1RU8skFe5rkh45t5LpjJc3QjzwcUAeu+FL28WZ11c7vc969G0XXLCy/exEJsOTgda8H0LxNbajtjsdUAmH/LORcE/jW9aXGoSThHmR2YHCKMbqAPUviJ4k0/xDo/2O3SQsp35I4zXzv4pttQtS/kRqqdcium1vUNZ07dIiEqg+ZcZxWHZeN0uyyX0Me7P8YoA5O38QXdo2J42J6HIrZsvFVpcA+faxhjwSOtdU954WukVpzHuA5BrJvtR8I2f+ojEhz0AoAdpX9nX99HG0wiRiOWr2zSfhDpWq6UkzS/f5XjINfNeueKNNYhbGzVcdwcV33wm+NUvh2aOx1EyTacx5Rjkx+6mgDR+JPwOl0mCS8scS2wGS8Y5H1FeEaxo9xp0pWVCV7N61+h+h63pviTS0u9MniuraQfMuc49iK8o+MPwwsrmym1DToAseMvCo+6f7woA+MMkEgDkdqcsm05JOfritXXNMNhfSxNkFTgVk4AX3/SgDRkVdWtx5a4vIx/32BWKRtOMEEcEVahle3kWRGww6Grl/BHeW3223GHX/AFyD+YoA+sfiX/yZtZ/9gbSf/Q7eviyvtP4l/wDJm1n/ANgbSf8A0O3r4soAKKK2vCGgXHiXX7XTLQZeZ8E+goAh0PQ77WpzHYwPJt+8QOBXdWvgufSbIS3Q/et09q+qPA3w90vwzocem2sUf2qRQZJSvzE1x3xcjtLaW1sLOASzIPnK+tAHkmn2aWkA81R5jdAO9dJo/hm61B1MwaOJuhI6Cuk8L+F4/LW7vwrOeisM7a7SKNokRI1VgOlAGXoPhGwsAjDMkg/v+tdPHB5aqsKKO5AAqCNzJgGMeaD2NWoY977lkKP3FAE0Enzuij50HOO2avRwSsqtuIyenY1zc91Ml20auevGDWvp1yQo86TBHOTQBqXmngYJkCAryKz7lSiERkAjgetWbx/OZn8zcNvAB6Vx97qSQXTI0jvJ7HigDmfH+rtZSbcspxj1BrzO38RQXOpLb3YGS2M9K9B+I8LahpjyQqCVGR6ivBdQZ0likCYkRsEjg0AfR2meEori2WSKeWNCM56irdz4Kl8vEdxuGODS/DHVZLnQ7TcxYBMNmu/EZfgLwRxQB5GPAOrgMIrtAWzgZqndeGfENqrbUEi45717Otvhtw2sq8EZwRUMdqRyo+fPALcGgD561PSvEOzEdqxyOgHSuA1zRfEpdg9tL9ADX2KbRiuZLduT2YYrOuLWOSV0eyyF/jZeKAPipPCmuXEn/HlNk9yK1bbwDrzKT9mcH6V9irplnJDmWGNWHIKriomgg8wLHEuf9rnj1oA+Sovhtr8/WFwO3FTD4U643RRX1qkERj3MqDqCF61RltIw7bABnOCfSgD5Tk+FusopyBkVnTfD3XEztgLnPQCvrC5tUEe2NV3DqeuazdQW3hQkt5b9W5oA+YE8M67pAE0kDoorY07xPeW0JEwbaPWul+JXiqKOGSGBt5JwBmvILzUJLiHB4yexoA+vP2U9SbVdW8X3DLtxb2Cj/vq6P9a+h6+V/wBhtmb/AITXcScCxAz/ANvFfVFAHgv7Zas/wz0hEBLNrMYAHf8A0eevku4b+zrT7JEw85+ZWHr6V9eftezCD4e6NKRnbrCEfX7NcYr4ydzIxMnzMT360AOi+ZuakbhjgcURKMrjrVkFTIqYBLGgD0T4EeEn8SeMLRWAaFDvkHbaOTX2c0Bmu0UM0Gm2QGFU4DkevsK8P/ZiW0s7i5Uxf6RIgVWHOBXr/ijV0lnGl2h3En98VOMD0oAzNaRtW1j7RIQ1tHxEM/rWhbtCsQGct06UxUSJEURn5emPSnGOJ5AQWWQjjI4oAHljIU7BnPY4P5VPBIsYx5ec/wAR44quIXyQyj8s1F9oKsiSPFgHHzdaAL9xdWMVlcebiM7TsA7muPs/EPlowWItz35q/wCIYVlgyrKAOQQa5ezMcLETBjyTuB6UAdjY6uZXATCsQCRk1X137ZcsJCy7B0A7Vl6LcRi43q2FHBLda2LyWKS1Licv6L0oAoeadvklAzEYIzx9a8q+IHh06dciaAHypGyRjODXrlmrNOQI/lb1NU/FOnLeWjRsI2KjIGe9AEXw0vJItFtBKmUXCkgYxXei53O6ou8noAORXJeELONdLaNyyg9k5raBkgPl28zAqOD3/OgDbKy5CyHgDv1pDcOjlEUEjoW/xqpHGLj/AI+HdiP71OWARF3ikyvoec0ATuRNHmVcsOetRqHCtLATjsTxRBcxJA5eKQtnggVEJg4GxnQ+hHP5UANWGUkSySKueoPepHcxYVsqvZgMGo7i6YKfPDSdsAc1SGoqCMMCO24c0AWp0wSwUtk9TWbdX0UIZjncvvisbxJ4whsYS00qq4GAoOK8a8W/EmafzFtn+XoT1zQB13xB8epZ2zxQOu/np3/GvBhrNxqd5eksxZlJHOaydb1y61KdlJbB7VS0e+ayvBhcgnBoAx3zvb15603p/Suj1LRmu7pnsFH7zkp6VqWPww8TXmmm8hswY17E80AcdZ3EltdRzRnayMDkV7J4B8RQa9rNvbhXW8AAQk9TXD6R8OfEmp3kkCWEkQjUszuMD869o+CHwquNKvJtZ1W4jWaJSscQ5/GgDrbLwiLO4urzV77zpJAdtqBlR9TXi3xg0dLS8jubNI44X4IUd6+h9QsmeQsbvMY52ivIPimbV7fyFcMwOc0AeGRs0km0sRn0FR3MckQDOOGPFaE5FrJmMfN64rNurmSUqrcgHigCu3YjrUhyQOx9qSOFmxk4+tdf4K8LR+ILrymuFVgemaAJ/h58QdY8F6itxYTOYf44WPyuM9CK+w/hz8R9E+IGjMEdIbsIVuLaQ4x6keor5p8TfB+ex057qzkLtGudvrXnXhvUrzQNXBWSSEg7HAOOO4oA9q+Kfgy1na9ls1RXjdsFe4r5/v7SS3ldHXGDivoLRbxrmx8/zjLFJ0y2a4zx7oQupDJaxYcfMxA6CgDyMA4Ix+lWdPuXs51fOVPDDHBFOnt/KZ1bIIqDbwMGgD69+Jf/ACZtZ/8AYG0n/wBDt6+LK+0/iX/yZtZ/9gbSf/Q7eviygAr6a/Zl8Lx2Gk3fia9iG9QVgJHtXzbp8AuLuOMkKGYDNffvw40iyg8F6XYpIHiSJXcr0z15oAn0c3lvZ3es6nMC8ikQxHjHpXnUNjLc6lNf3isZ3ckK3T8K6zxNqia3rAtrSfFnaDHA4Y96Q28ZbJk4PagCvEkUcKncCeucUSPGVVhEGBPJDY/SlawbzC8bg4HC1H5YLkOvbk9OaALsEqRoWCbj1+lWkvLcMhl2qucljWQZ3ihMflb+eoPQVDfjzbZgFI3DnHNAGF4m12G21+T7GQ6n7rDpmnWvieadyHUBFHJPeuP1CAw3hBJ2g5xVqOW3WJMSMpz0NAHoNrezXNq3kyABx1A5Fczf2VxFdhmkY5OcnpWrolwEsgrSqhzjNR6qsaSoWkaZvQcUAZxeS4/dKq7D8rE968v+IHh37LdiSCPajHPHTNeuaaJGlaMpx2DdKqeLNLF3bFPkyg4HoaAMf4Wm5hsP3eTswSCe1euWt8ZtrxqQW7hu9cF8PrOKKB1mX5sYOyute3hgVfsxaPd1A60AdIsLJbiS5ZQzdcNmopLmEx4ikBbpyKzLKOTADKHweuTV14JSjDy4M54O4igCdtxKNlh6jtUkm513qASeCGqk/wBpiKo0aOoGSQxIq1Nd3DRoq26kj+6ccUANkiiZUj/5aNyBngVHNDDADmNS2MMwNMaTzJMSJtUDJJbpVK8upEQ+SEf3zxigCaUqcSQ/e7elQ3zBLdZJ2w7cbawL/WDCMyKYwDzzwa4fxP46trKOXEyk9hnpQB1eu6vDZxhlmXC9QT1ryPxx40SMSLDKGbsQa4PxN41uNQlcQuQpPU1xs88kzlpGJJoAm1O+lv7lpZmLEmqyjKkDr1ptGaAPqn9hn/mdv+3H/wBuK+qa+Vv2Gevjb/tx/wDbivqmgDwb9srj4Z6T/wBhmP8A9J7ivjtNuN2ATX2L+2T/AMk10j/sMx/+k9xXxy7bj939KALFvLhyRge1T2S7p92M81Ut2CH5geemKuRyEAGME/N0xxQB638P9V1PSb5J9PIQyJsz6V794Jgla2+0zKGuHOWZznJr59+F5lvnZ7lAqpwPavpjw0AljCFKHjv3oA1JT+6BI2E9fQ1GjDABkzyDjjipmf5ijRKq54OcinQ7Qzbmi9QCvX8aAKN3ffZwW+UnnO41zuo6nbeWH3xKx9+a1fEUpeMmIRr7MK861KPdLl/mDt90dvpQBvXDyatsitZFC9SahvNNS0ZMSEkjk4zzUekGOxdVjDK2O5rSvFLQs235n4znjFAEHlmK2yip9c1ahvnTTXQiI453Y61lR2l15agPx0Cn+lbWn+HHLCZWLHHzKW6UANstS3SnysLxz703xBrFlZWvmX0qqm37p4NT2dokd9NE6KMjgd8157438OS3QupLm4+VR8i7s0AdH4N8WWMl06QzB0J+VS1d4rLOCzNt7gr6V8waFoOoPdkWPmKw+8RxivWdFudW0eO3ivWaZepOeVFAHqNs0jqqLLjjqalhbG8O2Oe55rGsrsXEEcltgKecMe9OeeQTnC84yfU0Aa5nMe/P3hyMdKqXGp20Cs0z4PoTg1nX11JMjIgMKEc+prlNSso9haeUtGTwScmgDX1Hxfp9qHKM0mOR839a8l8W/E65e4eO2+WMEjgdvrSeNr6z0+ylS1bEjDHXmvF7m4eeVyzHrk+lAGzq/iO61N28yQkE8FjVK3iV/MDSfPjgVkySqrBQeR3xT7W5MNwGfH1oAsWyQQyyK+WfGORWTM0aSNtzkGrkk8ZaRm3bs9u9Zkiq8pxwKALtnrVxZSqU5CnvzXuPw0+IVpPZLaX0rRnpz0BrwWwsTc3AQZr0XRfCXmWgkj3KyjdkcUAfRg8RaaYDseIq6464rKPi+0sIiqSL3BIFeVr4cvEtozDcTHdyNxrmtfi1izvPJlZ8NwDjigD0rW/GsciOLWQ5bPPpXlHiDUBd3W1p97Mcnmsa/wBRa3dYC+5zkMfQ1zSs7XGckuSRwaANHV5BHcsAeOmQazY2Z2AUE+lSyRTsx85WAH96tjR7CN3UyHHuKAK5thHa+bLnaKfouvvpl9HJajYm7rnmtfxAIxpMiQJkjqQK4nIoA+ofC/jeO/0wR3oLbxjd2P0ryT4kWtlB4g862IWKTlhXM6X4ga2sUgYsNvTFVdSvnu3yxPPQ7qAO7+HGrsTLp29ip5Tmuyu8+YsFyGjm6gN0YV474Q1D+zfEFlcN0WVQeOozX2xrnhPTPFNvavEoSeS3EsbKODx0oA+QvHulra3KyRrw/wCVcc67TjJHFex+PbCK3S5tb9VWaNmCHPpXjk4IdhwcUAfXXxL/AOTNrP8A7A2k/wDodvXxZX2n8S/+TNrP/sDaT/6Hb18WUAWdPlMNwsg6qc19LeFPiME8Gw6bYMfts/yM390V8y2wUyjcfl716z8OdPRrm3GBhmyKAPoDwjZJBZq88n75+efWt2eHYwBQEEZ3A9fpUGk2wFoqhFJAxgmr8sJbYAwUY6GgCo0QI37HVgeoPBFRyTxoFaUKp9KvRR+auDMpAOMAYrE8Rx/ZoX/eqFPT2NAGZqtzHIjusrBRxgcVgy6qY7dzukwvGAa53W9VuY3McUzFP7wrLsZbyeX94x2Z9etAGk1vfXxedgyrnIJ70W9uxlRZQWHXIrfaYm0VE6kDvWHPI1lcqYx3+Yd6ANA3JhdFRWf1BrYv9Qt/LtmSEgY2sQeRXLyXM106qoxIfbpV61tbu5jK3Y4Tp2oA3rLUkWR1hAIXufSl1u8tkti1y6rFt5I4rJ0i13GcKxBUZzXn/jWTVNRaeJS6Rx5GBxQB2PhjxDb2+q7Y590HoT1r02C/S7CmPiIjg9xXxxYvf2l0GjdyQema9Y8IeKdWtoh9p3NFjnjgUAe/2jtE+1JcqRmrsu8KGeQkdQR2rjPD2tx39ssqyZkC/d9a2PtxEByjKnf1oA6BmGzIYbyPXPFVJbwKig5IbqOmayE1FV5lBC44wOSKxdcu7q7h2xN5SdiOpoA2r7X7S2gdZ3Q4ODk4wK4fV/HdpbKy26hj2PasHVbNmbN1KQM85PWvP/F13BZWsggf5jwKAK3jPx/eXl06wysFHTB4rgL3Ubi7kZpXJJ61Vkcu5YnJNNoAPrStjqOlJRQAUUUUAfVP7DP/ADO3/bj/AO3FfVNfK37DP/M7f9uP/txX1TQB4N+2UcfDPScf9BmP/wBJ7ivjkKDzjHvX2N+2SM/DTSB/1GY//Se4r44IIB5oAlTg+pr0DwfoCXdh5rx7yxwoFcFEuFUNySa97+H9qzadaQKDufGMUAbPgfRTaFkjj2565Fe26fbGGzgVowyqvJ9Kuaf4ZtdM0GRdu6cx7mY+uM0yylKJtZmX5cUAIGQx/Id7Z6ZpsUkpfAjSRO+D0qbzoAGDMysRgZXFMQ7E6BifTqKAMi+tt0bBjtTJwDzXEavYqZuNwYcjnrXoN1FI48yXZsHXn+lcpfwwCQy5JBOOtAHOeTN9oXfKQfQV1+mYlgSHAkcjjcaytsKyDMgPoFAJFdFoemPdbDbE7h1NAGY0Ugu41Mm0g8gDNdZbQm2tzIrfvGGTzjd+dZuo2U1hch54gR6//XqlPeC7njhM3lj0B5oAiu9UjS+HJWUN26Zqhr7efCwRVleTkgDkVo3dvFISUtyWXjfjGajgt2CgeUj57t2FAHN6Hod/daoigR28ROMgYOK7jxr4YW20GS5glbfDHlvU8U62sjEY5YmkBBzheah8TnU9XtHtldo0IwRnrQB5h4R8cRib7HcAB0bhiccV6daa1HcEZ8vGPvcZIryvUfhrdRO1/axmSZcnYp61macfEmnRs91aSJCDgqOSKAPX9Qu4YrdpF/eZ75rzjxX4i2RFRweflNZl34ieSAhw6MBjax61wut6qZJD5mCPXNAGN4i1Ce5nYnAHoe9c/O4CYYZY+lXbiZWYsCWZj65rMlctKODz6mgCuqPK5VFbd7Cti18PXckHmMm1ewbtVnTpo9MhMrIHmPQkdK1YtZuLiyk3CMlecZ6UAYU+kSQqoR97t1AHSse9t3jk+YjI9K6uPWZbxPJWGMcYLDGawNUt3gc9NpPrQBW0ec2t6hY7RnNe4+D9RS5sRGGU/Udq8BdgH6YPua3vD2uXGnyrsf5KAPqizntioXYNiKABtrA8XadDdRyTYiXYpbG3nFcf4d8Z+eiLLIH49Km8eeLpLTw5KNNVWmn+RvUA0AeHXOL7V7gDj5iEIGaveHNKdL7zriPATJG6uo8JadbaPYXF9qSRyXUgJVW/hrB1HWQ7XBUkFvlGKAM/U5JLi6cuwHPRelSafINw43L6dKzoiVYu7bmI4BpUufLI2nv0FAHTwXsckhilCCMrgg1xV+sa30qw/wCr3HFXvtUjFt4+U960vDumWkl2Gunwp5APagDmdjYDY4z1rSu9Oe1s4ZmcEOAcA9K9jh8P6F/YrrFECCu5nb1rzPWtMaFHcPmBSdg7YoA5+3cCdGY9CDmvvP4UXP8AbXgzw/qMEgaS3j8mQZ7Y718GoEVTu5J6Yr6Q/Z78enRPCt7ZSqHCNvTJ6e1AGb+0baRf8JTeBQBtbf8AKfUV4FOVLZHA6dK9Y+MWsyavrMl67LulPIHpXlEo+cjOQaAPrj4l/wDJm1n/ANgbSf8A0O3r4sr7T+Jf/Jm1n/2BtJ/9Dt6+M7KE3FykYGcmgCOKNnkVVByTXvfw1haKWyXZuyB1rgNI0BmYOIwQOnrmvavAWhz217bNcIYsruAbvQB6fYkCHbJC6j1Bq0mFwQCwPUHqKbHBLHC7Y3oT0FObe0YKqUx19aAHQOwDDEcj5JAHGB2rmdcnWWKQEfMpIKMO9bkdszOWR3jwc8jNZeqRIHmVzvcYOSPXpQB5NroKLJ8h54+UdKyoLlYIR94PnvXW+JkxIQEOSfwrnHst6lggz3BNAGtoN6Lh1jZM5Gc1p3VisTbpQNp5GOTWVosbW8i4Ubj2rrIIIZ7Y7siYHnmgDP0gwPdlQm51+72rurcB7ErcRIJm53Y4xXOeH7Yx3RkMWFJxkjNbmq6nAq/Z8ZyOPrQBgeVHb37MQ22RsMAeBXP+JrZJIrgpJhTwvy9at31vqC3m9lIhPI57UtxbS6lCI8DywM4JxQB5jbadZ2t4rFRK5OSpFeoaP4buL7w+0y2oVRyuB1FRWGhWsUqvJb5IOckZr13TNYsLHQU8wfKq8qBigDwG01b+x9e8qf8Ac/w4r0LSNatblHMkqkdNwNeL/FXzNT124u7BGT5shRVDQfEF3p1un2whO21qAPokywNAPIYkg8Z5Fc/rd3Fbx5kl59PWuKsfF5mgQRP8vf3rL8ReIWmDZCjA4OaAI/F2vIIzubhenPNePa5qD3tyzFiRWrr+oGeQgMMelczIctmgBlFFKoyQKAEpdjdMGrMUkMJHybj3NPmuI2lBKkp6elAFIjBwaKmneNj+6Uge9Q0AfVP7DP8AzO3/AG4/+3FfVNfK37DP/M7f9uP/ALcV9U0AeDftlf8AJM9J5x/xOY//AEnuK+OYyCeW4+lfY37ZQz8M9IH/AFGY/wD0nuK+OScDigCe1OZwd/AOelfSPwiMdzqelq4z86dDjvXzVGflG1sE1778EdQeKWxmLMfLkXJxQB9cXozZzgcfI38q5KBJAN/mZXGGGa6jUpVXT5HJwpXAI965xBGcmFVY56scGgAYKdoOMk8EnNNuU8pgAcbh1XnFWJVcxbUjUFSOc9agPnRMNyKw7EDOB9aAM3U/Ka3Cmcq574rndSh5jh80bSPvBetdTq0P2q3OG+Ydc44FVLOAKoJVWVe3egDB0zQ9qO0j/Mehb+VdX4YuIbNimSCvB4qC8uYlXYUZSeACeprES9S3uW80nHYk8UAel3jJd2pWMo5zkBjisptJhicM6IbmToABXM22qwvIpjYbo8Hdng0/V/ECrcqikMxIwRQBdvLIkyeajIB6ciqoWFNojJDDoccfj6U8TS8spYBuTuyAarzNFEGZkGW/2jzQBpQajEZEiWFhIRg7T096vxkrECdjM/cisTTZYwqsI0AzgEA1sK5EQMqRAHoc/wA6AHxSKhI3Jj+IY6/jSYhuVYGEbDwcp/WizjW6vljMcJi77cmumjhSOPYigL6UAec6r4P06/SSOaCM55LBeR9K4fVPg9pN0zPGJlGCck8V7DrCiG4IUiOMjtwc1i6pftZWMrY3hVOO9AHyL8S/Co8Nar9nt7jMRHBJ5rJ0Tw/qFxJFILSR4s53bTzXeeJrS68Qa80xjyitg5GRXSnURpdsHlKhwmxUxgLQB5Hr1l5F5K2DhSPkYdKzppjHalognz9citrX/td3eSSqrFWOeF4zWFPbySSLEAVdRz70AQWCSNMvynce44q9qVnMHHmbsYr0Hwh4HfVvD8t9EpLRDgrzyPWuX1GfN40b5+Tg8cGgDlW0uSQEjkfWpLTS5S+NhI6HFdRaC13puJXJx0r1/TPDOkado0eoG6jnLj5omQjbQB4gllfWTZTevcbgeamklu2UPOSCex6V7Tcz6bqumyQS20YkQYjkj44968p8QQvGxjRWIUkZzQBzOrXtzLEI2Y7awJA6hiCcetat+pCZKHd9az2Q7ehzQBSLsTyT9KdboXkwDSuvzc4q5o8Iku1V+FJ6igC5a2Ms1szBG46YFUWiu4ZeAeenHSvSNE06C2t5pDOZEPASk1LR2WKOWKNcE5oAoeGGupbRo7iTEI5+tS+I5bT+zGaLazHgDsKWU3CRorlIVbgcdaydfCW1gYo1+brmgDjpcAkD17Cu2+GsjvJeW6sRuXiuK/eE89BXZfDXyxq8nm906CgBPHYeGcRs+TjOK4t9wXOP0rtPiK0Z1FcKQCMCuK8zAK8nAoA+vPiX/wAmbWf/AGBtJ/8AQ7evkLwym7U1J7Cvr34l/wDJm1n/ANgbSf8A0O3r5F8LOE1D6igD6O+DHhePXL+SW4U/Z4FBJ969n8TaRHZfYfs6YIBXIHaua/ZxhRNAu5FBLNJ1r0HxqjPBbMhwQexoA5eN1WIj5jntTTcxKhSTzN/+0OaIopVU7wdjHOalK7iqoAGH9480ARq5RModxYd6zbm38xmLzAbecEZArTvYfKK7VwSOSKyb5Y/szq8hP1oA5PWliuLqRgCwVcZ7Zrmp5bfYfOzlT0x1rpb6AR2chhmzu4PqKyrXREu51kVmbsfrQA7RHiknTESgdiOten6R4YW5s/NjIDMMgCuTh0+GweOZRuCjnj9K77QdVj8tArFAR+BoA5XVNFvdPuWWKKTpng8Vk6fFO1+zSWjHjO5q9QvMX8qiO4QMeCOpqpNFAkv2eMoHH8TdKAPO7y3kIdp5cdSEA6VXt7JDEgJfk9+K7C4sSTKZPLlYdSvGfas15VP7oRrxyQTkigC3p9oVtwCpAxhTinXelidQjNvboy9BVJNTniHl253rn5QR0resd0mJZgC23rigDmrzwZZNcKWiX5hz6VzXiH4SWGozJLG5XHOO1eoFlxny2Zs856Use+RxHbxkE9RjgUAeF6x8LJ7RFaxnHl9wOn0rjNe8JavbQDMRkQ9CtfWkmlyiI+bCNnoBWNe6dCAzSogYf3hzQB8QajoeqpMweymB/wB2sSeKSGQpKjI46gjFfbmoaFbSwmR0RxjP3elfMnxiitV1pfssYVhkNigDzqnlGWMPjg1v6P4dN5brPPL5audqqOSak8TaRFpMccSS7+5oA5kUrHOPajvxSd6AAGg1PFbsSrOpCHuRxSTxqshCnNAH1H+wz/zO3/bj/wC3FfVNfK/7DYIPjbP/AE4/+3FfVFAHg37ZX/JM9J/7DMf/AKT3FfG+7pz0NfZP7ZHPw10jH/QZj/8ASe4r42Y4PX9KANXToFu7WYEEFRkECvW/hFN5Gmt+8CndxmvLtCkVIJwcHK96774czxww+XIoUlvxFAHv2j+MLvWr6GwmdQkCgFR/EfWusKqnLbRzx14ryvweY31cSo8eehPQ16nCDz+8jkxzz2oAsC5YqDHMCoHzcVOqcKzyk5XgDvUUUcEpJyAeOG4qW6bbGI0wiKM5WgDPv7pCSsqqRjGQMGsi9u4bO2KwtvPXk1V1+88iRRGxYnkgjpXMOZZ8vIzMP4VWgCe81aWbIVxkeg6VSDySNiSRm7/e4rRtLRpGXELDPoK6HTdJt3yZomL5oAxrO3kWASqjbQOT2rT0PTxcXKzyfNt5CNzUupu9naPFAQueigc4p2kXcUdiu1cueoI5oAs6hcGOQqAVkBz1/pWUTdTzBXkPzHjI6V0qW/2oJKcDd0Vh3p6wRJOC6gSAdSMmgB+mKYrRIBKqnqSyjNT5BcLJh88HcuM0vlcGTGfUMKadrNj548d8ZFAGjpBWC9CbVTcONo4roRXGzzlbf9yTvjGQ/qazPD3xFtG1JtN1mVYLgfdduAaAOt8QOVSPbtJY4wRmvNvGd26wtGrAN3xxW14z8TQPcLFZzBgoyGUHB/GvNtX1KJI3ur2Y+UuTjPU+lAGPfj7JbGWQMvG7du6n6VhaHpl34m1ZI1Dspboa5XxZr9zqOplkZltwMIq9h619Bfs46Qg0mbUpm8x2wFJHSgDb0r4cxW1qoltIJjt+7IOa5TxX8P8ATVDs9kYOeoXj8K98qK5t47iF45lDIwwQRmgD5z+Hutr4Fl1DTdUgEunTruj55FeP/EAW8via5uNNCLbSNuSMNkjNe1fFvw4ll9oWRNyqpdHHpXzPJPL9ocZG3dgZoA1LV2WaMyDGDkAivZIfEf8Awklr9mt7Py9qKuEGRxXjdptkOx8njj2rpvCPia98ManFc2rISGAaJhkMPQigDpdXSfSgm+Fkzw3pWDrd1yGZFVGHcV9IanY6X4++Hx1W1tBDcmMsAowQw6ivJJvC0er6UPsruZlOCu30oA8Z1eOJ5f3eM/rWFJEUBzk45ya990jQdN0idW1u3cITgsU4rb8VeGvCmtaaf7GhMkgHDKMbTQB8tOpx1q5YssKlgfmJwK2vEvhe7026dRG3lAnk9qydOjk88qpXp37UAdFp+uJbxiNw7HrV2TX5r0rAjbVxgA9TXJqAsoeQs6q3O2pbWyu9QvmukbyoIjuDE4wBQBvX32tnQSb/AJRwvNZ2sXxli2FDkDmqWu+JLq8liEbtGsIxkd8UtjdDU90MmFn25DDvQBm5yvCnk16f8CtBudc16eG2Ub9nJJ6V5dIWikdWblTX09+yHpREWq6m2SOIwSOM0AeV/HvQpNB8UpauwP7sH868u2EKxXk19NftPadFe6vPMoAltolP1r5jLbXJ4wKAPr/4l/8AJm1n/wBgbSf/AEO3r460STytShPGC2DX2L8S/wDkzaz/AOwNpP8A6Hb18ZWJ23kJ/wBoUAfbn7OF6h0m7t8YcMGHPavSPF53mFNwA68mvnj4OeJbbw/qG+6kKQSx4J969Lk8VxeI7yR7dj5MeQpoA1kVVxHukcM3pkU+4ICIYwxYNg+oqnbzSiMGNwRkHHc1eF0vCtGQW54oAgaZkbEsbYHIJqHUohcWrAbenAxzV797MVKoCvctVO9eEKA3mB/7w6CgDlbWxZC6ugZiefYVpwm3tYsMp45G0VBIrpctKZv3JB571ganrogcxxu8nByelAF/V7xGiLROwHrimadrUKrGC4Qr2J6/WuHvtWuXYrEcJnJJOf0qkjPJIHdyRnsKAPYNM1mIzieFhGrZB5yKzdS8SqLsRpjcz9utcZA8kUOCzFew9K2fDemvcXi3c43oh+XPWgDpjLK6FlJBPOSOv1qOWURKWdIiSKTUJxEpG4hhzgf4Vzl1PdzMcEFOwFAHT6ZetJMxjC/LzgLXRWUkkuHRlT1BGK5/wrBPbxs7FS7cEMM10LCRQWncAN0AXigCWadsMonCOeCoGa6Tw7bubcPL856ciudhCvGG2RsR1OOTXWeHpka2VV6+lAGhIjMpUr8vbFcXrcf2e4k8xWIJ/iXPFd2c/LjKjqTXG+L5CtypSRhu6jHNAHAeJrqS306YwSBflIxnBr5n1/TJtT1R3nc7Qe5r3H4g3Tqrx7zuzzXl10vlwvI4QLzljQBiKkWmWwBK/IMriufvbe71uUtEjMfetDY2qX4ijB2ZwD619D/DP4XGTTI7i5i2lhkHFAHy5c+FtVt03vavt9cVmtZTQOPOidcHuK+6dS8EERfZ4lWZgoIjZccfWvJ/GvgryFkjuLTZu/jA4FAHMQ+BBf8Aw6TUrNA+E3YAzzXiFyrxTukgw6nBHpXsOk+Mb/wXp1zpIuM2zMSAwyK8n1y4ju9TmuI2yJDuPGKAPpr9hslj41z6WP8A7cV9UV8rfsM9fG3/AG4/+3FfVNAHg/7Y/wDyTXSP+wzH/wCk9xXxsTzgfrX2R+2Vx8M9I/7DMf8A6T3FfHLL0IUY9qANnw3JEl0fPI246V03h7VYY9ZIBwpORnmuV0IQ/aMTDnoMjvVm8jOn34dm75G0UAe9+AruB5ZpJAS3mZzXs9uIXiQqAoZepya8Q+C2iya/BPPZsSUween0r2TTWniQQNtBQ7SMcigDUGVIJwM8cVEzEKSzeYVOeuKdIVGFkkUvjgYwKalurjBJGepHNAGNc2cM8rZQ5PIODmpLHRIkbeyE+u2tsxeWqBZMIM5z3oYRmQYc7QPug4BoAitNOSS4AjZFA6jdyPqKl1Ty7aILa7GYd+nNWIsQkbYSM8kkdqztQnASR9oKnjFAHM6raS3PzSyAMx6DtS6WzW7iIqJcnuMAUzUJ2mkCwjYe2TU+iKJGEd5OFQHl2GDQB06rJ5IBTIHI9qURHaCR5jD1qvNf2tnk2s/ndAAxqGLU5biUBVGR/EOAKANkzlUUPEyDu2OKe1xGseA7MW65GMio0WeEK1xGfmXkA7qcjiQhDkDrwtAEDlTkkuA3GMV4L4q8N3utePWFuWWJDlj+Ne73RKlg4VsKduT1ritA06fUtUuBYAbpGJZychKAOd1CAaNZ7tQuAFC/KOpP4VxDWes+NbprDTbCQjP3sfKB6mvV5vhFq97rxudR1eGW1LAgBTkD0xXrGhaJY6JB5VhAse4DewHLEdzQB84zfAHXPsak3cLS7c7QelejfBGC98MJc+HNbjaK5Uh42J+Vx7V65VS/sYbxQZEHmLykgHzKfY0AWxQelclq3iuPwxNFBr+fKl4juVHDex96w/EfxS0u0015rFvMJHDE8UAZfxqcS/LHtJjhYNjrXx5LGG1CVeOHJ/Wvb9S8SS63p2oak1yyjaRg9MmvEISJLhmdyTuJ470AdFp8bbkR0GD0YGtl7PySJJUBTqCRzVLR4lmCsQVHqRW7qMCS2gmDEFABt6g++KAPoD4S6va2nw1YyyKjx7yVbvnpXl0erajDPcXGnSKquzFo16da5BfE97ZaQbSHiNvw/StL4cTxajc3ceoXAQiM7M+tADtb+JspCW+o2pfZxjtXT+F9ZsfEPh29bTrf7PNEMjBxnivFvFMJj1O5WWcPtY/jWp8OtRntmuIISdjqeKAMuXUblNVuobuRpI2JBDHOKytYtRFIDC3Mg7U7Vpfsurz+dGSS5OMVe1ILqNrFdWJbKLyuOlAGLqTG306NYmC7uDx81Gi3wt7adZUJOM7WPatDS1t7mRReR5IONpOMV00Xh+0vnaK3thsxl3J5PtQBxE9vY/ZlmibdLJ29KfoRgs7hluCN55UKMkV2a+AZL0yyQwukYYKigE4rYv8A4X32jaLJcQ2jXl3Iv3hwVFAHlF4qzaiwjHJfAGK+5fgVoo0D4c2QkCq8oMznGOK+MvDGiy3Piu1tblHR/NAdW619ifFfxLbeB/hgYYpAlzNbi3t1HXJGCaAPn74teKG1nU9ZuYyxiMxjQ/7I4FeIykeZk11et3UZ0G3USlpJCWJznNcm/LHHSgD7B+Jf/Jm1n/2BtJ/9Dt6+MYPluIz/ALQr7O+Jf/Jm1n/2BtJ/9Dt6+LVyCG9KAPVbCZ5LELlVwODXp/wsuZIoJBKQcDrXieg6g4snJxgY6mvXvhteosoxDkuOuOKAPXLZmm2vE4UY6iraLMSQ53Hs2ao2UoKFjCA+eD6VqW80ina6o4x0IxQBbJ8q0VpGywHRK5fXboohkA2j1raubiN0/d9QcYFcb4o+1zB4o1Y7upz2oA5vV9bdP3cTl88gVzswluXJlYIc+tap02483mJmI7d617Hw28uJHVhkd6AObtdOaVvkHzHuTXRWXhiREEszjjng5zXRaV4bU7VQHcT0btWreW8VjG3nMgwOKAOT1mS2gtI4/I+Zj948VuaMqW1nGS5DsM5HQiuL127e4uPuBlB6+lbXh9xcwJGZSmOMO3WgDob6yW7l3pHvQ/xg4qT+y4pQpIJwcYX+taFgEhs1SJgHB5PansDcZ2gIwPUDAoAmht1KhAq4AwBmrQePywh3KfU9KWyQbOWUuo5qdIjMxPl7/THagCO3UqQSyGPr8pzVDU/EjaChuYhugJ+YdMVfuIowxAjAI9DgZrlvGCmXQbo7VwoOMmgDvPCnjbTtcs99vcR+YnDoWwRXA/EHxUg1GVLeVGZRjhsmvm/R7zVl8SzLYySpErHdtOOK7OQXE6PLKOepLcZoANXvDdSyTXMxEfVua8q8Z6217dLFbErbJ0963fEOoC6jltbRiX+6QO5rPsfh74kvLMTpps5iPRipoA1/gdpLaz4rt43fK7+QfSvvTTLeK2tI44QAAoHHsK+Kvgxa33hDxxaNrFvJbwu20ll45r7btyjxI8WNrKCCPSgCXFYfibQYNY02eAgKzDg4rcpGIAOegHNAHw18XtC/s5ryOWMb4jgMBzXidfT37QJWTVr8xJhGU5FfMJ6kUAfVP7DP/M7f9uP/ALcV9U18rfsNf8zt/wBuP/txX1TQB4L+2X/yTLSf+wzH/wCk9xXx2rgcEcV9j/tjKX+GukhRk/2wh/8AJe4r41yc8CgDT0qaKC/jM3Kj16Vva2oeMsFQEjK9+K5dHJVDgYBrp54VnsI5irKoX72aAPef2PNRjZNb09iDMNsi4HbOK9i8S2iW2seaoIE4zxxyK+RPgF4n/wCEX+JNjJPLttbkm3kJOB83A/WvtTxZatc6UZoADLARIvGcigDHi8jyvmb5j3cZxTyFKkCUHOOowKpWt4ZVSQqrE9dozU5kQsHkDbs/dPGaALQiHl5MRIxxtpjRIzZML5AGDipzMhiG1Sj44Dmq73U6kKAgwOxoAlmWQAtLyqjjd1rn73yEVizq3pyRT9V1DyY2bbKzdyeQK4bUtRluJTnafYdaANe6ulLIAUGP89apTao0cpit1Bf1PIqlCZ3GW8wr/tDitbS7CS9kCx+WkfRm7/jQBf8AD4knjlkuVAA5Xjiuj022WEM7FQX7heMVPDYQ2trFbwSCUA5cleCae0jRKU2hVJ7dKALc7tOIwjKABt4bOaURRKN0TYkXhx0JFQ2TYPybMH+81TNdRbNqKqtzls9aAIpbmN0aM2oVgpHmZxmsbwJqVrZ6rcWUmEa4b936kjtWjPtkjcAbygzx3rkPCluH8c2T5kGGdtuOM4oA9koBzRRQAUUUUAZHijQLLxJpM2n6jHuicfKw+8jdiK+aNX8O2Hh6XWdC1qUtOq77eTONw7Gvq6vnr9qHw1LILLXrdWZUHkyle3pmgDySSdLLwZNEzKGZtvA61w1i4EhA259TWn4guium2duxK5GSD3rmop9s5LDp0zQB3GnXUiqEJXjsq81en1FktSHA+bjntXK6ZquGw/IFM1TUg54BAPbOaANS4uhJGBlix4GDVywsL6yuYrlgyRkbjjuK5G2vnS4SQ5IQ54rprnXrm+kieOby4eFKEDkUAWvF9ha3CR3MEyHfgsM85r1r4T/CE3ekxas2oRjzRwgGa8tXwZNqaLdRTMiOcfMcAV6f4VnuvA9pb27a7Mbdmz5MfK5NAHK/GHwB/YVwXE1vM7Dc2DyteUxXpsIgINxkH3hnj8q978Yaff8AiFZZQiTSD5lIbqD61z+gfCK/1G68/WFFnD/dAB3UAeaaZqMGozrHJZj7S33GjHOa9I8C/DnXb2/inv7mWC03btoOCa9V8M/Dfw3oLCdLcyXB6MwyB9K7CJPs5+7hQMqoWgDO0vSYdPRIVTeF9hzWhdzJsMfkjd2BpkzCTbksmPSuc8Z+I4vD+lO7sDM3yxJnJZjQB5j4ksba18ey6jbKiRwYL4wea83+LXjS88Z+IgJZG+yQARxRZ4ArpvFmomHSWldwZ5su59WPSvLbS0uJ7hp/LYr1JoAl123S2gtoVOMJuI61gMwB4xV/WLhJbk4Byvy5qgAC3oMUAfYHxL/5M2s/+wNpP/odvXxaW+UCvtL4l/8AJm1n/wBgbSf/AEO3r4txkfSgDR027aKJ0zXtnw41UoLUqcjjJHUV4HG21wT0719JfCrwjLf+GYNQtgchSwA7gUAes2kxkXcVDoRnPSrjMVQYzk85PpWLo4doUUynGcHHatl1jjwhZyT3JzigBhmiw4UEZ7iqEtvNdquCDg8lq047fepXhgOpIxmp/KgWIrwq45oAyI9OVDucDdjlquIEUYjBlHZccVcLIluUwWQdyOasWuZlC24VVXrQBNaEW1nmOEI/cE5xXLa1E8zCUjIJyQf6Vv3VwyRSCV0+Y4+WuU1m6wMWzr6Nk9aAMLUnhS5YSKgRe5FFhFG6rPGVkjB6Csu+R5JX+0EnaOpHGav6BMtjOjvEkgXkDOBQB3dqYnRd6Mp2gcjirmI41JDKx4AVTya5u58TSXkjJHbhWxjg9KhtjcTXCQkOCTnIoA66MwMT8rN681cjTZgLMwQjhfSq2m6dALeRnDbl64JwacQQNsbO69QooAJI8tueQuvrXO+KvMXSrxhsYFSFBNdVEHmhEa/MxJ+XGK5jxZZ3I0W4BiVWByAeaAPL9As4LG3luJYVMjZbpk1zmp6lf+INS+xW9vLHHuCBEQjNfRnwl8OWjWB1K6jjlmY4UEZVfwr0OHSdPhnaeKytkmPV1iANAHj3wy+DFjps6anrcKTSlQUhYfdPqa9ohtIIYRFFDGsY6KF4FTUY5zQBi694Y0vW7QQXtqnyncrqMMp9Qar2bzeH4Vt7rfLZpgLPnO0e9dFTJY0mieOVQyMMMD3FAFSPVbGSMSR3MTKe4auG8e/EWw0SznWK6RpSuFC815L8ZdA1/wAH6i95pU9w+kTvuUqSREf7pryLxsurXOiLqLNuhfhiDQBpeM/EF1qtnfXLkOjA814yeTzXX3U5Twkg3nLNz71yA60AfVX7DX/M6/8Abj/7cV9UV8r/ALDeM+Ncelj/AO3FfVFAHh/7XE6W3gHRJJRmMayit9DbXA/rXx3q9p9lunVGBjPKt6g19c/tnf8AJMNK/wCwxH/6T3FfJMb/AG7TApI862GOnVaAKcJ5I7V2vhq6NzbLYvAsgPc1wysQpB6nvWpo+ovZXSSoRjPzUAWfEFu+m6qPK/dsh3Ke4r7U+BHjqDxr4Lt4rmRTqdpGIrhCeWHQN+NfIfie1TUrRb+BgSRyB2ql4B8X6l4N12G/0qYo6nDr2Yeh9aAPtNWGn6rd2K/KUfKfQ9K0PKkyzhVLdixzivFJviCNZ1u21e2cLFcKoliP/LNhXq2j3f263jmhkAfHOTkUAaaQES4YP7baWe3BbBChsdTU0W4qfMZW/wB1qdJgD5SGI9RmgDm9WgeeNkjMmCOdvQ1jQaXISA1vnHUMK7dIhwEdQp5NRlI+QqtkH+EigDE07RPPfMg8sDoua2IbQWzARpvx0O3GKImBlxJxn0OKvIz2ihgH56DGaAGx7kjfdncexFRs7so37vLA5GOc1bjumRBLOSHJ4XPWopLuMRuXj3EHgEc0AV4Bl1bHCnJz3qyQwc5hBU9gOKpG4E0mUWRSvRc4z9aVXlLgkt5Z6EnnNAE2ozpHbuDHmR1+VOlcz8N5J5PHF/GyFYooccnoc102nXTz6vbW5AfGWbIBIA9a09Ph09tfmvrQxLO6GKUDgsQetAHQUUDpVHWNTt9JsJLq7fbGgzjuT6CgC9RXi+ofETWr2WQWAitoc/LxlsetbXhD4iPPOLTXdofos6LgE+9AHp1c18RNMOreDdTslj815I8KuM854ro42DorKQVIyCO9KelAHxj49+G+paD4eMmqwhJ1y8TBgfl7g+9eMyEq/Ar7v+LGmw+KPBt/HArfarTLAHrjvXxN4j02bTrto5QQDyMjrQBlxuVbOT9BVmGJridVB+ZjWYWIPStzwxBJNfLtyMdMUAdhofga71GLbagtIexHFeieHPg7cFEl1XarfwoMcV2fw10gW2nLNL8zye/zCvR2wzKroHUKACOooA5PSPAlrb2P2YuZUU5Xdx+FaqaBZYEUlrB8pxyobFbUMCgM4DbunJwKRISsi4O4ucigCHTdEtQzKFjVR0VR1q02beNonQCP0bqKtreNaxeUdjN3+Xmop5TMo8wZDd+BQBWmtYkVCv7wNg5z0phuI13ru2Y4GOafHGqyArtwP4C3WsrxJrVnodhNe3zLBGoJC56+1AFbxDrdpoumy3142xVXOSRya+cp9Q1Hxz4qa7kybCFvlBOABTvEWsan4/1lnkZ49LjYhI1/ip2u3lt4b0gQWfySsu0Jnkn1NAHO+Pr/AO0X39nWrHy4fvN1FU9NuPsOmTFThY16uOpqHSYJLm4czjO753J71n+J7xTK9vCuFB+Yg0AYFy7TTM5wdxJwKQrs574poG3n+dJuZ2x1oA+v/iX/AMmbWf8A2BtJ/wDQ7evi5OhGOTX2j8S/+TNrP/sDaT/6Hb18WDr6UAB619s/sq3sGofDuKEcywOY346Zr4mPWvoH9kXxUdP8UXWhzykQ3iGSNe28UAe5a5pyadrtxFyFZvMTAwOe1XYHt1gySc4wdwzWp8RrVzaW2pQxh2hPzgHtXOwXaSIkjxhdwHBNAGiWjIZvO3kDGAMCpoo1KhVCyY5FUXaOYkFgAByRV2zlt/LwJHB+6T0FAEjJjePIP59aRIiCdsTISKZLcywySLHETGBwwPWqV3fu6Ey5RMdjyKAE1FxGhSYkAnqBXH63fW6RhI3TeDnJHNN8Ra8sKtHbkljxlq8+vLySaTd1Of4TQBuXN8HuMs7HHY9DWbPfTzymOAHb6qMYqpAk5PzeYQecGtrSdOur6VUiKiPPOOMCgDW8H2M73DzSlpUC55GMGu00i1BlaVELEds4qfTNLttL0/7PFO0k7jc2BVtpHixkJxwNvX8aALsFwFXy1Mke4cjrVm2IgTeY854IPFZkMoMgyw3dcnpWgtw0W0s0bpjoDnn6UASXLZXdAfLDdPasDXZmOmzrPK7OFOCBWpLceYSxbJJztA/QVi+IDI2lTugAJGOTQAfCLxDKNX/sdQrQupkLE8g17JXhfwgtv+KwMqQHCREFweFNe5qu0YFAC01d+5t2NvbHX8aXv04pQc0AMO4OMEbMcjHOaeKKKAKOuabBq2lXNjdoHimQqQRnHHWvgTx1qF5oeo6joUqk28crKufrX6E18qftXeAvIkTxFZL+6lbEwUdG9aAPnLVro/2fbwL0PzVi1d1JHUx5zt28GqVAH1T+w118bf8Abj/7cV9U18rfsM/8zt/24/8AtxX1TQB4J+2d/wAkw0r/ALDMf/pPcV8c2Nwba4WQcjOGX1FfY37Z3/JMdK/7DMf/AKT3FfGPXpyKANbUbdUImgBMMnKn+lU4vvHPQ1Pp1wCptpyPKf7p/untUNxFJBKUYcg0AdD4cvo1zZ3ZIjbgHNQ6xpawysYGG3tk1jIcrnd8w9K6LSb+K4g+z3CKXAwGJ5NAFXw/qk2l3gyGaLoy19AeAvFiQrF5k3mwHAA9PavB7m0ARzFGDn+H+tN0LV5dKnwxLws2GX0oA+3tL1G2vbQNbMpJ/u81eBDIQYyG7EnFeA+E/E8y2qXFhOpUjJj3Yr1Dw94lttUtxuAWccOCSMGgDqXjjbbnc23rg4pjOLd/lVY1PYnLGoAzNCCfu9gGzUikFuN2cYGR0oAntyTKS4b1BxT5ZGkAO7bjqSetRMMkK7lGxj5TQVVGGZcDt3NAE8ih413tuHoB/WqNwi5J9OgyasSu5QqjMijniqEzrH9+TD56uOaAGtlVyZQIwegqG61O3soGkkYBQM4DVz/iPxPYaYjfaJQ8ns3P5V5VqOv33ibUvIjeSDTi3ORjIoA9I0XXbjUNYmvLNX2nMaBTyw7n6Vxus+MLlPGkFtp3miQTBXGTgnOKpeIfEH9g6d5Wlt86pt3jjH0rzzw7rl8usx3oHmukgkweehoA+8dLW4SxhF4ytPtG4qKzvF+iHXNJa3R9kynch7E+lVPA3jPS/Femxy2NwhuQo82An5kPfj0rpzQB886javY3H2a5HlzKdp3cH61q+DfCja9qRn37bOBhvbuT/dFdR8YfDsmr2dq2l28r6q0gVXjXjb6sfauw8I6P/Yfh+0sm2GaNR5jL0Zu5oA14o1jiSNBhFUKB7Vwnxe1nVdC0CK90eUI6ybWXHWu9zgc1wnxhtBfeEpkUsWjbdtXvx3oAT4d+J7TxNoaXESwtqCptuoCfm98eoryP4qfDZrya6uLW1k+wElgwUgwn6elc3oGgalpl9FqOnX8tld9Qd2B9K9x0Lx68diI/EVuGnA2maFcq/wBRQB8VeIvDt5o1wVlBaM8q4HBFbHwzeL+2I4pPlYt1PWvWfiGttcanJJY2vn2chy0ZA49xXDweFLWWfzdMuvs0+c+TN8vP1oA+odDRo7OJUQFQv3ttai7MDzCMnqBxmvMvAevXlhbpZ68jhVXCyg8H8a9Et7yCcL5MhZCo5BDUAaIm8tQMgxn+92pE8knMgI5428YquTxuQle/PQ06WULHtknUNjtxg0AWmZAvzB/bIyaikcrGW4Ck+2aytQ1mKzgO6QmQDopyTVKxsNf8SAF1WwsD0d/vsPpQBS8U+MLfSF+z2mbvUHOFiTmuD8ReEPEWv2jaz4jRorbGUgzjHpxXtul+HNB8KW0t9MIhIo3SXc+M/r0rxL4x/FO51dH03w5HizB5nbhpD7e1AHD6le2fhyzKpg3A5Eadq85fUJNW1RZr2Tauc4NWLuOdSZtSmwTzg8k1kalf28kYSAZI/iIxQBr6rqkVhCYbEnzH+82a5SSRpnLu2SeT71GdzNknJ9c0rcIcUANckcDt1OauaTB51wXcgRoNzZ9qzwCdo43VqXY+w6WtueJ5/mb/AGV9KAPq/wCJf/Jm1n/2BtJ/9Dt6+LB1r7T+Jf8AyZtZ/wDYG0n/ANDt6+LKALEsasm6JgSByKu+FdZn8PeIbHVLUkS20of6juKqWLoGZXHUcVWcYcj3oA/R7wprNp4x8IQ3VrIrw3UQyQfunHI/CuBtVGn3t3ZXJLvE+AG5yO1eAfAP4qv4Kvv7N1N2bSJ3znP+qb1r1Px34ssx4tiubaRWguo1dWU8MKAO+aVZmUHCqf7nWpC+VZI8hOBhhWNpOtR3FpHJbKrKB19K2oriGdR0B9SMUAT+U3llGfPH8JrNuI2VTlmAORlq113bWCICjdxzVS8UtH5e45U9MdaAPN/E1vJM+WYFUPOBzWVa6bCZAXjbb1BFeotZxSlh5SqRyTjOaatgkS/KkeGPOT/SgDlNI0KS6IIJCDoCOK6mz06Oz2/LH/wHirdqMviAhe3zDAq/aqVcmaNWQdHxwaAEs1zMZBhQy/jj0FNZmUSKikO3bGasxyxzO4jjRQnWpZJYGZQqrg8cHOKAMpiEYZJfjBwMc1ZtmKRFCm7+IHHIplzNaoxAk+bkc+tVo7t0VtsilsZBUdqANKG4xgGPr3x0NZXie5jNg8UUaySnk+1TRX7bdxfb7Yq/4cnt7vWnWaCMrGhZ+MmgDm/gJLM+t60ZeIhgDJ6Gvbq4bw3olpZa5eXOkhVtrrDkZ798V20KhFOARn1OaAH0nAOAKHdURmchVAySe1eP+Oviw9jfPZ6CiSMhw0rcjNAHsNFfNdn8VPEtnfC4upkmhY8wsOPwr2zwX4ysPE9qpgby7nbl4j2PtQB1Brjfit4bm8V+FH0u3A8yWReT0A9a7Kkc7UZvQZoA+J/i78Kz4M0dEe4WcSKXVguNrDqK8GPFff8A8UbG38a+Er2yaMC8t8yRg9Tj0r4W8Q6TNpl0wdTsJIBx0PpQB9J/sM/8zt/24/8AtxX1TXyt+wz/AMzt/wBuP/txX1TQB4J+2d/yTDSf+wzH/wCk9xXxl0PQV9mftn/8kw0r/sMx/wDpPcV8Zke1ACqa1YHXUIPLlP8ApKD5Sf4x6VkDOR2p8bNG4ZWww5zQBMfkfaw9iKXOxsr19fSrrIL2Dz4xmVf9Yo/nVI5XAODQBt6VqgSRVnwc8bvWumfTbe/t9yRxxyY4K9689ORyM1f07VprN+HY45xmgDodPOq6Ne5t2+Xrs9a9/wDg3470OWU6f4htUiuJiFWaRcDPv7e9eGWOv217Gq3DLFJ3J5rScJOECFSRyCG6/jQB9oS+GbKTEtjI9sWGcxncpH41m32j6tbqTAsdyg7K21j+dfPfhL4k+JvCRjiQpfaaOsErZIHs3avevB3xR0DxHAm+f7BdHgwzkDn2PegDntS1a8sAxudI1BCDjIhJ/UVkJ41m3fu9K1B+3MLf4V7lHIkqBo3V0I4KnINZOueItK0NFOoXCIW6Ioyx/CgDxm8+IFzG7Ium3HmYwPMUrWHe+ItZ1TKvi3U8Dby1eq67400W+gaOyFtMzLy8ijI+leXXGlQTXEtwZH8w8rsONooAxYfD5luvMuElc5yWetaS0is7YCNI1CjORzVfRbTU4r99959osSeFYc1vTFkiJ2RZ/hXvQB5t4htLy9tpkRF2Nzkjiua0W1uLSJ54Y0cx8MNvNewXFlHe2ey6hIJ67ai0XS4bLzGuIkMS/dXb1FAHHaLb6pbKmq6HM1tcodzGMbT+Ve0fDn4tLfyQ6Z4oQW98SES4/hkPv6GsGK6s4mKwQpiTjJOMVwPjrTomvJPs8qrdR/MFQ9aAPrxcEe1Y/i3xDZ+F9Fm1K/J8tPuoOrt2ArkvgZ4pm8S+DVF8c3ti3kSHOdwA+U/lXn3x/u73UvFtrpJLrYW0QlKjozHuaAMXVPHGt+KtZjuTJPbW0bbo7eJ9oA9/U113i/xfCfCSyGSQ3suIhagEkHuxNcZ4QlsLSOVpLmDcgwEbua0oZRfwSyLGeWK9OPwoAl0pZJoIdzJINgOO4NXJlkk3Iy8ehNVdP06O0T5ZZC5OeTwKuTSgBgSDjoQKAM2bTrd8O8Y3A9SeaoajBpMMbySHySo5Z0/rWt58VyoZTwpwTiqXie0+26XLEN5jYcYAoAxbaeW4/wCQdcrcRcfJncBVu1vdVs5gI5MMTgRDK7qXw7YppmmRJbxMGAyCBznvmqN14omTVzBNCo8o8T45FAHb6HeeL9Ul8nT7KQ7eryZVF+pNdjZeDPEl64bV9UtoI+6QJvb8zXK+FfibcaXA8V6huLZMsXbhqvah8aZJov8AiR6OZD0LzOcL+AFAHpGjeE9M0xxMI2uLgf8ALWY7iD7DoKi8T+NNG8PRN9puUkuBwIIzliff0rw3X/iR4guo2+33kVtERzHCdnH8zXkniLxpasZBbBp58/6xjx/9egD0D4o+Op/ELk3tx5VmpylsrcD6jua8kvfFjwgpZqpI4DOM4rmr6+lvJS0jH6elU84OKALN3ezXUpedixP5VXJPtSYBA7U4R8ZY8UAKnyk5HXsaazjPA49MUM5fjHSrGmWhu7kAnbGvLN6CgC1aW8dtb/bboY7ImPvGsy4needpZWy7HnNWNXu/tdx8vEMY2Rr7CqP44oA+x/iX/wAmbWf/AGBtJ/8AQ7eviyvtP4l/8mbWf/YG0n/0O3r4soAAcHI61LKwkUNgBhwaip0b7GzgGgBtbljr1z9mitLiQtHGf3bE8p7fSsRsZ46UlAH0B8O/FYi2xzsM8ZX1969s0q9a4jQrFGAwznOeK+MPD+sNZzKHOCPutXtvgXxw8XlpNkqeCSelAHu6zE/KgAJPO2o7gOJF35PcAjOaxrPU4LuNZI5s5/uc5rRF0ByA5kAwM0ASl5mLrHFuTvxiokhUjErDzDwNvWke4VCHJkZ+pCelRtIGkbygqqOST96gCW3jJmXy2Y4ODn0rQvZIxboWTgngdzVCOSKBw8hZSRyeuKUSqV3gKSTj5s9PWgCzDOBbFY1MbHOSvNU7gOsQzt3A5HqaspJtibnavTKjrWZc3CbsREsexI6UAVrr7+5wCCecDkUi3EhwFCoqH+LrUU10qlwHBkPGAM81h6trBtEaSQiPA+tAG1qOpLbW000sioCM+hrm/C3jSSA6gwYBbg7Q564rzXxJ4wbW777HZOXG7Due30qVdZsNBsZTdRiUiPbGvfd60AdVF8Tb3R/EUMMNzugMnQGvqLwvqUmq6RDdSxPGzjPzDGfevzt0i+trjxJFc3LMF80Mcngc1+iXhWe2uPD9hJYsGtzCuwjnjFAFnWrWS90q6t4X2SSRlVb0NfLPiDRLrTNQuYb+Ly5Q3J/ve9fWYrk/iD4Ui8S6VIIgqXyL+7k7n2NAHy28TsvGPQHqa9v+CfhK7tCNWvg0aMv7lT1bPcivMPAmh3GrePl0a9DhLdy0xAyBjtX1bDEkMSRxjCIAoA7CgBzDIwa8r+N/i7WfClrazaZs8pyQwxnPsa9Vrx39pCCebw1C8e3yo2+Y55BoAk8B+JLfxHosWpWcaSXi8TxA/Mp78eleSfGLwYl/qFxeaXbM8UnzTQqOY29QK808Nal4i0HVhf6LdOnzfdHRh719GeCviVZ63EkfiK2XT74DmdV+Rh70Ac7+xnpzaZe+NoHOcrYsPYZuB/SvpqvLvhgunD4heL5NJEXkS2GnOxi+6W8y8yfyAr1GgDwT9s7n4YaV/wBhmP8A9J7ivjHBHXmvs79s4Z+GOlDOP+JzH/6T3FfGWCOtAB+QooxR+P4UATW1w9vIHjPzd/er1zEksZuLdflPLDP3TWZ3681PZXLW0u5fmQ8Mp6MKAEBOcN/OnkDHA/GtGe0juIPtFiQVHLJ3Ws4K3sKAGcgHHWrdlez2zgxyHjtVcbQcMBTthONpUA0Adro3iK2dfKvl+Yjrniun0+O1klR7VSQf4lP9K8icEEd/etHTNXvNOkVoJSoHbPFAH0NaeIr/AEq0EcLSrCF52sRj8KyLu+fWrl5oLmSZ+6k9DXGaF4/TaI9RiByMbq1Le7tJLky2EoG/kgHGaANa0tfstwJLmR3kz0U10iagYrdVEwabHG6svTDDK4ZQWmxnDdPzqa62Icz/ACOeQVANAGzp16DGGlQ7s89AKtyXsaj5FCkdNx5rhNQvZLeMskkhGfuniqh15pYgAj78YJNAHfNfws672JKnkE9RVk6jbFSSAIyOncV5Vdfbb1tyO6ccYNY9xHrKwymW+eMKDwWHNAHZ+K9We2dZ7Vv3CnkE4P5VyOh6/Bd6vI9wHMjHgu2a4a7uLp3f7RcSOuectmktpUikV/m454PWgD7g+Beg/wBleHbi+Zdn9oyeai5/hHANYv7QtrFDa2d+gxM4aJyvBK9eteT+Df2gdR8O6HFp0umxXkMK7YmdypUenvXBeP8A4ka54z1Q3N9P5EIBCQRn5FHpQA7T9XtpNbWJU8tG43OcjPrXqWj6nFHGIs4CnAIPFfPD3km/Jxx7VqWHiW9tmVRISg/hzQB9EtqcaBVDfN2JHWoWme62+XIVjz94968WPjSQ/K29R14arI8ebIx5ZkLjjk8UAezReRarkEZH8XXn6UtxclVGRlf4twxxXiCeI7u7uBI9+sSg5wWrqovG1hFFH9tuzcMvZVzQB1ks8kqzMryR244Vscg1kvaRFBchiNpz84+8R61zuo/Eu12MtrbyP6bjgVyWo+Nr67YhUSNT2BoA9IuL8XSf6QVghXqE43Vz2seOLXT0e30xSGAwG4rzm61S8uPllmdl9M4qkSxyHz/hQBoarrF3qczPcSu2e2eKzcNjPWn+WQuWNN3AfdJGKAEAJGSOaXyxk7vSjcSfvDNNwWOQenQigBScAhcH603Jcd+vIpzKOMtk9+KcsLSsqxgkk4GKAI0jaRwqjJ6DFaupFdPsVskI89xulYfyqysKaHbia5Ie9kH7uL+57muelkaV2eRss3JPvQBH6cUc96UnmjGelAH2N8S/+TNrP/sDaT/6Hb18WV9p/Ev/AJM2s/8AsDaT/wCh29fFlABRRRQAoPGO1JRRQAdK3NB1c20ojuHPln+L0rKhYNlWVSDSTQMhJXlfWgD2Hw94ju7GSOazkeSM9VBr2PRNekvbSOS5EsIYZyV4/OvkrRdWudMuFkjLMgOdtfXnwS+JWg+I7OHTtSit7e/QbQJAArj8e9AG3bTLcxhrWUP7kYqYIdv7wKFPBIrt7jwbpNy5mgQ28jd4m4/Kuf1PwXrEeW0+8huAOiy8cUAYskyxyKqAso4JxkUSXMeVCqrEnofWsDVdM8aWQfGhNMuePLcNXNlvG5kYQ+G7pcdCUoA9DmuAoTcRzxtz0rMvb5LUPMZFUAfdzwa4LUx47t4982lTx++3Jri9Xm1qRidUnlgGeQ/FAHZ+JfG1pY7inltI2fudQa8t1rWdW10skBeONzg96uJZRTAuHjLdNzHJNaNrY+QMEgn/AGKAMHR9Lm0rdIdjS4yWbmuZ8VtLK3mySBgTgAGvQNRt5ymER2zXJazo6pCz3DHHbA6GgDlNMiEtygZgBnqTivcfhZ8XNW8GyCzunS50gH7pbJUe1eT6VoM1zE4MThj9w4rrdB8NTNGLa8h3FuhA6UAfbXgzxtoni+zWfR7xJHxlom4dfwrop4lmiaNshWGDg4NfBUQ1LwfqX2vT7qaB4jnKHFfUvwQ+JkXjrTHgu3VdVtwA6dN4/vCgDt9B8L6XoL3EmnQFZrlt0srNlm/GtHU9QttMsJby+lWG3iG5nY9Ktk45PSvkH49fEOfxB4nm0fT7h/7NtX2EIcBmHUn1oA9Ok+OEN34mSz06xBsd2zz5G5+oHamfErXY7vw9dJIqvEo3GQn5c+leD+H9La6VnEgGwZyTjFafiC+1PVdEi0lrsrZRHO0DlsepoAgtTBLbx7B5eemBWm/7pAH2txj61haRcSIFhaFiI+NxHBFbmEfBQBSP71AHp/7MQYa94v3HP+j2GPpuuq9+rwb9mog+IfF+0YAtrAf+P3Ve80AeB/tnkD4YaUTjH9sx9f8Ar3nr4xDgdCPzr9SqKAPy4Eqn720/jQDGf4gD9a/UeigD8uDsHIZD/wACppYDjcp/Gv1JooA/LyzvHtJhJDIFI6jPB9jWyZrHUkLCWG1uccq7YRvx7V+lVFAH5gSmONyDJGfdXBFNEkefvpx6mv1BooA/METR9C6EfWl3wtz5sY9s1+ntFAH5gCSMZAeMf8CFSxXrIRsnC47h6/TqigD83NP8WX1iwMV3nHTLZrbT4k3zZFwLeQY74r9CKKAPzsu/Ga3IJeCEse5esd9dmLEpOqA84VulfpXRQB+aR165BGLs49n61HcaoZzlp8/WSv0xooA/MQzpk5kTBHrmk+0xqflZTn3r9PKKAPzFWaIA5kjyf9qnyyxgZE0TZ6fMDX6b0UAfmEJ4yMs6fTNAmi7Omf8Ae4r9PaKAPzAMqdnTPu1IZ14y0Z+hFfqBRQB+YKTrg/OmR6kUG4XPDp+dfp9RQB+X5mU/xoP+BUebGTkumfqK/UCigD8wFkiP35Fx9aebiLjayDHfNfp5RQB+YRmiYHLpnOfvUnmRY5kQ/wDAhX6fUUAfmGskWPvx/wDfQqxbWqT/AHbq0jHq86L/ADNfppRQB+cdvpGmR/vL7WrELjJWKUO36Gmza9p+nApocQMnT7RLyfwFfo9RQB+XtxcNcyvLPMrSMcli3JqPfH3K/ga/UaigD8u/NQDI2D8aaZQf4l/Ov1GooA8A+Jf/ACZtZ/8AYG0n/wBDt6+K6/VOigD8rKK/VOigD8rKK/VOigD8rc1NFOU4blfSv1MooA/LhJE3bsjHpnFWLS7MF0s0LiNweCGxX6f0UAfEnw9/aA13w3JDa6syahpy8YLZdR7Gvovwt8a/BOs2iO+t2GnSHlo724SMj8ScV6hRQBya/EfwPyB4y8Ode+qQf/FVBe/FDwNa2zyyeLNBkC87IdQikY/QBs12dFAHjGqfHTwlLbv/AGfqFn5xOAZpVAx69a8U8aeJ9J16/Ms2rWLqTk7Zkx/OvtKigD8/tYfRrhQsGo2sTHo6Trx+tXdCv7GxtfLk1iyd+zNcL/jX3pRQB8LXms6c0YVNXs2bv+/XH86il1LSZrfbJf6ex9DOn+Nfd1FAHwbp17pNpI0o1SzyOVH2lOP1rQHi2xQEpf2aOc8iZf8AGvuKigD4M8ReItKmsoZPtkM0rcOquCfqcVl+AfE8fhbx3p2pWd6iW5kAlHmADaeua/QeigDg9W+I/g+bQrv7N4w8PCd4G2L/AGnDuDEdPvda+K7y6sYXup5L21ndpGbCShixz7Gv0QooA/PvT/GNlHYeQAqOc5bcBWjp+t2Ulti41O0Vj2Mqgj9a+86KAPh2DXtLiUIupWO3vmdOf1p82v6USoXUrAYGcidT/Wvt+igD58/Zau4LzW/GMlrPHOggsF3RsCM7rrjj619B0UUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan of the upper abdomen (A) shows a grade V complex liver laceration of the right lobe of the liver. The contrast difference between normal and injured tissue is better seen in the magnified, narrowed window (B). The &nbsp;linear and extensive nature of this pattern, which involves segments IV, V, and VI, is described as a 'bear claw injury.'",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_403=[""].join("\n");
var outline_f0_25_403=null;
var title_f0_25_404="Zollinger Ellison syndrome";
var content_f0_25_404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zollinger Ellison syndrome: Appearance of gastric ulcers on upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper GI series performed in a patient with intractable epigastric pain demonstrates three different-sized ulcers (arrows) in the wall of the stomach. The patient had a high fasting serum gastrin concentration consistent with Zollinger Ellison syndrome and a small duodenal wall gastrinoma was identified at surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_404=[""].join("\n");
var outline_f0_25_404=null;
var title_f0_25_405="Amyl nitrite: Pediatric drug information";
var content_f0_25_405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amyl nitrite: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"    see \"Amyl nitrite: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42867?source=see_link\">",
"    see \"Amyl nitrite: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cyanide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator, Coronary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"      see \"Amyl nitrite: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15-30 seconds; repeat every minute until sodium nitrite can be administered.",
"     <b>",
"      Note:",
"     </b>",
"     Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes. Amyl nitrite is a temporary intervention that should only be used until I.V. sodium nitrite infusion is ready for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     Inhalation: 0.3 mL ampul crushed into a gauze pad and placed in front of the patient&rsquo;s mouth (or endotracheal tube if patient is intubated) to inhale over 15-30 seconds; repeat every minute until sodium nitrite can be administered.",
"     <b>",
"      Note:",
"     </b>",
"     Must separate administrations by at least 30 seconds to allow for adequate oxygenation; each ampul will last for ~3 minutes. Amyl nitrite is a temporary intervention that should only be used until I.V. sodium nitrite infusion is ready for administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Inhalation: 2-6 nasal inhalations from 1 crushed ampul; may repeat in 3-5 minutes",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, for inhalation: USP: 85% to 103% (0.3 mL) [crushable covered glass capsule]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer nasally via inhalation. The patient should be lying down during administration. Crush the ampul in a gauze pad and place in front of patient&rsquo;s mouth (or endotracheal tube if intubated) and allow patient to inhale for 15-30 seconds; repeat every minute until sodium nitrite can be administered. One ampul lasts for ~3 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F), protect from light; flammable, avoid exposure to heat or flame",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of angina pectoris (FDA approved in adults); has also been used as an adjunct treatment of cyanide poisoning",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Given the widespread use of newer nitrate compounds, the use of amyl nitrite for patients experiencing angina pectoris has fallen out of favor.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cerebral ischemia, facial flushing, hypotension, orthostatic hypotension, pallor, shock, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, intracranial pressure increased, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Fecal incontinence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia, methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitrates or any component; recent head trauma or cerebral hemorrhage; glaucoma; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with coronary artery disease and patients with hypotension; transient episodes of dizziness, weakness, syncope, and cerebral ischemia secondary to postural hypotension may occur. Use with caution in patients with increased intracranial pressure; use is contraindicated in patients with recent head trauma or cerebral hemorrhage. Use with extreme caution or avoid in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia; considered by some to be a contraindication (Reagan, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amyl nitrite may cause methemoglobin formation and severe hypotension resulting in diminished oxygen-carrying capacity; serious adverse effects may occur at doses less than twice the recommended therapeutic dose. Monitor for adequate perfusion and oxygenation; ensure patient is euvolemic. Use with caution in patients with pre-existing diminished oxygen or cardiovascular reserve (eg, smoke inhalation victims, anemia, substantial blood loss, and cardiac or respiratory compromise), in patients at greater risk for developing methemoglobinemia (eg, infants or patients with congenital methemoglobin reductase deficiency) and in patients who may be susceptible to injury from vasodilation; the use of hydroxocobalamin is recommended in these patients. Amyl nitrite may cause harm to the fetus if administered to a pregnant woman; may significantly decrease systemic blood pressure and blood flow.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the risk for serious adverse effects, use with caution in patients in whom the diagnosis of cyanide poisoning is uncertain; however, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate. Monitor patients for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return. Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fire victims may present with both cyanide and carbon monoxide poisoning. Carbon monoxide poisoning leads to carboxyhemoglobinemia which decreases the oxygen-carrying capacity; use of amyl nitrite which induces methemoglobinemia may worsen oxygen-carrying capacity. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Due to the slow onset of action of sodium thiosulfate, may consider using hydroxocobalamin alone or in combination with sodium thiosulfate (Howland, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Amyl Nitrite.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13315273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Because amyl nitrate significantly decreases systemic blood pressure and therefore blood flow to the fetus, use is contraindicated in pregnancy (per manufacturer). In addition, fetal hemoglobin may be more susceptible methemoglobin conversion (Valenzuela, 1986).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and heart rate during therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide poisoning: Monitor for at least 24-48 hours after administration; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15589398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms associated with blood cyanide levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flushing and tachycardia: 0.5-1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obtundation: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coma and respiratory depression: &gt;2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Death: &gt;3 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angina pectoris: Vasodilator (vascular smooth muscle relaxant) which decreases afterload and improves myocardial blood supply via coronary artery vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide poisoning: Promotes formation of methemoglobin which competes with cytochrome oxidase for the cyanide ion. Cyanide combines with methemoglobin to form cyanomethemoglobin, thereby freeing the cytochrome oxidase and allowing aerobic metabolism to continue.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Angina: Within 30 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Angina: 3-5 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Inhalation: Readily absorbed through respiratory tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to form inorganic nitrates (less potent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amyl nitrite: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methemoglobin: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal; ~33%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42867?source=see_link\">",
"      see \"Amyl nitrite: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remain seated or lying down during administration because of possible hypotension and dizziness; do not get up suddenly after use; avoid alcohol; if angina pain is not relieved after 2 doses, seek immediate medical attention",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), \"Medical Management Guidelines for Hydrogen Cyanide (HCN),\" 2001. Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM Jr, \"The Treatment of Cyanide Poisoning in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, \"Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, \"Cyanide Poisoning and Its Treatment,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin for the Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/19650716/pubmed\" id=\"19650716\" target=\"_blank\">",
"        19650716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavon O and Bentur Y, \"Does Amyl Nitrite Have a Role in the Management of Pre-Hospital Mass Casualty Cyanide Poisoning?\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2010, 48(6):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/20653465/pubmed\" id=\"20653465\" target=\"_blank\">",
"        20653465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichol LM, Mills NL, and Starkey IR, \"Amyl Nitrite Induced Cerebral and Coronary Vasospasm,\"",
"      <i>",
"       QJM",
"      </i>",
"      , 2011, 104(1):83-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/20843773/pubmed\" id=\"20843773\" target=\"_blank\">",
"        20843773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reagan BW, Helmcke F, and Kerut EK, \"Commonly Used Respiratory and Pharmacologic Interventions in the Echocardiography Laboratory,\"",
"      <i>",
"       Echocardiography",
"      </i>",
"      , 2005, 22(5):455-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/15901303/pubmed\" id=\"15901303\" target=\"_blank\">",
"        15901303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valenzuela A, Guerra R, Lazcano L, et al, &ldquo;Differential Prooxidative Effect of Adult and Fetal Hemoglobin,\"",
"      <i>",
"       FEBS Lett",
"      </i>",
"      , 1986, 196(2):353-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/25/405/abstract-text/2419158/pubmed\" id=\"2419158\" target=\"_blank\">",
"        2419158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12728 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_405=[""].join("\n");
var outline_f0_25_405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051097\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051089\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135335\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051100\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051092\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051099\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135369\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051104\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051088\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051087\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298751\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315273\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051096\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589398\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051086\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051102\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051103\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051094\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=related_link\">",
"      Amyl nitrite: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42867?source=related_link\">",
"      Amyl nitrite: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_25_406="Subarachnoid hemorrhage grading scales";
var content_f0_25_406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subarachnoid hemorrhage grading scales",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/406/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/406/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/406/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/406/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/406/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/406/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/406/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/406/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/25/406/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) is often a devastating event. The appropriate therapy for SAH depends in part upon the severity of hemorrhage. Level of consciousness on admission, patient age, and the amount of blood on initial head computed tomography (CT) scan are the most important prognostic factors for SAH at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of grading systems are used in practice to standardize the clinical classification of patients with SAH based upon the initial neurologic examination and the appearance of blood on the initial head CT. This topic will provide an overview of the more commonly used clinical and radiologic grading scales for SAH. Treatment and other aspects of SAH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDIVIDUAL GRADING SCALES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ideal SAH grading scale would provide the following capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guide management decisions that are influenced by the severity of SAH",
"     </li>",
"     <li>",
"      Provide prognosis for clinicians, patients, and family members",
"     </li>",
"     <li>",
"      Assist practitioners in their ability to compare individual patients and groups of similar patients regarding studies that examine the impact of new treatments",
"     </li>",
"     <li>",
"      Enable practitioners to detect and quantify changes in disease severity while following an individual patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While a number of SAH grading scales have been proposed, none meets all these requirements or is universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, there is a paucity of validation studies, and no prospective controlled comparison studies have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glasgow Coma Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Glasgow Coma Scale (GCS) (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ) was devised in the early 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/5\">",
"     5",
"    </a>",
"    ]. The GCS is not a true SAH grading scale, but is rather a standardized method for evaluating the level of consciousness in a number of neurologic conditions including SAH. The GCS assigns points based on three parameters of neurologic function:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eye opening (spontaneous = 4, response to verbal command = 3, response to pain = 2, no eye opening = 1)",
"     </li>",
"     <li>",
"      Best verbal response (oriented = 5, confused = 4, inappropriate words = 3, incomprehensible sounds = 2, no verbal response = 1)",
"     </li>",
"     <li>",
"      Best motor response (obeys commands = 6, localizing response to pain = 5, withdrawal response to pain = 4, flexion to pain = 3, extension to pain = 2, no motor response = 1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective series of 765 patients with SAH, a higher GCS correlated with better outcome after aneurysm surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a significant difference in outcome was observed only between patients with GCS scores of 15 and 14, while no significant differences were found between the remaining adjacent GCS scores.",
"   </p>",
"   <p>",
"    The interobserver variability of the GCS for patients with SAH is moderate (kappa 0.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The GCS has been incorporated into several additional SAH grading systems. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'World Federation of Neurological Surgeons'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Ogilvy and Carter'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It should be recognized that sedating medications and intubation can confound interpretation of the clinical SAH scales, particularly the GCS and those that incorporate it, since such interventions will reduce the level of consciousness and impair verbal responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hunt and Hess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The grading system proposed by Hunt and Hess in 1968 (",
"    <a class=\"graphic graphic_table graphicRef69179 \" href=\"UTD.htm?8/57/9115\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/8\">",
"     8",
"    </a>",
"    ] is one of the most widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/9\">",
"     9",
"    </a>",
"    ]. The scale was intended as an index of surgical risk. The initial clinical grade correlates with the severity of hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1: Asymptomatic or mild headache and slight nuchal rigidity",
"     </li>",
"     <li>",
"      Grade 2: Moderate to severe headache, stiff neck, no neurologic deficit except cranial nerve palsy",
"     </li>",
"     <li>",
"      Grade 3: Drowsy or confused, mild focal neurologic deficit",
"     </li>",
"     <li>",
"      Grade 4: Stupor, moderate or severe hemiparesis",
"     </li>",
"     <li>",
"      Grade 5: Deep coma, decerebrate posturing",
"     </li>",
"     <li>",
"      The grade is advanced one level for the presence of serious systemic disease (hypertension, diabetes, severe arteriosclerosis, chronic pulmonary disease) or vasospasm on angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent modification proposed by Hunt and Kosnik added a Grade 0 for unruptured aneurysms and a Grade 1a for a fixed neurologic deficit without other signs of SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the Hunt and Hess scale is easy to administer, the classifications are arbitrary, some of the terms are vague (eg, drowsy, stupor, and deep coma) and some patients may present with initial features that defy placement within a single grade [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, a rare presentation of SAH may include severe headache (ie, Grade 2), normal level of consciousness, and severe hemiparesis (ie, Grade 4). In such cases, the clinician must subjectively decide which of the presenting features is most important for determining the grade.",
"   </p>",
"   <p>",
"    A systematic review of SAH grading scales found conflicting data regarding the utility of the Hunt and Hess scale for prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]. In a study assessing a series of 185 patients with SAH, the Hunt and Hess score correlated more strongly with outcome at six months than the GCS or World Federation of Neurological Surgeons Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/11\">",
"     11",
"    </a>",
"    ]. However, individual grades for all three scales demonstrated suboptimal sensitivity, specificity, and predictive value. In addition, nearly half of the patients with poor scale grades on admission had a good outcome.",
"   </p>",
"   <p>",
"    Furthermore, it is unclear if there are significant differences in outcome for adjacent Hunt and Hess grades.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies evaluating Hunt and Hess grades found significant differences in outcome for some adjacent grades and not others [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/7,12\">",
"       7,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A study of 230 patients with SAH found a significant difference in outcome for compressed but not adjacent Hunt and Hess grades; patients with grades 1 to 3 had better outcomes compared with those with grades 4 and 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Another study of 405 patients with SAH found no significant difference for the risk of poor outcome or death between patients with Hunt and Hess grades 0 to 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"       2",
"      </a>",
"      ]. Furthermore, the risk was significantly different only when comparing patients with Hunt and Hess grade 3 to those with grade 0.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interobserver variability for the Hunt and Hess scale is moderate (kappa 0.41 to 0.48) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/7,14,15\">",
"     7,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     World Federation of Neurological Surgeons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The grading system of the World Federation of Neurological Surgeons (WFNS) (",
"    <a class=\"graphic graphic_table graphicRef65468 \" href=\"UTD.htm?13/56/14219\">",
"     table 3",
"    </a>",
"    ) was proposed in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/16\">",
"     16",
"    </a>",
"    ]. It is based on the Glasgow Coma Scale (GCS) score (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Glasgow Coma Scale'",
"    </a>",
"    above) and the presence of motor deficits.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1: GCS score 15, no motor deficit",
"     </li>",
"     <li>",
"      Grade 2: GCS score 13 to 14, no motor deficit",
"     </li>",
"     <li>",
"      Grade 3: GCS score 13 to 14, with motor deficit",
"     </li>",
"     <li>",
"      Grade 4: GCS score 7 to 12, with or without motor deficit",
"     </li>",
"     <li>",
"      Grade 5: GCS score 3 to 6, with or without motor deficit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike the Hunt and Hess scale, the WFNS scale uses objective terminology to assign grades [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is also more complex to administer than the Hunt and Hess scale.",
"   </p>",
"   <p>",
"    A systematic review of SAH grading scales found conflicting data regarding the prognostic power of the WFNS grades [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]; two studies showed a stepwise increase in the likelihood of poor outcome with increasing WFNS grade [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/7,17\">",
"     7,17",
"    </a>",
"    ], while others did not find consistent significant differences in outcome between adjacent WFNS grades [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/6,12,18\">",
"     6,12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study involving prospective evaluation of 15 patients with SAH found that interobserver variability for the WFNS scale was fair (kappa 0.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/7\">",
"     7",
"    </a>",
"    ], however another study in 50 patients with SAH reported a kappa of 0.6 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fisher",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fisher scale (",
"    <a class=\"graphic graphic_table graphicRef81122 \" href=\"UTD.htm?8/36/8779\">",
"     table 4",
"    </a>",
"    ) was devised in 1980 as an index of vasospasm risk (but not clinical outcome) based upon the hemorrhage pattern seen on initial head CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group 1: No blood detected",
"     </li>",
"     <li>",
"      Group 2: Diffuse deposition or thin layer with all vertical layers of blood (in interhemispheric fissure, insular cistern, or ambient cistern) less than 1 mm thick",
"     </li>",
"     <li>",
"      Group 3: Localized clots",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertical layers of blood 1 mm or more in thickness",
"     </li>",
"     <li>",
"      Group 4: Intracerebral or intraventricular clots with diffuse or no subarachnoid blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Fisher scale was validated in a small prospective series of 41 patients with SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/20\">",
"     20",
"    </a>",
"    ]. The interobserver variability for the Fisher scale indicates excellent agreement between observers (kappa 0.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Fisher scale has also been incorporated into other SAH grading systems (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Ogilvy and Carter'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Claassen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the Fisher scale, the Claassen grading system (",
"    <a class=\"graphic graphic_table graphicRef57558 \" href=\"UTD.htm?12/19/12603\">",
"     table 5",
"    </a>",
"    ) proposed in 2001 is an index of the risk of delayed cerebral ischemia due to vasospasm after SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/21\">",
"     21",
"    </a>",
"    ]. It does not address clinical outcome. Unlike the Fisher scale, the Claassen scale takes into account the separate and additive risk of SAH and intraventricular hemorrhage (IVH).",
"   </p>",
"   <p>",
"    Ten cisterns or fissures are evaluated for blood with the Claassen scale. These include the frontal interhemispheric fissure, the quadrigeminal cistern, the bilateral suprasellar and ambient cisterns, and the bilateral basal sylvian and lateral sylvian fissures. The scale is graded as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0: No SAH or IVH",
"     </li>",
"     <li>",
"      Grade 1: Minimal SAH and no IVH",
"     </li>",
"     <li>",
"      Grade 2: Minimal SAH with bilateral IVH",
"     </li>",
"     <li>",
"      Grade 3: Thick SAH (completely filling one or more cistern or fissure) without bilateral IVH",
"     </li>",
"     <li>",
"      Grade 4: Thick SAH (completely filling one or more cistern or fissure) with bilateral IVH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Claassen scale was derived from analysis of data from 276 patients with SAH who had a head CT scan within 72 hours of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/21\">",
"     21",
"    </a>",
"    ]. The best predictors of delayed cerebral ischemia due to vasospasm were thick SAH completely filling any cistern or fissure (odds ratio [OR] 2.3, 95% CI 1.5-9.5) and bilateral IVH (OR 4.1, 95% CI 1.7-9.8 ).",
"   </p>",
"   <p>",
"    This scale awaits prospective validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ogilvy and Carter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A SAH classification system proposed by Ogilvy and Carter (",
"    <a class=\"graphic graphic_table graphicRef70705 \" href=\"UTD.htm?29/55/30587\">",
"     table 6",
"    </a>",
"    ) in 1998 stratifies patients based upon age, Hunt and Hess grade (clinical condition), Fisher grade (SAH volume and vasospasm risk), and aneurysm size [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Hunt and Hess'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Fisher'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One point is given for each of the following variables:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 50",
"     </li>",
"     <li>",
"      Hunt and Hess grade 4 to 5 (in coma)",
"     </li>",
"     <li>",
"      Fisher grade score 3 to 4",
"     </li>",
"     <li>",
"      Aneurysm size &gt;10 mm",
"     </li>",
"     <li>",
"      An additional point is added for a giant posterior circulation aneurysm (&ge;25 mm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total score ranges from 0 to 5, corresponding to grades 0 to 5.",
"   </p>",
"   <p>",
"    The Ogilvy and Carter scale mitigates the potential subjectivity inherent in the Hunt and Hess system by compressing it into two grades (coma or no coma). Similarly, it compresses the Fisher scale into two grades. Nonetheless, it is more complex to administer than the Hunt and Hess scale, and requires knowledge of aneurysm size.",
"   </p>",
"   <p>",
"    In a prospective evaluation of this system in 72 patients with SAH, the authors reported good to excellent outcomes in greater than 78 percent of patients with grades 0 to 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"     2",
"    </a>",
"    ]. In comparison, good outcomes were seen in 67 percent of grade 3 and 25 percent of grade 4 patients. Of note, there was no statistical difference in outcomes between grades 0 and 1. However, patients with grades 2, 3, and 4 had statistically worse outcomes compared with those in the adjacent lower grade. Only surgically treated patients were included in the study, and none with grade 5 had surgery.",
"   </p>",
"   <p>",
"    The interobserver variability for the Ogilvy and Carter scale is very good, reflecting substantial observer agreement (kappa 0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a number of subarachnoid hemorrhage (SAH) grading scales have been proposed, there are few validation studies of these scales and no prospective controlled comparison studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, the available data concerning SAH grading scales are limited and often conflicting. As a result, none of the existing scales is universally accepted or clearly established. Thus, the use of any particular SAH grading scale is largely a matter of individual or institutional preference. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Individual grading scales'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Glasgow Coma Scale (GCS) (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ) is not a true SAH grading scale but is rather a standardized scale for evaluating the level of consciousness. However, it is widely known and has some utility for predicting outcome after SAH. Sedating medications and intubation can confound interpretation of the GCS. It has moderately good interobserver variability. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glasgow Coma Scale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Hunt and Hess grading scale (",
"      <a class=\"graphic graphic_table graphicRef69179 \" href=\"UTD.htm?8/57/9115\">",
"       table 2",
"      </a>",
"      ) is one of the most widely used, and is easy to administer, but the terminology is subjective and atypical presentations of SAH may be difficult to classify. Data regarding its utility for prognosis are conflicting. The interobserver variability for the Hunt and Hess scale is moderately good. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hunt and Hess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Federation of Neurological Surgeons (WFNS) grading scale (",
"      <a class=\"graphic graphic_table graphicRef65468 \" href=\"UTD.htm?13/56/14219\">",
"       table 3",
"      </a>",
"      ) is also widely used and uses objective terminology to assign grades. Like the Hunt and Hess scale, data regarding the prognostic power of the WFNS grades are conflicting. Interobserver variability for the WFNS scale is fair. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'World Federation of Neurological Surgeons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Fisher scale (",
"      <a class=\"graphic graphic_table graphicRef81122 \" href=\"UTD.htm?8/36/8779\">",
"       table 4",
"      </a>",
"      ) is an index of vasospasm risk (but not clinical outcome) based upon the hemorrhage pattern seen on initial head CT scan. It has been validated in a small prospective study and interobserver variability is excellent. The Claassen grading system (",
"      <a class=\"graphic graphic_table graphicRef57558 \" href=\"UTD.htm?12/19/12603\">",
"       table 5",
"      </a>",
"      ) is an index of the risk of delayed cerebral ischemia due to vasospasm after SAH. Unlike the Fisher scale, the Claassen scale takes into account the separate and additive risk of SAH and intraventricular hemorrhage (IVH). This Claassen scale awaits prospective validation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fisher'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Claassen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ogilvy and Carter scale (",
"      <a class=\"graphic graphic_table graphicRef70705 \" href=\"UTD.htm?29/55/30587\">",
"       table 6",
"      </a>",
"      ) incorporates a number of features that may impact on outcome, including age, Hunt and Hess grade (clinical condition), Fisher grade (SAH volume and vasospasm risk), and aneurysm size. The potential subjectivity inherent in the Hunt and Hess system is mitigated by compressing it into two grades (coma or no coma). However, it is more complex to administer than Hunt and Hess and has been applied only to patients who have had aneurysm surgery. In a single prospective study, patients with Ogilvy and Carter grades 2, 3, and 4 had statistically worse outcomes compared with those in the adjacent lower grade. Interobserver variability for the Ogilvy and Carter scale is very good, reflecting substantial observer agreement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ogilvy and Carter'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/1\">",
"      Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke 1988; 19:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/2\">",
"      Ogilvy CS, Carter BS. A proposed comprehensive grading system to predict outcome for surgical management of intracranial aneurysms. Neurosurgery 1998; 42:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/3\">",
"      Takagi K, Tamura A, Nakagomi T, et al. How should a subarachnoid hemorrhage grading scale be determined? A combinatorial approach based solely on the Glasgow Coma Scale. J Neurosurg 1999; 90:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/4\">",
"      Rosen DS, Macdonald RL. Subarachnoid hemorrhage grading scales: a systematic review. Neurocrit Care 2005; 2:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/5\">",
"      Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/6\">",
"      Gotoh O, Tamura A, Yasui N, et al. Glasgow Coma Scale in the prediction of outcome after early aneurysm surgery. Neurosurgery 1996; 39:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/7\">",
"      Oshiro EM, Walter KA, Piantadosi S, et al. A new subarachnoid hemorrhage grading system based on the Glasgow Coma Scale: a comparison with the Hunt and Hess and World Federation of Neurological Surgeons Scales in a clinical series. Neurosurgery 1997; 41:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/8\">",
"      Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968; 28:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/9\">",
"      van Gijn J, Bromberg JE, Lindsay KW, et al. Definition of initial grading, specific events, and overall outcome in patients with aneurysmal subarachnoid hemorrhage. A survey. Stroke 1994; 25:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/10\">",
"      Hunt WE, Kosnik EJ. Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 1974; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/11\">",
"      Aulmann C, Steudl WI, Feldmann U. [Validation of the prognostic accuracy of neurosurgical admission scales after rupture of cerebral aneurysms]. Zentralbl Neurochir 1998; 59:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/12\">",
"      Hirai S, Ono J, Yamaura A. Clinical grading and outcome after early surgery in aneurysmal subarachnoid hemorrhage. Neurosurgery 1996; 39:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/13\">",
"      Proust F, Hannequin D, Langlois O, et al. Causes of morbidity and mortality after ruptured aneurysm surgery in a series of 230 patients. The importance of control angiography. Stroke 1995; 26:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/14\">",
"      Lindsay KW, Teasdale GM, Knill-Jones RP. Observer variability in assessing the clinical features of subarachnoid hemorrhage. J Neurosurg 1983; 58:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/15\">",
"      Degen LA, Dorhout Mees SM, Algra A, Rinkel GJ. Interobserver variability of grading scales for aneurysmal subarachnoid hemorrhage. Stroke 2011; 42:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/16\">",
"      Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 1988; 68:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/17\">",
"      Rosen DS, Macdonald RL. Grading of subarachnoid hemorrhage: modification of the world World Federation of Neurosurgical Societies scale on the basis of data for a large series of patients. Neurosurgery 2004; 54:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/18\">",
"      Lagares A, G&oacute;mez PA, Lobato RD, et al. Prognostic factors on hospital admission after spontaneous subarachnoid haemorrhage. Acta Neurochir (Wien) 2001; 143:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/19\">",
"      Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/20\">",
"      Kistler JP, Crowell RM, Davis KR, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology 1983; 33:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/406/abstract/21\">",
"      Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke 2001; 32:2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1094 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_406=[""].join("\n");
var outline_f0_25_406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDIVIDUAL GRADING SCALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glasgow Coma Scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hunt and Hess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      World Federation of Neurological Surgeons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fisher",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Claassen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ogilvy and Carter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/57/9115\" title=\"table 2\">",
"      Hunt and Hess grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/56/14219\" title=\"table 3\">",
"      WFNS SAH grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/36/8779\" title=\"table 4\">",
"      Fisher SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/19/12603\" title=\"table 5\">",
"      Claassen SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/55/30587\" title=\"table 6\">",
"      Ogilvy Carter grading system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_25_407="Lung cancer extension CT";
var content_f0_25_407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74264%7EPULM%2F53251%7EPULM%2F65039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74264%7EPULM%2F53251%7EPULM%2F65039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic extension of lung carcinoma on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT sections through the lower chest and liver show an irregular low-attenuation lesion in the right hepatic lobe (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic extension of lung carcinoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T2-weighted section at the same level as the previous CT scan shows high T2-signal intensity in the right hepatic lobe (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic extension of lung carcinoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted section shows transdiaphragmatic extension of the lesion (long arrow). There is also a posterior pleural effusion (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_407=[""].join("\n");
var outline_f0_25_407=null;
var title_f0_25_408="Frontotemporal dementia: Treatment";
var content_f0_25_408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Frontotemporal dementia: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/408/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/408/contributors\">",
"     Bruce L Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/408/contributors\">",
"     Suzee E Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/408/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/408/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/25/408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9729241\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frontotemporal dementia (FTD) is a neuropathologically and clinically heterogeneous disorder characterized by focal degeneration of the frontal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporal lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/1\">",
"     1",
"    </a>",
"    ]. Age of onset is typically in the late 50s or early 60s. The primary initial clinical manifestations include changes in personality and social behavior or language, progressing over time to a more global dementia affecting cognitive domains as well. A subset of patients may also exhibit symptoms of extrapyramidal or motor neuron involvement at some point in the disease process.",
"   </p>",
"   <p>",
"    There are no currently FDA-approved disease modifying treatments for the treatment of frontotemporal dementia (FTD). Since the underlying pathology of FTD most often consists of abnormal tau or TDP-43 protein aggregates, treatments geared toward beta-amyloid reduction that appear promising in Alzheimer disease (AD) are not expected to be effective for FTD.",
"   </p>",
"   <p>",
"    Symptomatic relief can be provided by a variety of agents; these medications should be considered in conjunction with non-pharmacologic interventions, such as thoughtful evaluation of the patient's living environment.",
"   </p>",
"   <p>",
"    This topic discusses treatment issues specific to patients with FTD. Clinical features and diagnosis of FTD, and the management of other forms of dementia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=see_link\">",
"     \"Treatment and prevention of vascular dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729248\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment in FTD is symptomatic and aimed at alleviating neurobehavioral symptoms. However, despite the fact that they are commonly used, there is limited evidence of the efficacy of pharmacologic treatments in FTD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729255\">",
"    <span class=\"h2\">",
"     Neurotransmitter systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neurochemical basis for FTD remains to be fully elucidated. Nonetheless, studies have indicated problems in certain neurotransmitter systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities in serotonin activity have been demonstrated in autopsy, neuroimaging, and cerebrospinal fluid studies in patients with FTD [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. In addition, serotonergic dysfunction has been linked to many of the behavioral problems that are common in FTD; however, these associations have been made, for the most part, in nondemented patients rather than in FTD patient populations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/5-9\">",
"       5-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dopaminergic function can also be altered in patients with FTD, usually in proportion to the severity of extrapyramidal motor symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. However, one study found that increased activity of dopaminergic neurotransmission and altered serotonergic modulation of dopaminergic neurotransmission was specifically associated with agitated and aggressive behavior, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cholinergic system appears to be relatively preserved in FTD, in contrast to Alzheimer disease (AD) [3,4,7].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729262\">",
"    <span class=\"h2\">",
"     Behavioral changes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729270\">",
"    <span class=\"h3\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral symptoms can be quite varied ranging from apathy and inertia to agitation with aggression; there may be socially inappropriate behavior and compulsions that can manifest as hoarding or abnormal eating behaviors. These are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H4#H4\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Behavioral variant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While these symptoms are most prominent early on in the course in patients with the behavioral variant of FTD, neurobehavioral issues can be problematic in other subtypes of FTD as well, and contribute substantively to the care burden of patients with FTD. These can be quite challenging to treat [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When neurobehavioral problems appear or worsen, clinicians should consider the possibility of delirium, pain or discomfort as a cause for their symptoms before initiating treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with FTD are susceptible to adverse effects of medications including paradoxical behavioral reactions, extrapyramidal side effects, confusion, and sedation. Starting with the lowest available dose of medication, slow upward dose titration, and frequent monitoring for side effects are recommended.",
"   </p>",
"   <p>",
"    Because it is common to see medications make behaviors worse, slow movement and reaction times, and cause deterioration in cognition, it is reasonable to continuously reevaluate the role of the medications and consider tapering medications in patients with FTD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729311\">",
"    <span class=\"h3\">",
"     Serotonergic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting the use of serotonergic medications is stronger than for other classes of medications; however, this evidence comes mostly from uncontrolled observations rather than from controlled clinical trials.",
"   </p>",
"   <p>",
"    Serotonin selective reuptake inhibitors (SSRIs) (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ) have been reported to decrease disinhibition, anxiety, impulsivity, repetitive behaviors, and eating disorders in case reports and small observational studies of patients with FTD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/5,13-19\">",
"     5,13-19",
"    </a>",
"    ]. Individual patients with sexual disinhibition have been treated with SSRIs with success [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. In a case series of four patients, pathologic stealing behavior was not attenuated with SSRI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An unblinded, randomized trial of 16 patients compared the SSRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (up to 20 mg per day) and piracetam (up to 1200 mg per day). At 14 months, treatment with paroxetine was associated with significant improvement in behavioral symptoms and decreased caregiver stress compared with piracetam-treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, another double-blinded randomized, cross-over trial in 10 patients found that six weeks of paroxetine, rapidly escalated to a dose of 40 mg per day, was not associated with improvements in behavioral or executive function outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , an atypical serotonergic antidepressant agent, have been reported to be effective in treating agitation and aggression in patients with FTD in observational studies [3]. A double-blinded, randomized, cross-over trial of trazodone in 26 patients with FTD, found a significant reduction in neuropsychiatric symptoms with trazodone as compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/23\">",
"     23",
"    </a>",
"    ]. Benefits of treatment were most notable for irritability, agitation, depressive symptoms, and eating disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729318\">",
"    <span class=\"h3\">",
"     Antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotic medications, (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ) can help with agitation and other neurobehavioral symptoms in FTD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/13,14,24,25\">",
"     13,14,24,25",
"    </a>",
"    ]. In one case series, 17 patients with FTD were treated with olanzapine (2.5 to 10 mg per day) and followed for 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment was associated with a decrease in delusions and other neurobehavioral symptoms as well as reduced caregiver stress. Somnolence was observed in almost a third, but could be managed by dose reductions.",
"   </p>",
"   <p>",
"    Patients with FTD are particularly vulnerable to the extrapyramidal side effects of antipsychotics. These medications should be used with great caution; depot preparations, typical antipsychotic agents, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Because of these adverse effects, antipsychotic medications should be considered a last resort only after trying behavioral modifications and SSRIs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    has moderate D2 receptor antagonism relative to other antipsychotic medications and thus may cause fewer extrapyramidal side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients and family members should be informed that use of antipsychotic medications has been associated with increased mortality in elderly patients with dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Serious adverse events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524651#H76524651\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729347\">",
"    <span class=\"h3\">",
"     Stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    have been used in a few studies with the rationale that they may ameliorate dopaminergic deficits present in FTD and thus affect behavioral changes. Methylphenidate increases synaptic levels of dopamine and norepinephrine. Apathy, in particular, is a neurobehavioral symptom, common in FTD that might be expected to respond to stimulant medication.",
"   </p>",
"   <p>",
"    The clinical evidence supporting the benefit of these agents is very limited. A case report [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/30\">",
"     30",
"    </a>",
"    ] and a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/31\">",
"     31",
"    </a>",
"    ] reported behavioral improvements in apathy and disinhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    , respectively. A double-blind placebo-controlled crossover study using a single, 40 mg, dose of methylphenidate in eight FTD patients revealed that treatment was associated with diminished risk-taking behavior as assessed by the Cambridge Gamble Task [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We have seen delirium precipitated by these compounds in patients with FTD, and we discourage their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729354\">",
"    <span class=\"h3\">",
"     Cholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data on acetylcholinesterase inhibitors effect on FTD patients is limited, with some reporting improvement in behavioral symptoms and others worsening.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, placebo-controlled study of 36 patients, eight weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"       galantamine",
"      </a>",
"      was not associated with improvements in behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an open-label study, 12 patients with FTD received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      and 12 did not [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/34\">",
"       34",
"      </a>",
"      ]. At six months, there was no significant difference in behavior between the groups; however, four patients who received donepezil had worsened disinhibition and compulsive behaviors that improved with discontinuation of the medication.",
"     </li>",
"     <li>",
"      Twenty patients with probable FTD were given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"       rivastigmine",
"      </a>",
"      and compared to 20 patients who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/35\">",
"       35",
"      </a>",
"      ]. At 12 months, patients treated with rivastigmine had reduced neurobehavioral symptoms, reduced caregiver stress, and improved depression compared with controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these trials did not show a convincing benefit for these medications on cognitive measures. (See",
"    <a class=\"local\" href=\"#H9729404\">",
"     'Cognitive dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The available data do not support the use of cholinesterase inhibitors in FTD and suggest potential worsening of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/14\">",
"     14",
"    </a>",
"    ]. We do not recommend their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729376\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      in FTD is under investigation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/13,36\">",
"       13,36",
"      </a>",
"      ]. A case series of three patients reported that memantine was well-tolerated and associated with improvements in agitation, anxiety, and apathy at a three-month assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/37\">",
"       37",
"      </a>",
"      ]. In contrast, two open label studies of memantine in FTD patients found no benefit for treatment of neurobehavioral symptoms or other clinical outcomes after six months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Another open-label study of a 26-week course of memantine in 43 patients with FTD found transient improvement in the neuropsychiatric inventory but variable declines on other outcomes measures; there was no control group for comparison [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/40\">",
"       40",
"      </a>",
"      ]. In a randomized trial in 49 patients with bvFTD, no differences in clinical endpoints were found between memantine and placebo-treated patients after one year of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiepileptic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ) have been used to manage neurobehavioral symptoms in other neurodegenerative dementias, but without convincing evidence of efficacy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of behavioral symptoms related to dementia\", section on 'Antiepileptic drugs'",
"      </a>",
"      .) One case report documented improvement in alcohol abuse, but not other compulsive behaviors with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      administration [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/42\">",
"       42",
"      </a>",
"      ]. Others have noted reduced agitation and self neglect with valproate therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/14,43\">",
"       14,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is sparse evidence for the use of MAO inhibitors in FTD.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       Selegiline",
"      </a>",
"      improved behavior and attention in three patients with FTD [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/44\">",
"       44",
"      </a>",
"      ]. In another report, six FTD patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/5/18518?source=see_link\">",
"       moclobemide",
"      </a>",
"      demonstrated improvements in depression, aggressivity, speech, and stereotyped behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one patient with inappropriate sexual behavior, premarin 0.625 mg per day appeared to be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benzodiazepines are generally not recommended in FTD, because they have negative effects on cognition and can precipitate paradoxical agitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729404\">",
"    <span class=\"h2\">",
"     Cognitive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;No medications have been demonstrated to improve or stabilize cognitive deficits in patients with FTD.",
"   </p>",
"   <p>",
"    There are limited data on the use of cholinesterase inhibitors in the treatment of frontotemporal dementia (FTD). One placebo-controlled eight-week trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    suggested a trend toward benefit in the subgroup of patients with primary progressive aphasia, but not in patients with behavioral variant FTD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/33\">",
"     33",
"    </a>",
"    ]. An open label study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    found a benefit of treatment on measures of executive function, but not global cognition as measured by the Mini-Mental State Examination [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/35\">",
"     35",
"    </a>",
"    ]. Finally, an open label study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    found no benefit of treatment on cognitive measure; some patients developed worsened behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9729354\">",
"     'Cholinesterase inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The available data do not support the use of cholinesterase inhibitors in FTD. However, a carefully monitored treatment trial is not unreasonable when there is uncertainty as to the underlying diagnosis (AD versus FTD).",
"   </p>",
"   <p>",
"    The serotonergic medications (SSRIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ) and atypical antipsychotic agents have been observed to be helpful in the management of some behaviors, but have not been found to positively affect cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/15,17,22\">",
"     15,17,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729426\">",
"    <span class=\"h2\">",
"     Parkinsonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FTD who have parkinsonism typically do not respond to dopaminergic medications such as levodopa or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , although some patients have transient motor improvements on these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/14\">",
"     14",
"    </a>",
"    ]. Psychosis and vivid dreaming can be limiting side effects. Patients may receive a treatment trial of",
"    <span class=\"nowrap\">",
"     levodopa/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3221?source=see_link\">",
"      carbidopa",
"     </a>",
"     ,",
"    </span>",
"    although response to this medication may be minimal or transient [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. A trial of dopamine agonists can also be considered in those who do not respond to",
"    <span class=\"nowrap\">",
"     levodopa/carbidopa,",
"    </span>",
"    although, the response can be poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729442\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to managing behavior, nonpharmacologic interventions focus on health maintenance and safety. Nonpharmacologic treatment requires a strong partnership with the patient's caregivers.",
"   </p>",
"   <p>",
"    Because of prominent behavioral changes and impulsivity, safety becomes a concern early on in FTD. Patients often need protection from serious consequences of impaired judgment; supervision of financial decision making, early retirement, and driving safety should be assessed and discussed in initial office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/8,48,49\">",
"     8,48,49",
"    </a>",
"    ]. A practice parameter published by the American Academy of Neurology provides some guidelines regarding driving safety and discontinuation of driving [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the evaluation of older drivers\", section on 'Cognitive function'",
"    </a>",
"    .) Because patients with FTD have difficulty with social boundaries, this needs to be taken into consideration when others, such as children, are present. Physical supervision may be required if patient demonstrates behavior that is dangerous to himself or others. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular cardiovascular exercise should be encouraged for both general health and also the enhancement of cognition in patients with dementia. Exercise programs have demonstrated benefits in both mood and cognition in patients with dementia, and its importance should not be underestimated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of dementia\", section on 'Exercise programs'",
"    </a>",
"    .) Mobility becomes a problem in patients with FTD later in the disease course, particularly those with prominent parkinsonism. Physical therapy can help with balance and help maintain physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/51\">",
"     51",
"    </a>",
"    ]. Physical aids such as a raised toilet seat, commodes, and removal of unsecured rugs can help reduce the potential for injuries in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Speech therapy and the use of communication aids may provide benefit early on in patients with semantic dementia or progressive nonfluent aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/51\">",
"     51",
"    </a>",
"    ]. Later in the course of the illness, evaluation of swallowing is important.",
"   </p>",
"   <p>",
"    Nonpharmacologic behavioral modification techniques can be a useful adjunct in the management of the problematic behaviors in FTD. A behavioral monitoring log may help identify triggers that can be avoided or otherwise managed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/52\">",
"     52",
"    </a>",
"    ]. Distraction, redirection, and offering of simple choices can be effective alternatives to medications for compulsive behaviors, agitation, and anxiety, but require caregiver education. A structured environment that avoids overstimulation can provide stability and predictability for the patient. Providing environmental cues for behaviors that should be encouraged (eg, laying out clothing, tools for self care) and removing environmental cues for behaviors that wish to discourage (eg, car keys) can also be useful in some patients.",
"   </p>",
"   <p>",
"    Caregiver stress is a significant problem in FTD. Respite care and support groups are available in most areas, often through the local agency on aging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Support for caregivers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729485\">",
"    <span class=\"h1\">",
"     FUTURE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-modifying approaches to the treatment of FTD and related disorders are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/36\">",
"     36",
"    </a>",
"    ]. With the recent advent of promising animal and human data with tau-modifying compounds such as davunetide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , new studies targeting FTD patients with suspected tau-pathology are under way. Similarly, medications that boost progranulin in cell culture and in animal models are being developed for this genetic form of FTD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/408/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9729492\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no effective disease modifying treatments for the treatment of frontotemporal dementia (FTD). Both pharmacologic and nonpharmacologic interventions are aimed at ameliorating symptoms, particularly the behavioral symptoms of FTD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When neurobehavioral problems appear or worsen, clinicians should consider the possibility of delirium, pain, or discomfort as a cause for these symptoms before initiating pharmacological treatment. (See",
"      <a class=\"local\" href=\"#H9729270\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with FTD are susceptible to adverse effects of medications including paradoxical behavioral reactions, extrapyramidal side effects, confusion, and sedation. Starting with the lowest available dose of medication, slow upward dose titration, and frequent monitoring for side effects are recommended. Medications should be regularly reevaluated and consideration made for drug withdrawal. (See",
"      <a class=\"local\" href=\"#H9729270\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a treatment trial of a serotonin reuptake inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      10 mg once or twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      (25 mg once daily) for patients with troubling neurobehavioral symptoms of FTD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9729311\">",
"       'Serotonergic medications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other treatment options include atypical antipsychotic agents to be used as a last resort. Patients with FTD need to be carefully monitored for extrapyramidal side effects for which they are particularly vulnerable. Because of this, we use a low dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (12.5 to 25 mg), with less reported extrapyramidal side effects relative to other antipsychotic medications. Families should be warned about the increased mortality associated with use of these medications in this setting. (See",
"      <a class=\"local\" href=\"#H9729318\">",
"       'Antipsychotic medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholinesterase inhibitors do not have convincing evidence of benefit in patients with FTD. However, a treatment trial is not unreasonable when there is uncertainty as to the underlying diagnosis (Alzheimer disease versus FTD). (See",
"      <a class=\"local\" href=\"#H9729354\">",
"       'Cholinesterase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9729404\">",
"       'Cognitive dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions are an important facet of the management of patients with FTD and can include an exercise program, modification of the home environment, increased supervision, physical, occupational, and speech therapy, behavioral modification techniques, and caregiver support and respite. (See",
"      <a class=\"local\" href=\"#H9729442\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/1\">",
"      Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994; 57:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/2\">",
"      Ross L, Neuhaus J, Knopman D, et al. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen 2010; 25:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/3\">",
"      Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/4\">",
"      Francis PT, Holmes C, Webster MT, et al. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 1993; 4:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/5\">",
"      Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/6\">",
"      Lanct&ocirc;t KL, Herrmann N, Ganjavi H, et al. Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 2007; 156:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/7\">",
"      Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 Suppl 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/8\">",
"      Perry RJ, Miller BL. Behavior and treatment in frontotemporal dementia. Neurology 2001; 56:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/9\">",
"      Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991; 48:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/10\">",
"      Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/11\">",
"      Frisoni GB, Pizzolato G, Bianchetti A, et al. Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand 1994; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/12\">",
"      Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 2008; 52:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/13\">",
"      Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci 2009; 24:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/14\">",
"      Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2002; 17:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/15\">",
"      Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003; 49:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/16\">",
"      Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord 2005; 20:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/17\">",
"      Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/18\">",
"      Manes FF, Torralva T, Roca M, et al. Frontotemporal dementia presenting as pathological gambling. Nat Rev Neurol 2010; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/19\">",
"      Anderson IM, Scott K, Harborne G. Serotonin and depression in frontal lobe dementia. Am J Psychiatry 1995; 152:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/20\">",
"      Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007; 8:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/21\">",
"      Mendez MF. Pathological stealing in dementia: poor response to SSRI medications. J Clin Psychiatry 2011; 72:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/22\">",
"      Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/23\">",
"      Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/24\">",
"      Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/25\">",
"      Fellgiebel A, M&uuml;ller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2007; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/26\">",
"      Kerssens CJ, Kerrsens CJ, Pijnenburg YA. Vulnerability to neuroleptic side effects in frontotemporal dementia. Eur J Neurol 2008; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/27\">",
"      Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 2003; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/28\">",
"      Czarnecki K, Kumar N, Josephs KA. Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics? Eur J Neurol 2008; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/29\">",
"      Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; :CD006625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/30\">",
"      Goforth HW, Konopka L, Primeau M, et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci 2004; 35:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/31\">",
"      Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008; 69:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/32\">",
"      Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006; 31:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/33\">",
"      Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008; 25:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/34\">",
"      Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/35\">",
"      Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004; 21:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/36\">",
"      Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol 2008; 21:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/37\">",
"      Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/38\">",
"      Diehl-Schmid J, F&ouml;rstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008; 23:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/39\">",
"      Chow TW, Graff-Guerrero A, Verhoeff NP, et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat 2011; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/40\">",
"      Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2009; 23:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/41\">",
"      Vercelletto M, Boutoleau-Bretonni&egrave;re C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011; 23:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/42\">",
"      Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol 2008; 21:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/43\">",
"      G&aacute;lvez-Andres A, Blasco-Fontecilla H, Gonz&aacute;lez-Parra S, et al. Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate. J Clin Psychopharmacol 2007; 27:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/44\">",
"      Moretti R, Torre P, Antonello RM, et al. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry 2002; 17:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/45\">",
"      Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 2003; 18:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/46\">",
"      Litvan I, Grimes DA, Lang AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 Suppl 2:II1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/47\">",
"      van Balken I, Litvan I. Current and future treatments in progressive supranuclear palsy. Curr Treat Options Neurol 2006; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/48\">",
"      Merrilees JJ, Miller BL. Long-term care of patients with frontotemporal dementia. J Am Med Dir Assoc 2003; 4:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/49\">",
"      Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/50\">",
"      Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/51\">",
"      Robinson KM. Rehabilitation applications in caring for patients with Pick's disease and frontotemporal dementias. Neurology 2001; 56:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/52\">",
"      Talerico KA, Evans LK. Responding to safety issues in frontotemporal dementias. Neurology 2001; 56:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/408/abstract/53\">",
"      Cenik B, Sephton CF, Dewey CM, et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem 2011; 286:16101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14139 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_408=[""].join("\n");
var outline_f0_25_408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9729492\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729241\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729248\">",
"      PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9729255\">",
"      Neurotransmitter systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9729262\">",
"      Behavioral changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729270\">",
"      - General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729311\">",
"      - Serotonergic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729318\">",
"      - Antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729347\">",
"      - Stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729354\">",
"      - Cholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9729376\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9729404\">",
"      Cognitive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9729426\">",
"      Parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729442\">",
"      NONPHARMACOLOGIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729485\">",
"      FUTURE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9729492\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=related_link\">",
"      Prognosis and treatment of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=related_link\">",
"      Safety and societal issues related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_25_409="Lymphoid interstitial pneumonia in adults";
var content_f0_25_409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lymphoid interstitial pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/409/contributors\">",
"     Karen A Fagan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/409/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/409/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/409/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/25/409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid interstitial pneumonia (LIP) is an uncommon form of interstitial lung disease in adults that is characterized histopathologically by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. First described in 1966 by Carrington and Liebow [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/3\">",
"     3",
"    </a>",
"    ], LIP is one entity within a spectrum of lymphoproliferative disorders that can involve the lung.",
"   </p>",
"   <p>",
"    An increased incidence of LIP has been seen in the pediatric population, especially in children with AIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=see_link\">",
"     \"Lymphocytic interstitial pneumonitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the classification of idiopathic interstitial pneumonias, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung is occasionally the primary organ of involvement in a variety of lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LIP",
"     </li>",
"     <li>",
"      Pseudolymphoma",
"     </li>",
"     <li>",
"      Lymphomatoid granulomatosis",
"     </li>",
"     <li>",
"      Benign lymphocytic angiitis and granulomatosis",
"     </li>",
"     <li>",
"      Plasma cell interstitial pneumonia",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma (angioimmunoblastic lymphadenopathy)",
"     </li>",
"     <li>",
"      Primary pulmonary lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LIP represents a benign polyclonal proliferation (usually of mature B or T cells) that can either diffusely involve the lung or be a focal process. Its malignant potential is poorly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Focal LIP is probably the same entity as pseudolymphoma of the lung, given the very similar histology and clinical outcomes of the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7\">",
"     7",
"    </a>",
"    ]. Identification of the infiltrate as a monoclonal proliferation of lymphocytes implies a malignant population rather than LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Other features of LIP may include type II cell hyperplasia, occasional non-caseating granulomas, and germinal centers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of LIP is unknown. It likely involves derangements in the immune system",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    manifestations of an underlying infection (especially viral).",
"   </p>",
"   <p>",
"    Among non HIV-infected patients, the most common associated conditions are hypergammaglobulinemia, Sj&ouml;gren's syndrome, other autoimmune conditions, and hypogammaglobulinemia with relative incidences of about 40, 30, 15 and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,8-10\">",
"     1,8-10",
"    </a>",
"    ]. Among HIV-infected adults, LIP was an uncommon complication prior to widespread use of HAART; since then it has become even less frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 20 percent of cases of LIP have no clear underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autoimmune etiology for LIP is attractive given its association with many autoimmune processes (especially those with dysproteinemias). These include pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, Sj&ouml;gren's syndrome, chronic active hepatitis, and biliary cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef70714 \" href=\"UTD.htm?28/17/28956\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When associated with a dysproteinemia or autoimmune process, LIP may predate the establishment of the protein abnormality or other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7\">",
"     7",
"    </a>",
"    ]. Immune complexes have been rarely reported in patients with LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome is associated with one-fourth of reported cases of LIP, often with a marked monoclonal or polyclonal gammopathy. The pulmonary disease may proceed or follow the diagnosis of the underlying process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=see_link\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A form of lymphocytic interstitial pneumonitis, known as granulomatous-lymphocytic interstitial lung disease, has been described in patients with common variable immunodeficiency and may be related to human herpes virus type 8 (HHV8) infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible infectious (especially viral) etiology for LIP is suggested by its increased incidence in persons infected with the HIV virus, especially children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. While the etiology is unclear, reports of improvement with antiviral therapy alone suggest that the virus itself may be driving the proliferation of immune cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/16\">",
"     16",
"    </a>",
"    ]. HIV antigen and antibodies have been isolated from some HIV-positive children with LIP but not other lung diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/17\">",
"     17",
"    </a>",
"    ]. Reverse transcriptase activity and HIV-specific IgG have also been isolated in BAL specimens from several adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/18\">",
"     18",
"    </a>",
"    ]. In some adults, a transient nonspecific pneumonitis has been reported, possibly related to an immunologic response to the HIV virus itself [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epstein-Barr virus (EBV) has been associated with lymphoproliferative disorders in immunosuppressed populations. As an example, post-transplant lymphoproliferative disorder has a strong relationship to EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/20\">",
"     20",
"    </a>",
"    ]. In situ hybridization studies of biopsy specimens of patients with LIP (both with and without HIV) show a significant increase in the presence of EBV genome compared to other chronic lung disease specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/21\">",
"     21",
"    </a>",
"    ]. Serologic evidence of recrudescent or primary EBV infection has been observed in children and adults with LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human T-lymphotropic virus type I (HTLV-I), a retrovirus, has also been implicated in LIP in Japanese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LIP is established by the demonstration of an interstitial infiltrate of lymphocytes, plasma cells, and histiocytes (",
"    <a class=\"graphic graphic_table graphicRef69805 \" href=\"UTD.htm?22/25/22939\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/25\">",
"     25",
"    </a>",
"    ]. Germinal centers and multinucleated giant cells with noncaseating granulomas may also be found (",
"    <a class=\"graphic graphic_picture graphicRef63982 graphicRef75674 graphicRef52227 \" href=\"UTD.htm?40/27/41402\">",
"     picture 1A-C",
"    </a>",
"    ). The infiltrates occasionally appear along bronchi and vessels but most commonly along alveolar septae (",
"    <a class=\"graphic graphic_picture graphicRef53820 \" href=\"UTD.htm?12/20/12613\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1\">",
"     1",
"    </a>",
"    ]. As the disease progresses, fibrotic changes are seen, with honeycombing and loss of lung parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demonstration of the polyclonality of the usually B cell infiltrates distinguishes LIP from pulmonary lymphoma. T cell-predominant infiltrates have been reported in some patients with HIV, although no clear pattern of cell type is known [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,15,26\">",
"     1,15,26",
"    </a>",
"    ]. Mutations in the 5' regulatory regions of B cell lymphoma 6 (Bcl-6) gene have been identified in several pulmonary lymphoproliferative disorders, including mucosa-associated lymphoid tissue (MALT) lymphoma, HIV-related, EBV-related, and virus-negative lymphocytic interstitial pneumonia (LIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is particularly important to establish the benign nature of the lesion. Features suggesting malignant transformation include lymphangitic or bronchovascular distribution, monoclonality, hilar or pleural involvement, bronchial wall infiltration, and loss of germinal center architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7,28\">",
"     7,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 5 percent of patients are asymptomatic at presentation. Cough (71 percent of cases) and dyspnea (61 percent), slowly progressive over months and in rare cases several years (mean duration before diagnosis = 19 months), are the most common presenting symptoms of LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/3,7,10\">",
"     3,7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs include constitutional features such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss (16 percent)",
"     </li>",
"     <li>",
"      Fevers (10 percent)",
"     </li>",
"     <li>",
"      Pleuritic chest pain (6 percent)",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Arthralgias",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the chest reveals crackles in most patients. Digital clubbing is seen in 10 percent of cases, and cyanosis is found rarely. Other findings often depend upon the presence of another underlying disease process (especially Sj&ouml;gren's syndrome) and include hepatosplenomegaly, lymphadenopathy, parotid gland enlargement, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory abnormalities generally reflect the underlying disease state. Up to three-fourths of patients have a serum protein abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. The dysproteinemia is most commonly a polyclonal gammopathy, but occasionally can be a monoclonal gammopathy. In children, hypogammaglobulinemia may be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/7,29\">",
"     7,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIP has a varied radiographic appearance. It can appear as basilar reticular opacities or as a nodular process. As the infiltrative process continues, alveolar spaces become involved, and a mixed pattern of interstitial and alveolar opacities appears. Air bronchograms may be seen in larger, mass-like lesions. Nodular disease appears to be more common in patients with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Cystic changes may be seen in endstage disease.",
"   </p>",
"   <p>",
"    Computed tomography is useful to establish the extent of disease, define the hilar anatomy, and identify any pleural involvement. Ground-glass attenuation, centrilobular nodules, and interstitial thickening are frequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/30\">",
"     30",
"    </a>",
"    ]. Lung cysts are common in patients with LIP, whereas they are rare in those with pulmonary lymphoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65519 \" href=\"UTD.htm?0/30/481\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/11,31,32\">",
"     11,31,32",
"    </a>",
"    ]. Pleural thickening and effusions are rare in LIP, as are hilar and mediastinal lymphadenopathy, which suggest an underlying malignant process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing characteristically shows reduced lung volumes (eg, forced vital capacity (FVC), total lung capacity (TLC)) and diffusing capacity (DLCO) with preserved airflow. Marked gas exchange abnormalities and hypoxemia also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage may reveal increased numbers of lymphocytes (especially helper cell subsets), although this finding is not specific for LIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/18\">",
"     18",
"    </a>",
"    ]. However, lavage specimens are useful in evaluating possible concurrent opportunistic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of patients with LIP is similar to that of patients with other suspected interstitial lung diseases. Initial evaluation is focused upon determining whether an underlying systemic process is the cause of the pulmonary abnormality. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of LIP is usually suspected in the patient with an associated autoimmune disorder (eg, Sj&ouml;gren's syndrome) and characteristic radiographic findings. Findings suggestive of LIP include ground-glass attenuation, centrilobular nodules, and lung cysts. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Chest imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients without known autoimmune disease, we generally obtain serologic testing (eg, antinuclear antibody, rheumatoid factor and",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies), quantitative immunoglobulin levels, and a serum protein electrophoresis. We also obtain HIV testing. In adults who are HIV positive, there is no correlation with CD4 count, although LIP is an AIDS-defining condition in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transbronchial lung biopsies may suggest the diagnosis of LIP, but are usually not large enough to determine clonality or define architectural elements such as germinal center formation. Therefore, open or thoracoscopic lung biopsy is often",
"    <strong>",
"     required",
"    </strong>",
"    to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of LIP is established by the demonstration of an interstitial infiltrate of lymphocytes, plasma cells, and histiocytes (",
"    <a class=\"graphic graphic_table graphicRef69805 \" href=\"UTD.htm?22/25/22939\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/25\">",
"     25",
"    </a>",
"    ]. Since LIP is a benign disorder, the lymphocytic infiltrate, usually B cells, must be polyclonal. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Pathologic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of LIP includes: pseudolymphoma, lymphomatoid granulomatosis, follicular bronchiolitis, benign lymphocytic angiitis and granulomatosis, plasma cell interstitial pneumonia, angioimmunoblastic T cell lymphoma (angioimmunoblastic lymphadenopathy), primary pulmonary lymphoma, bronchocentric granulomatosis, and hypersensitivity pneumonitis.",
"   </p>",
"   <p>",
"    Features that help distinguish these disorders from LIP include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical setting of underlying autoimmune disease (particularly Sj&ouml;gren's syndrome) or HIV infection would favor LIP.",
"     </li>",
"     <li>",
"      The presence of the following histologic findings is most consistent with an underlying malignancy: monoclonality, lymphangitic or bronchovascular distribution, hilar or pleural involvement, bronchial wall infiltration, and loss of germinal center architecture.",
"     </li>",
"     <li>",
"      The pathologic appearance of LIP and hypersensitivity pneumonitis is similar, although the latter tends to be more patchy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/2\">",
"       2",
"      </a>",
"      ]. Pneumonitis is more likely in patients with a history of exposure to agents known to be associated with the disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=see_link\">",
"       \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Characteristic histologic patterns distinguish LIP from lymphomatoid granulomatosis, follicular bronchiolitis, benign lymphocytic angiitis and granulomatosis, and plasma cell interstitial pneumonia. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      In HIV-infected patients, infectious etiologies of diffuse pulmonary opacities (eg, Pneumocystis jirovecii pneumonia (PCP), cytomegalovirus, and mycobacteria) must be excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"       \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"       \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled clinical trials have not been reported for LIP. Information on treatment comes from case reports and case series. The treatment of adults with LIP differs depending on the severity of the patient's symptoms, the degree of functional impairment, and the presence or absence of an associated autoimmune disease, immunodeficiency, or HIV infection.",
"   </p>",
"   <p>",
"    The treatment of LIP in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=see_link\">",
"     \"Lymphocytic interstitial pneumonitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with LIP have significant symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physiologic impairment and will require therapy. For asymptomatic patients with idiopathic LIP and mild disease (based on physiologic and radiographic studies), we suggest careful longitudinal clinical, functional, and radiological evaluation before drug treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. This approach is based on the observation that spontaneous remission is observed in a small percentage of such patients.",
"   </p>",
"   <p>",
"    We initiate medical therapy for symptomatic patients with either physiologic impairment at presentation or deterioration in lung function over time, although it is unclear whether treatment alters the natural history of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]. We define physiologic impairment by a FVC or DLCO less than 70 percent of predicted and deterioration in function by a decrease in FVC or DLCO by 10 percent or more.",
"   </p>",
"   <p>",
"    The optimal choice for initial therapy is unclear. Overall, the most data are derived from patients with autoimmune disease who were administered glucocorticoids. In the largest reported series, 13 of 15 patients (three had idiopathic disease) were administered glucocorticoid therapy. Among the nine in whom the response could be evaluated, clinical improvement was noted in four, clinical stabilization in four, and disease progression in one. Median survival was approximately 12 years. Overall, about one-half appeared to respond with improvement or stabilization of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dose and duration of glucocorticoid therapy are also not known. Choosing a dose requires balancing the risk of side effects with the likelihood of response. The goal is to choose the lowest dose necessary for a maximal beneficial effect.",
"   </p>",
"   <p>",
"    Our initial regimen is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or the equivalent dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given once per day (based upon the patient's ideal body weight but not exceeding 100",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    This dose is continued for 8 to 12 weeks, at which time the patient is reevaluated. The response to therapy is determined by improvement in symptoms, radiographic appearance (ie, HRCT), and physiologic parameters (ie, FVC, TLC, DLCO).",
"   </p>",
"   <p>",
"    If the patient's condition is stable or improved, the dose is tapered over 6 to 8 weeks to 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is maintained at that level for an additional 6 to 12 weeks, and then tapered further as tolerated.",
"   </p>",
"   <p>",
"    The proper length of therapy in patients who respond to treatment is not known. We usually aim for a treatment course of at least 6 months to 1 year; discontinuing treatment prematurely is a relatively frequent cause of relapse in patients who initially responded.",
"   </p>",
"   <p>",
"    Lifelong treatment with low dose therapy (less than 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may be required by a small number of patients who respond to initial aggressive treatment. Alternate day oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy is not recommended, since no data are available to suggest that it is effective.",
"   </p>",
"   <p>",
"    We suggest Pneumocystis prophylaxis for any patient with LIP receiving moderate to high dose glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 mg or more per day). We recommend Pneumocystis prophylaxis for patients who are on a combination of high dose glucocorticoid and another immunosuppressive agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .) Management of other complications of chronic systemic glucocorticoids is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 20 percent of patients have progressive disease despite systemic glucocorticoid therapy. For these patients and for those who experience side effects from the glucocorticoids, we add another immunosuppressive agent. There is no clear consensus on the optimal agent to choose. However, several case reports and small patient series (usually including patients with connective tissue disease and heterogeneous associated diagnoses) have reported some success with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. The use of these agents is described in the discussion of immunosuppressive therapy for nonspecific interstitial pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link&amp;anchor=H19#H19\">",
"     \"Nonspecific interstitial pneumonia\", section on 'Other immunosuppressive drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with autoimmune disease and LIP is largely the same as that described above for those with idiopathic disease. Medical therapy is initiated in symptomatic patients with either physiologic impairment at presentation or deterioration in lung function over time. Systemic glucocorticoid therapy is most commonly used. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Idiopathic'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Detailed discussions of the management of patients with specific connective tissue diseases are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=see_link\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of granulomatous-lymphocytic interstitial lung disease (GL-ILD) in the setting of common variable immunodeficiency is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"     \"Treatment and prognosis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the management of LIP in HIV-infected adults varies based upon the severity of disease and whether HAART is currently being administered.",
"   </p>",
"   <p>",
"    Among those who have not been previously treated, we suggest initiating HAART for symptomatic LIP, even though LIP is not an AIDS defining illness in adults infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .) This is based on a couple of observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several case reports and a case series have described improvement in LIP after initiation of HAART [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The overall incidence of LIP is decreasing, which has been temporally associated with the introduction of HAART [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If HAART therapy is not effective alone, the addition of glucocorticoids may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. We typically use the dosing regimen described above for idiopathic LIP. However, the use of any agent that may lead to further immunosuppression in a compromised patient must be undertaken with caution and close surveillance.",
"   </p>",
"   <p>",
"    Among HIV infected patients who develop LIP despite being treated with HAART, we assess whether the HAART regimen is optimal and modify it, if necessary. If an optimal HAART regimen is ineffective, we suggest the addition of glucocorticoids based on personal experience and the response of HIV-infected patients with LIP to glucocorticoids in the pre HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend Pneumocystis prophylaxis in HIV-infected patients with LIP, who need high dose glucocorticoid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 mg or more per day), in addition to those who meet other criteria for Pneumocystis prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Idiopathic'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and prognosis of LIP are poorly understood. Possible outcomes include spontaneous resolution, stabilization of disease, resolution following treatment (eg, with glucocorticoids or other immunosuppressive agents), progression to lymphoma, or progression to pulmonary fibrosis with respiratory insufficiency and death despite glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,7,9\">",
"     1,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Including patients who received no therapy and those who received glucocorticoids or glucocorticoids with other immunomodulatory therapy, outcomes reported in two case series were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      52 percent of the cases improved",
"     </li>",
"     <li>",
"      11 percent remained stable",
"     </li>",
"     <li>",
"      37 percent of the patients died (with a median survival from diagnosis of 20 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression of LIP to pulmonary lymphoma has been documented in case reports (about 5 percent of LIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/2\">",
"     2",
"    </a>",
"    ]. This malignant transformation may occur years after the initial diagnosis of LIP. Lymphomas arising from LIP lesions are generally associated with prolonged survival, as they are well differentiated and slow growing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary infections are a serious and potentially fatal complication of the primary immunologic abnormality (eg, HIV, hypogammaglobulinemia) or as a complication of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/409/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. Infections with both typical and atypical organisms occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoid interstitial pneumonia (LIP) is characterized by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LIP represents a benign polyclonal proliferation (usually of mature B or T cells) that can involve the lung diffusely, or be a focal process. Germinal centers, noncaseating granulomas, and multinucleated giant cells may also be seen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the disease progresses, fibrotic and cystic changes are seen along with loss of lung parenchyma. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific etiology of LIP is unknown: its association with autoimmune diseases (eg, Sj&ouml;gren's syndrome, systemic lupus erythematosus) suggests an autoimmune etiology and its association with HIV infection suggests a possible infectious etiology (especially viral). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations include cough, dyspnea, and less commonly, weight loss and fever. Lung examination reveals crackles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On high resolution chest CT, ground-glass attenuation, centrilobular nodules (single or multiple) or masses, mixed alveolar-interstitial opacities, and interstitial thickening are typical. Lung cysts are also common, especially in HIV-associated LIP. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chest imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open or thoracoscopic lung biopsy is often",
"      <strong>",
"       required",
"      </strong>",
"      to confirm the diagnosis, as biopsy specimens need to be large enough for the pathologist to define architectural elements and test for clonality. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with idiopathic or autoimmune-associated LIP who are asymptomatic and have mild disease (based on physiologic and radiographic studies), we suggest not initiating treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We follow these patients with longitudinal assessment of clinical, functional, and radiological parameters. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults with idiopathic LIP who are symptomatic, have significant physiologic impairment, or who demonstrate progressive disease on longitudinal assessments, we suggest treatment with oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically administer oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or the equivalent dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ) 0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given once a day (based upon the patient's ideal body weight but not exceeding 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The course of therapy is usually 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with idiopathic LIP, who do not respond to, or are intolerant of glucocorticoid therapy, we suggest adding an additional immunosuppressive agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with LIP associated with an autoimmune disorder, we typically follow the regimen outlined for idiopathic LIP, modifying it as needed based on the specific autoimmune disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest Pneumocystis prophylaxis for any patient with LIP receiving moderate to high dose glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      20 mg or more per day) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest Pneumocystis prophylaxis in patients treated with a combination of glucocorticoid and another immunosuppressive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .) We follow current treatment recommendations for prevention of other potential adverse effects of glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In HIV-infected adult patients with symptomatic LIP and no other indication for HAART, we suggest initiating HAART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest not initiating glucocorticoid therapy until after a trial of optimal HAART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients whose LIP progresses despite optimal HAART, we follow the treatment protocol for glucocorticoid therapy outlined for idiopathic LIP. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant transformation of LIP to lymphoma may infrequently occur years after the initial diagnosis. Lymphomas arising from LIP lesions are associated with prolonged survival, as they are well differentiated and slow growing. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/1\">",
"      Koss MN, Hochholzer L, Langloss JM, et al. Lymphoid interstitial pneumonia: clinicopathological and immunopathological findings in 18 cases. Pathology 1987; 19:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/2\">",
"      Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. Chest 2002; 122:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/3\">",
"      Carrington, BC, Liebow, AA. Lymphocytic interstitial pneumonia (abstract). Am J Pathol 1966; 48:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/4\">",
"      Bragg DG, Chor PJ, Murray KA, Kjeldsberg CR. Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features. AJR Am J Roentgenol 1994; 163:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/5\">",
"      Banerjee D, Ahmad D. Malignant lymphoma complicating lymphocytic interstitial pneumonia: a monoclonal B-cell neoplasm arising in a polyclonal lymphoproliferative disorder. Hum Pathol 1982; 13:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/6\">",
"      Schuurman HJ, Gooszen HC, Tan IW, et al. Low-grade lymphoma of immature T-cell phenotype in a case of lymphocytic interstitial pneumonia and Sj&ouml;gren's syndrome. Histopathology 1987; 11:1193.",
"     </a>",
"    </li>",
"    <li>",
"     Cosgrove GP, Fessler ME, Schwartz MI. Lymphocytoplasmic infiltrations of the lung. In: Interstitial Lung Disease, 4th ed, Schwarz MI, King TE Jr (Eds), BC Decker Inc, Hamilton 2003. p.825.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/8\">",
"      Alkhayer M, McCann BG, Harrison BD. Lymphocytic interstitial pneumonitis in association with Sjogren's syndrome. Br J Dis Chest 1988; 82:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/9\">",
"      Strimlan, CV, Rosenow, EC, III, Weiland, LH, et al. Lymphocytic interstitial pneumonitis: A review of 13 cases. Ann Intern Med 1978; 68:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/10\">",
"      Cha SI, Fessler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/11\">",
"      Rajagopala S, Swamy S, Kumar A, Rout P. Ace in the hole! Respiration 2011; 82:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/12\">",
"      Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE. Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 1978; 298:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/13\">",
"      Rubinstein A, Morecki R, Silverman B, et al. Pulmonary disease in children with acquired immune deficiency syndrome and AIDS-related complex. J Pediatr 1986; 108:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/14\">",
"      Joshi VV, Oleske JM, Minnefor AB, et al. Pathologic pulmonary findings in children with the acquired immunodeficiency syndrome: a study of ten cases. Hum Pathol 1985; 16:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/15\">",
"      Travis WD, Fox CH, Devaney KO, et al. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis. Hum Pathol 1992; 23:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/16\">",
"      Principi N, Marchisio P, Massironi E, et al. Effect of zidovudine in HIV-infected children with lymphocytic interstitial pneumonitis. AIDS 1991; 5:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/17\">",
"      Resnick L, Pitchenik AE, Fisher E, Croney R. Detection of HTLV-III/LAV-specific IgG and antigen in bronchoalveolar lavage fluid from two patients with lymphocytic interstitial pneumonitis associated with AIDS-related complex. Am J Med 1987; 82:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/18\">",
"      Teirstein AS, Rosen MJ. Lymphocytic interstitial pneumonia. Clin Chest Med 1988; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/19\">",
"      Griffiths MH, Miller RF, Semple SJ. Interstitial pneumonitis in patients infected with the human immunodeficiency virus. Thorax 1995; 50:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/20\">",
"      Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/21\">",
"      Barber&agrave; JA, Hayashi S, Hegele RG, Hogg JC. Detection of Epstein-Barr virus in lymphocytic interstitial pneumonia by in situ hybridization. Am Rev Respir Dis 1992; 145:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/22\">",
"      Katz BZ, Berkman AB, Shapiro ED. Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. J Pediatr 1992; 120:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/23\">",
"      Kramer MR, Saldana MJ, Ramos M, Pitchenik AE. High titers of Epstein-Barr virus antibodies in adult patients with lymphocytic interstitial pneumonitis associated with AIDS. Respir Med 1992; 86:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/24\">",
"      Setoguchi Y, Takahashi S, Nukiwa T, Kira S. Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis 1991; 144:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/25\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/26\">",
"      Lin RY, Gruber PJ, Saunders R, Perla EN. Lymphocytic interstitial pneumonitis in adult HIV infection. N Y State J Med 1988; 88:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/27\">",
"      Kurosu K, Weiden MD, Takiguchi Y, et al. BCL-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. J Immunol 2004; 172:7116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/28\">",
"      Turner RR, Colby TV, Doggett RS. Well-differentiated lymphocytic lymphoma. A study of 47 patients with primary manifestation in the lung. Cancer 1984; 54:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/29\">",
"      Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 1988; 60:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/30\">",
"      Johkoh T, M&uuml;ller NL, Pickford HA, et al. Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 1999; 212:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/31\">",
"      Ichikawa Y, Kinoshita M, Koga T, et al. Lung cyst formation in lymphocytic interstitial pneumonia: CT features. J Comput Assist Tomogr 1994; 18:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/32\">",
"      Honda O, Johkoh T, Ichikado K, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol 1999; 173:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/33\">",
"      Das S, Miller RF. Lymphocytic interstitial pneumonitis in HIV infected adults. Sex Transm Infect 2003; 79:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/34\">",
"      Innes AL, Huang L, Nishimura SL. Resolution of lymphocytic interstitial pneumonitis in an HIV infected adult after treatment with HAART. Sex Transm Infect 2004; 80:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/35\">",
"      Scarborough M, Lishman S, Shaw P, et al. Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy. Int J STD AIDS 2000; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/36\">",
"      Dufour V, Wislez M, Bergot E, et al. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 36:e127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/409/abstract/37\">",
"      Kourtis AP, Bansil P, Posner SF, et al. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007; 120:e236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4361 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_409=[""].join("\n");
var outline_f0_25_409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4361|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/30/481\" title=\"diagnostic image 1\">",
"      LIP CT scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4361|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/46/13032\" title=\"picture 1A\">",
"      LIP with lymphoid hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/37/35415\" title=\"picture 1B\">",
"      LIP with nodular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/20/6468\" title=\"picture 1C\">",
"      LIP with germinal centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/20/12613\" title=\"picture 2\">",
"      LIP along vessels and bronchi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/17/28956\" title=\"table 1\">",
"      Diseases of LIP on biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/25/22939\" title=\"table 2\">",
"      Histologic features LIP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5897?source=related_link\">",
"      Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=related_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7335?source=related_link\">",
"      Lymphocytic interstitial pneumonitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_25_410="Overview of infectious complications following purine analog therapy";
var content_f0_25_410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of infectious complications following purine analog therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/410/contributors\">",
"     Elias Anaissie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/410/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/25/410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/25/410/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/25/410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine analogs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine, 2-CdA),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    (2'-deoxycoformycin, 2'-DCF), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"     nelarabine",
"    </a>",
"    are active agents in the treatment of many hematologic malignancies such as chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia, non-Hodgkin lymphoma (NHL), S&eacute;zary syndrome, and hairy cell leukemia (HCL).",
"   </p>",
"   <p>",
"    This class of drugs can cause neurotoxicity at high doses and can induce severe immunosuppression, which increases the recipient's risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of the frequency of life-threatening infections with unusual pathogens associated with purine analog therapy, fever should trigger a prompt diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nature of the immunocompromise produced by these agents and the types of infections that result will be reviewed here. The use of purine analogs for the treatment of hematologic malignancies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSION ASSOCIATED WITH PURINE ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine analogs are associated with several immune defects, the most important of which is profound and prolonged CD4+ T cell lymphopenia. Other potential immune defects include neutropenia, B cell lymphopenia, monocytopenia, and hypogammaglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T cell lymphopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound T cell lymphopenia, particularly of CD4+ T cells, is universal, develops within two to three months after purine analog therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1,3\">",
"     1,3",
"    </a>",
"    ], and may persist for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This T cell lymphopenia frequently aggravates the T cell-mediated dysfunction associated with advanced stage hematologic cancers, particularly in patients who have received prior antineoplastic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"     2",
"    </a>",
"    ]. This effect appears to be more severe in patients with lymphoid malignancies compared with solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/6\">",
"     6",
"    </a>",
"    ], an observation that suggests that the nature of the immune defects relates partially to the underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Granulocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of neutropenia (absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &lt;1000/microL)",
"    </span>",
"    with single agent purine analog therapy ranges from 10 percent in newly diagnosed patients to &gt;50 percent among previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. Myelosuppression develops with all purine analogs and in different hematologic malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), hairy cell leukemia (HCL), prolymphocytic leukemia, Waldenstrom macroglobulinemia, and multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1\">",
"     1",
"    </a>",
"    ]. Myelosuppression can be particularly severe and prolonged in the setting of purine analog-based combination therapy, at times necessitating dose reduction or discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of the long-term results of newly diagnosed patients with CLL receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as first-line therapy showed that 19 percent of patients had cytopenias lasting &gt;3 months and 8 percent developed cytopenia-associated infections. Advanced Rai stage was the only factor predictive of prolonged cytopenias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/11\">",
"     11",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H4#H4\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Rai staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study using a different cut-off for myelosuppression reported a 43 percent rate of prolonged cytopenia and a 19 percent incidence of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/12\">",
"     12",
"    </a>",
"    ]. The etiology of prolonged neutropenia in this setting is not fully elucidated but is thought to be related to damage to hematopoietic stem cells by purine analogs, autoimmune cytopenias known to occur in CLL, and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in this patient population. Prolonged neutropenia following therapy with purine analogs can last for several months before resolving [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other immune defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with purine analogs also induces a decrease in B cell and monocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1\">",
"     1",
"    </a>",
"    ], but these cell lines recover more rapidly than CD4+ T cells. The effect of purine analogs on immunoglobulin levels is variable. However, the hypogammaglobulinemia associated with malignancies such as CLL may improve with successful purine analog therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential synergistic effect has been noted with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , which may be responsible for lowering the threshold for unusual infections such as listeriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251216811\">",
"    <span class=\"h2\">",
"     Cumulative disease and other therapy-specific immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cumulative immunosuppression may result from the effects of purine analogs as well as the effects of the disease itself",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the other antineoplastic agents used as combination with purine analogs. The most important of these factors are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2,14-21\">",
"     2,14-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease-related &mdash; Disease type and advanced disease stage: poor, slow, or no response of the underlying cancer to purine analog therapy.",
"     </li>",
"     <li>",
"      Treatment-related &mdash; Extensive prior therapy, higher than recommended dosage schedule, combination of purine analogs, especially with glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , prolonged cytopenias, no dose reduction for age and organ dysfunction or for toxicity with prior therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325396958\">",
"    <span class=\"h3\">",
"     Disease-related immune defects in CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine analogs are the cornerstone of therapy for CLL, but CLL itself is associated with several inherent immune defects including",
"    <strong>",
"     :",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defects in humoral immunity, such as hypogammaglobulinemia, deficiency of IgA, IgG2, IgG3, and IgG4; deficiencies in secondary antibody response to common antigens, such as low IgG titers to Streptococcus pneumoniae, and significant impairment in salivary mucosal immunity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects in cell-mediated immunity that are quantitative (eg, reversed",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      qualitative (suppression of helper T cell function and excessive T-suppressor function with depressed antibody-dependent cytotoxicity and delayed hypersensitivity responses).",
"     </li>",
"     <li>",
"      Defects in dendritic cell and natural killer cell function.",
"     </li>",
"     <li>",
"      Defects in innate immunity with quantitative and qualitative defects in neutrophils and monocytes, complement defects (suppression of classical and alternate pathways, decreased complement component levels, and defects in complement activation and binding).",
"     </li>",
"     <li>",
"      When splenomegaly is present, defects in splenic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325396975\">",
"    <span class=\"h3\">",
"     Therapy-related immune defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents commonly used in combination with purine analogs include systemic glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , and autologous or allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251216869\">",
"    <span class=\"h4\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids cause severe defects in cell-mediated immunity and are associated with various infections, including bacterial, viral, fungal, mycobacterial, and parasitic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251216895\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    causes defects in B cells and defects in antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/22\">",
"     22",
"    </a>",
"    ], as well as mild neutropenia (sometimes late onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/23\">",
"     23",
"    </a>",
"    ]), and mild hypogammaglobulinemia. Infections associated with rituximab use are usually those caused by reactivation of viruses, such as cytomegalovirus (CMV), hepatitis B virus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/24\">",
"     24",
"    </a>",
"    ], parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/25\">",
"     25",
"    </a>",
"    ], enterovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/26\">",
"     26",
"    </a>",
"    ], and JC virus (leading to progressive multifocal leukoencephalopathy [PML]), particularly in patients with very low CD4+ T cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Use of rituximab with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has also been associated with fatal West Nile virus infection",
"    <em>",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/29\">",
"     29",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"    Severe West Nile virus infections have also been associated with rituximab in other patient populations, presumably as a result of rituximab-associated B cell defects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251217062\">",
"    <span class=\"h4\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    causes the rapid onset of severe and persistent B and T cell lymphopenia, which can increase the risk for infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Infections that have been reported in patients receiving alemtuzumab include those related to viral reactivation with CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], herpes simplex virus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/33\">",
"     33",
"    </a>",
"    ], varicella-zoster virus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/33,36\">",
"     33,36",
"    </a>",
"    ], adenoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/37\">",
"     37",
"    </a>",
"    ], parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/38\">",
"     38",
"    </a>",
"    ], hepatitis B virus, and JC virus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, infections have been caused by bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/33\">",
"     33",
"    </a>",
"    ], nontuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], Pneumocystis jirovecii (formerly P. carinii) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/36\">",
"     36",
"    </a>",
"    ], Candida spp, Aspergillus spp, and other fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/36,39\">",
"     36,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251217260\">",
"    <span class=\"h4\">",
"     Autologous or allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT is associated with a range of infectious complications. Infections in HCT recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1734576\">",
"    <span class=\"h2\">",
"     Other risk factors for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that influence the risk of infection in patients receiving purine analogs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Host-related &mdash; Comorbidities involving organ damage, such as severe mucositis, liver dysfunction, and especially, renal failure.",
"     </li>",
"     <li>",
"      Related to microbial exposure &mdash; No primary antimicrobial prophylaxis given",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      history of severe infection (and secondary antimicrobial prophylaxis is not given) or significant current exposure to potential pathogens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INFECTIONS ASSOCIATED WITH PURINE ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of purine analogs in patients with hematologic malignancies is associated with a different spectrum of infectious complications than that seen with traditional alkylating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/42\">",
"     42",
"    </a>",
"    ]. The infections that occur in patients receiving these drugs are caused by a variety of pathogens including bacteria, fungi, viruses, and parasites. Infections caused by Listeria monocytogenes, Pneumocystis jirovecii (formerly P. carinii), and cytomegalovirus (CMV) occur more frequently in patients receiving concomitant glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence and timing of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of infections associated with purine analog therapy varies from zero to almost 50 percent among different series [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/4,5,7,15,43-52\">",
"     4,5,7,15,43-52",
"    </a>",
"    ]. As much as two-thirds of the reported infections are caused by opportunistic organisms. Most infections occur during the first six weeks of therapy (early) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/53\">",
"     53",
"    </a>",
"    ], whereas late infections may develop several months after the discontinuation of therapy. Early infections after purine analog therapy are associated with neutropenia and include infections with encapsulated bacteria (eg, Streptococcus pneumoniae and Haemophilus influenzae), herpes simplex virus (HSV), and fungi. Staphylococcal infections are also common. Late infections (particularly after repeated cycles of purine analog therapy) include opportunistic infections associated with depressed cell-mediated immunity (eg, Pneumocystis pneumonia, herpesvirus infections, candidiasis, tuberculosis, nocardiosis, cryptococcosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. With antimicrobial prophylaxis, the overall infection-related mortality rate is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the data vary widely, it appears that the type and stage of the underlying disorder and prior antineoplastic therapy substantially affect the incidence of infectious complications. As an example, patients with certain malignant hematologic disorders (chronic lymphocytic leukemia [CLL], certain non-Hodgkin lymphomas [NHL]) carry a high risk of developing life-threatening infections, especially if the malignancy proves refractory to cytotoxic therapy. By contrast, patients with hairy cell leukemia or indolent lymphoma are at low risk for developing infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/53\">",
"     53",
"    </a>",
"    ]. The lower incidence of infectious complications seen with hairy cell leukemia is probably due to the shorter duration of cytotoxic chemotherapy required, since this disease is particularly sensitive to purine analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infectious complications in indolent lymphocytic malignancies treated with purine analogs are of bacterial origin. Gram-positive bacteria such as Streptococcus and Staphylococcus spp are the most common pathogens, but gram-negative bacilli are also frequently encountered, particularly following hospitalization. Other pathogens include L. monocytogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/14\">",
"     14",
"    </a>",
"    ], Nocardia spp, and Legionella spp [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/19\">",
"     19",
"    </a>",
"    ]. As noted above, L. monocytogenes infections have been observed when purine analogs are administered concomitantly with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/14,56\">",
"     14,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although pneumonia is the most frequent respiratory tract infection, upper respiratory tract infections such as sinusitis are also common. Other manifestations of bacterial infection in these patients include bacteremia (including central venous catheter-associated infections), urinary tract infections, meningitis, and skin infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mycobacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterial infections in patients treated with purine analogs are rare (&lt;0.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/19,57\">",
"     19,57",
"    </a>",
"    ]. When they occur, mycobacterial infections are usually pulmonary and due to Mycobacterium tuberculosis. Extrapulmonary infections, such as bloodstream (catheter-related infection or other), soft tissue, and",
"    <span class=\"nowrap\">",
"     bone/joint",
"    </span>",
"    infections, are more often caused by nontuberculous mycobacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Viral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of HSV accounts for the majority of early viral infections after purine analog therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/53\">",
"     53",
"    </a>",
"    ]. Varicella-zoster virus (VZV) is the most frequent later viral pathogen, with a median time of onset following treatment of seven to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/58\">",
"     58",
"    </a>",
"    ]. Other herpesvirus infections include CMV and Epstein Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV can produce pulmonary, hepatic, and disseminated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/13,19\">",
"     13,19",
"    </a>",
"    ], whereas VZV most commonly causes dermatomal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/57\">",
"     57",
"    </a>",
"    ], but occasionally disseminated, infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Two cases of sight-threatening posterior segment ocular infection with VZV detected in ocular specimens by polymerase chain reaction (PCR) were reported in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and subsequently developed cutaneous zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/60\">",
"     60",
"    </a>",
"    ]. HSV causes stomatitis most commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"     2",
"    </a>",
"    ]. Infections due to influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/57\">",
"     57",
"    </a>",
"    ] and hepatitis A [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/13,19\">",
"     13,19",
"    </a>",
"    ] have also been reported in patients treated with purine analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fungal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections in patients treated with purine analogs may be localized or disseminated. Fungal pathogens include Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/13\">",
"     13",
"    </a>",
"    ], Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/13,18,19\">",
"     13,18,19",
"    </a>",
"    ], Cryptococcus neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/19\">",
"     19",
"    </a>",
"    ], and other fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pneumocystis pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis pneumonia (PCP) has also been reported in patients treated with purine analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Fever, cough, and progressive interstitial infiltrates are the usual manifestations of PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFECTIONS ASSOCIATED WITH THE UNDERLYING MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of infections encountered also depend upon the underlying malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious infections occur in up to 40 percent of patients with chronic lymphocytic leukemia (CLL), which is more frequent than in patients with other indolent lymphocytic malignancies. Distinct types of infections occur at different times during the course of CLL, particularly when patients are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    with [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2,14\">",
"     2,14",
"    </a>",
"    ] or without [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/61\">",
"     61",
"    </a>",
"    ] glucocorticoids and in the setting of refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of myelosuppression is similar in trials involving CLL and low-grade lymphoma, infections may be less common in patients with lymphoma who are receiving a nucleoside analog as their initial therapy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    ). One study evaluated the infectious complications among 73 patients with indolent lymphoma treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/63\">",
"     63",
"    </a>",
"    ]. All patients received prophylaxis against Pneumocystis pneumonia (PCP). Most infections occurred during neutropenia, often with concurrent low CD4 counts. Another study described a high incidence of non-neutropenic infections among patients with indolent lymphoma and identified two independent risk factors for such infections: therapy with fludarabine in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and female gender [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/64\">",
"     64",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hairy cell leukemia (HCL) who have received purine analogs commonly develop fever while neutropenic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/5,65,66\">",
"     5,65,66",
"    </a>",
"    ]. However, a causative pathogen is only rarely documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=see_link\">",
"     \"Treatment of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION OF INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the immune defects in patients receiving purine analogs (both inherent to the primary disease process and therapy-related) will help clinicians to formulate optimal prophylactic interventions to reduce the risk of infection. No randomized trials have been performed to demonstrate the benefit of antimicrobial prophylaxis in patients receiving purine analogs. The following recommendations represent our approach based on the risk of infection in this group of patients. The decision of whether to recommend antimicrobial prophylaxis must be based upon an analysis of the risk of infection. In general, among patients receiving a purine analog, those with chronic lymphocytic leukemia (CLL) or some non-Hodgkin lymphomas (NHLs) are at the highest risk for infection, especially if they have advanced or refractory disease and if they are receiving other immunosuppressive medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    or glucocorticoids. In contrast, patients with hairy cell leukemia (HCL) or indolent lymphomas are at much lower risk of infection. Therefore, we generally reserve antimicrobial prophylaxis for patients with advanced CLL or NHLs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of general measures are recommended to attempt to reduce the incidence of serious infections, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of foods known to potentially harbor Listeria monocytogenes (eg, unpasteurized milk, raw vegetables, undercooked poultry or meat). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Prevention of foodborne infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restriction of the concomitant use of glucocorticoids, and limiting the length and the number of courses of therapy with purine analogs; purine analog therapy should be discontinued early in poorly responsive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should be counseled to present for care at the first onset of signs and symptoms of infection (eg, fever and chills). As a precautionary measure, patients who may not have immediate access to care can be given a supply of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      for self-administration at the onset of signs and symptoms of infection. Early antibiotics can lessen the severity of bacterial infections associated with encapsulated bacteria, such as Streptococcus pneumoniae and Haemophilus influenzae.",
"     </li>",
"     <li>",
"      Provision of a supply of an antiviral agent with activity against herpes simplex virus (HSV) and varicella-zoster virus (VZV) to be commenced if mucocutaneous or cutaneous lesions appear. Antivirals may abort or shorten the course of HSV or VZV infections and may decrease the severity of postherpetic neuralgia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Viral prophylaxis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis for bacterial infections, Pneumocystis pneumonia (PCP), fungal, and viral infections is usually given when patients have a specified level of immunosuppression, as discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5624174\">",
"    <span class=\"h3\">",
"     PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP prophylaxis should be provided to all patients receiving a purine analog in combination with glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/67\">",
"     67",
"    </a>",
"    ]. We also give PCP prophylaxis to patients receiving a purine analog who have advanced CLL.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX; one double-strength tablet orally once daily) is the preferred agent for preventing PCP.",
"   </p>",
"   <p>",
"    The appropriate duration of PCP prophylaxis with TMP-SMX is unclear. Prophylaxis should be discontinued after the completion of purine analog therapy in patients who have achieved a major response to treatment because such patients are at low risk for serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/57\">",
"     57",
"    </a>",
"    ]. By contrast, patients with known risk factors for serious infections (including those with low CD4+ T cell counts and those receiving concomitant glucocorticoid therapy) should continue to receive prophylaxis for as long as these risk factors persist. Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    should continue receiving PCP prophylaxis for a minimum of two months after completion of therapy or until the CD4+ T cell count is &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    whichever occurs later [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In other patients known to have CD4+ lymphopenia, CD4+ T cell counts should be monitored and TMP-SMX should be continued until the CD4+ T cell count is &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP prophylaxis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bacterial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibacterial prophylaxis should be reserved for patients at the highest risk for infection, particularly those with advanced disease with CLL or NHL, renal dysfunction, an absolute neutrophil count (ANC) less than 500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and those who have received cytotoxic therapy previously. As noted above, TMP-SMX is the agent of choice for PCP prophylaxis and it also prevents certain bacterial infections such as streptococcal infections, listeriosis, and nocardiosis.",
"   </p>",
"   <p>",
"    Fluoroquinolone prophylaxis is sometimes used for the prevention of bacterial infections in patients receiving a purine analog [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/67\">",
"     67",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link&amp;anchor=H447665527#H447665527\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\", section on 'Intermediate-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fungal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We give antifungal prophylaxis against Candida spp if severe and prolonged neutropenia occurs (absolute neutrophil count &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for &gt;7 days), particularly in patients with severe mucositis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/69\">",
"     69",
"    </a>",
"    ]. In such patients, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 or 400 mg orally once daily). The evidence for efficacy comes from randomized trials of patients with acute leukemia and chemotherapy-induced neutropenia, and from allogeneic hematopoietic cell transplant (HCT) recipients during the preengraftment period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Viral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    (200 mg PO three times daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (500 mg orally twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg orally twice daily) should be given to all high-risk patients (positive HSV or VZV serology or previous herpetic infections), particularly when CD4+ T cell counts are expected to drop below 50",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    This recommendation is based upon retrospective data showing that patients with CLL receiving a purine analog who had a CD4+ T cell count &lt;50",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    had a higher incidence of cutaneous zoster than patients with a CD4+ T cell count &gt;50",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    (5 of 19 patients [26 percent] versus 9 of 139 patients [6 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"     2",
"    </a>",
"    ]. Antiviral prophylaxis should be continued in patients with persistently depressed CD4+ T cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients previously treated with purine analogs who have had PCP or significant bacterial infections are at risk for relapse of these infections with continued immunosuppression. Administration of daily TMP-SMX (one double-strength tablet once daily) as secondary prophylaxis during subsequent courses of chemotherapy is reasonable in such patients who have had PCP or bacterial infections.",
"   </p>",
"   <p>",
"    Patients who have had a previous episode of herpes zoster should also receive prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or one of its analogs in the doses listed above to prevent recurrent episodes. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Viral prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85402281\">",
"    <span class=\"h2\">",
"     Treatment of latent tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients receiving purine analogs who have latent tuberculosis (TB) that has not previously been treated, treatment for latent TB is recommended. Specific regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) should be used sparingly, if at all, mainly because of its high cost. However, patients with low IgG levels (&lt;500",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and repeated bacterial sinorespiratory infections with encapsulated organisms may benefit from this therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\", section on 'IVIG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients should generally be vaccinated with inactivated vaccines, such as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    , as indicated (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ). In contrast, patients with cancer should generally",
"    <strong>",
"     not",
"    </strong>",
"    receive live virus vaccines, although the United States Centers for Disease Control and Prevention (CDC) states that patients with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least three months may receive live-virus vaccines such as the measles, mumps, and rubella vaccine, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    according to age-specific recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination of patients with hematologic malignancies can be effective in decreasing the incidence of influenza and pneumococcal infections; patients receiving a purine analog should be vaccinated against both of these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/71\">",
"     71",
"    </a>",
"    ]. These vaccines should be administered prior to chemotherapy when possible. Immunizations in patients with cancer are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with anatomic or functional asplenia should also be vaccinated against meningococcus and Haemophilus influenzae type b. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with malignancies that are inherently immunosuppressive such as CLL, particularly those with advanced disease and extensive prior therapy, may have inadequate responses to vaccination, even if given before chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/25/410/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunizations in patients with cancer\", section on 'General approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination of household members probably decreases infection risk among patients treated with purine analogs since household contacts are less likely to transmit infections such as influenza and are also less likely to become asymptomatic carriers of certain organisms such as H. influenzae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF INFECTIONS IN PATIENTS TREATED WITH PURINE ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of infections in patients treated with purine analogs depends upon a number of principles, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the patients at high risk for life-threatening infections",
"     </li>",
"     <li>",
"      Initiation of appropriate clinical and laboratory evaluation",
"     </li>",
"     <li>",
"      Administration of prompt antimicrobial therapy based upon the patient's risk factors and probable source of infection (pneumonia, meningitis, mucositis, other)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment recommendations depend upon the specific infection (see other topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91020372\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Purine analogs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      (2-chlorodeoxyadenosine, 2-CdA),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      (2'-deoxycoformycin, 2'-DCF), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"       nelarabine",
"      </a>",
"      are active agents in the treatment of many hematologic malignancies such as chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia, non-Hodgkin lymphoma (NHL), S&eacute;zary syndrome, and hairy cell leukemia (HCL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Purine analogs are associated with several immune defects, the most important of which is profound and prolonged CD4+ T lymphocytopenia. This effect appears to be more severe in patients with lymphoid malignancies compared with solid tumors, an observation which suggests that the nature of the immune defects relates partially to the underlying disease. Other potential immune defects include neutropenia, B cell lymphopenia, monocytopenia, and hypogammaglobulinemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunosuppression associated with purine analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infections that occur in patients receiving purine analogs are caused by a variety of pathogens including bacteria, fungi, viruses, and parasites. The majority of infectious complications are of bacterial origin. Gram-positive bacteria such as Streptococcus and Staphylococcus spp are the most common pathogens, but gram-negative bacilli are also frequently encountered, particularly following hospitalization. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Infections associated with purine analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early infections after purine analog therapy are associated with neutropenia and include infections with encapsulated bacteria (eg, Streptococcus pneumoniae and Haemophilus influenzae), herpes simplex virus (HSV), and invasive fungal infections. Staphylococcal infections are also common. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence and timing of infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late infections (particularly after repeated cycles of purine analog therapy) include opportunistic infections associated with depressed cell-mediated immunity (eg, Pneumocystis pneumonia [PCP], herpesvirus infections [particularly varicella-zoster virus (VZV)], candidiasis, tuberculosis (TB), nocardiosis, cryptococcosis). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence and timing of infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections caused by Listeria monocytogenes, Pneumocystis jirovecii (formerly P. carinii), and cytomegalovirus (CMV) are rare",
"      <strong>",
"      </strong>",
"      and occur most commonly in patients receiving a purine analog in combination with glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bacterial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Infections associated with purine analogs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H251217062\">",
"       'Alemtuzumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of severe infection following therapy with purine analogs results from several factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Disease-related factors, such as type and advanced disease stage and refractoriness to therapy.",
"     </li>",
"     <li>",
"      Therapy-related, including extensive prior antineoplastic therapy, combination chemotherapy, and no dose-reduction for organ dysfunction or prior toxicity.",
"     </li>",
"     <li>",
"      Host-related factors (presence of comorbidities, especially renal failure) and lack of antimicrobial prophylaxis can significantly increase the risk of serious infections. (See",
"      <a class=\"local\" href=\"#H251216811\">",
"       'Cumulative disease and other therapy-specific immunosuppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1734576\">",
"       'Other risk factors for infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence and timing of infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision of whether to recommend antimicrobial prophylaxis must be based upon an analysis of the risk of infection. In general, among patients receiving a purine analog, those with CLL or some NHLs are at the highest risk for infection, especially if they have advanced or refractory disease and if they are receiving other immunosuppressive medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or glucocorticoids. In contrast, patients with HCL or indolent lymphomas are at much lower risk for infection. Specific recommendations are provided above. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention of infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/1\">",
"      Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/2\">",
"      Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.",
"     </a>",
"    </li>",
"    <li>",
"     O'Brien S. Infectious complications of nucleoside analogs. Hematology, American Society of Hematology Education Book 1995. p. 445.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/4\">",
"      Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Blood 1994; 84:4061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/5\">",
"      Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/6\">",
"      Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs 1990; 8:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/7\">",
"      Solal-C&eacute;ligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/8\">",
"      Hagenbeek A. Fludarabine vs conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients. Purine analogues 1999; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/9\">",
"      Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/10\">",
"      Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/11\">",
"      Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/12\">",
"      Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010; 21:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/13\">",
"      Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/14\">",
"      Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/15\">",
"      Pigaditou A, Rohatiner AZ, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/16\">",
"      Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/17\">",
"      Saven A, Piro L. 2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia. N Engl J Med 1994; 330:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/18\">",
"      Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/19\">",
"      Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995; 49:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/20\">",
"      Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86:2463.",
"     </a>",
"    </li>",
"    <li>",
"     Anaissie EJ. Infectious complications in patients with chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia, O'Brien S, Gribben JG.  (Eds), Informa Healthcare, New York City 2008. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/22\">",
"      Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/23\">",
"      Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/24\">",
"      Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/25\">",
"      Purhonen AK, Mikkola M, Karjalainen L, et al. Cryoglobulinaemia and rapidly deteriorating renal function in chronic lymphocytic leukaemia. Nephrol Dial Transplant 2011; 26:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/26\">",
"      Kiani-Alikhan S, Skoulidis F, Barroso A, et al. Enterovirus infection of neuronal cells post-Rituximab. Br J Haematol 2009; 146:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/27\">",
"      Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/28\">",
"      Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008; 88:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/29\">",
"      Mawhorter SD, Sierk A, Staugaitis SM, et al. Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2005; 6:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/30\">",
"      Chan-Tack KM, Forrest G. West nile virus meningoencephalitis and acute flaccid paralysis after infliximab treatment. J Rheumatol 2006; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/31\">",
"      Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2010; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/32\">",
"      Elter T, Vehreschild JJ, Gribben J, et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009; 88:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/33\">",
"      Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/34\">",
"      Vallejo C, R&iacute;os E, de la Serna J, et al. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Rev Hematol 2011; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/35\">",
"      Skoetz N, Bauer K, Elter T, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012; 2:CD008078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/36\">",
"      Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/37\">",
"      Cavalli-Bj&ouml;rkman N, Osby E, Lundin J, et al. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002; 19:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/38\">",
"      Herbert KE, Prince HM, Westerman DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood 2003; 101:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/39\">",
"      Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/40\">",
"      Kamboj M, Louie E, Kiehn T, et al. Mycobacterium haemophilum infection after alemtuzumab treatment. Emerg Infect Dis 2008; 14:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/41\">",
"      Saadeh CE, Srkalovic G. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia. Pharmacotherapy 2008; 28:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/42\">",
"      Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/43\">",
"      Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/44\">",
"      Saven A, Emanuele S, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995; 86:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/45\">",
"      Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/46\">",
"      Duggan DB, Anderson JR, Dillman R, et al. 2' Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study. Med Pediatr Oncol 1990; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/47\">",
"      Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991; 9:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/48\">",
"      Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 1995; 18:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/49\">",
"      Robak T, Basiska-Morawiec M, Boski JZ, Dmoszyska A. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/50\">",
"      Ho AD, Thaler J, Willemze R, et al. Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treat Rev 1990; 17:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/51\">",
"      Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/52\">",
"      Johnson S, Smith AG, L&ouml;ffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/53\">",
"      Van Den Neste E, Delannoy A, Vandercam B, et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/54\">",
"      Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/55\">",
"      O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/56\">",
"      Rondelli D, Lauria F, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 1997; 58:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/57\">",
"      Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/58\">",
"      Byrd JC, McGrail LH, Hospenthal DR, et al. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol 1999; 105:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/59\">",
"      Deane M, Gor D, Macmahon ME, et al. Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment. Br J Haematol 1997; 99:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/60\">",
"      Chee YL, Culligan DJ, Olson JA, et al. Sight-threatening varicella zoster virus infection after fludarabine treatment. Br J Haematol 2000; 110:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/61\">",
"      Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/62\">",
"      Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/63\">",
"      Tsimberidou AM, Younes A, Romaguera J, et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005; 104:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/64\">",
"      Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/65\">",
"      Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/66\">",
"      Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994; 330:691.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/foi/label/2007/103948s5070lbl.pdf (Accessed on July 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/69\">",
"      Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995; 86:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/70\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Aslan T, Anaissie EJ. Infections in Hematological Malignancies. In: Medical Management of, 1, Freireich EJ, Kantarjian HM (Eds), Marcel Dekker, New York 1998. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/72\">",
"      Bucalossi A, Marotta G, Galieni P, et al. Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1995; 93:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/25/410/abstract/73\">",
"      Gribabis DA, Panayiotidis P, Boussiotis VA, et al. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1994; 91:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1405 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_410=[""].join("\n");
var outline_f0_25_410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91020372\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOSUPPRESSION ASSOCIATED WITH PURINE ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T cell lymphopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Granulocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other immune defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H251216811\">",
"      Cumulative disease and other therapy-specific immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325396958\">",
"      - Disease-related immune defects in CLL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325396975\">",
"      - Therapy-related immune defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H251216869\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H251216895\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H251217062\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H251217260\">",
"      Autologous or allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1734576\">",
"      Other risk factors for infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INFECTIONS ASSOCIATED WITH PURINE ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence and timing of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bacterial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mycobacterial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Viral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fungal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pneumocystis pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFECTIONS ASSOCIATED WITH THE UNDERLYING MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION OF INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5624174\">",
"      - PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Viral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85402281\">",
"      Treatment of latent tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MANAGEMENT OF INFECTIONS IN PATIENTS TREATED WITH PURINE ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91020372\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1405|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/17/4378?source=related_link\">",
"      Treatment of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_25_411="Bleomycin pneumonitis appearance";
var content_f0_25_411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiographic manifestations of bleomycin-induced pneumonitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bilateral reticular or fine nodular infiltrate (50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alveolar densities (10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal (10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular lesions with smooth or irregular borders which may cavitate (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No pleural effusions or adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare pneumothorax when honeycomb lung is present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_411=[""].join("\n");
var outline_f0_25_411=null;
var title_f0_25_412="VIT patient selection";
var content_f0_25_412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection of patients for venom immunotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Reaction to sting immunotherapy?",
"      </td>",
"      <td class=\"subtitle1\">",
"       Result of skin test or RAST",
"      </td>",
"      <td class=\"subtitle1\">",
"       Venom immunotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       In child:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic, non-life-threatening, immediate, generalized urticaria, angioedema, erythema, pruritus",
"      </td>",
"      <td>",
"       Positive or negative",
"      </td>",
"      <td>",
"       No*&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic, life-threatening: possible cutaneous symptoms but also respiratory symptoms (laryngeal edema or bronchospasm) or cardiovascular symptoms (hypotension, shock)",
"      </td>",
"      <td>",
"       Positive",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       In adult:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic",
"      </td>",
"      <td>",
"       Positive",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic",
"      </td>",
"      <td>",
"       Negative",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       In child or adult:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Large local (&gt;2 in diameter, &gt;24-hr duration)",
"      </td>",
"      <td>",
"       Positive or negative",
"      </td>",
"      <td>",
"       No*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Normal (&lt;2 in diameter, &lt;24-hr duration)",
"      </td>",
"      <td>",
"       Positive or negative",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Exceptions occasionally made.",
"     <br>",
"      &bull; It is unknown whether this applies to imported fire ant hypersensitivity in children.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Graft, DF. Insect sting allergy. Med Clin N Am 2006; 90:211. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_412=[""].join("\n");
var outline_f0_25_412=null;
var title_f0_25_413="Prevalence renal anomalies";
var content_f0_25_413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of renal anomalies detected by ultrasonography in 709,030 births*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of renal malformation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases detected antenatally&bull; (percent of antenatal diagnoses)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total number of cases, detected antenatally and postnatally (percent of total cases)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of total cases detected antenatally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilatation of upper tract",
"       </td>",
"       <td>",
"        259 (28)",
"       </td>",
"       <td>",
"        309 (27)",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral multicystic dysplastic kidney",
"       </td>",
"       <td>",
"        102 (11)",
"       </td>",
"       <td>",
"        105 (9)",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral renal agenesis",
"       </td>",
"       <td>",
"        36 (4)",
"       </td>",
"       <td>",
"        58 (5)",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral renal agenesis/dysgenesis",
"       </td>",
"       <td>",
"        86 (9)",
"       </td>",
"       <td>",
"        95 (8)",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic kidney disease",
"       </td>",
"       <td>",
"        27 (3)",
"       </td>",
"       <td>",
"        31 (3)",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supernumerary kidney",
"       </td>",
"       <td>",
"        37 (4)",
"       </td>",
"       <td>",
"        39 (3)",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectopic kidney",
"       </td>",
"       <td>",
"        15 (2)",
"       </td>",
"       <td>",
"        27 (2.5)",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior urethral valves",
"       </td>",
"       <td>",
"        19 (2)",
"       </td>",
"       <td>",
"        27 (2.5)",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solitary cyst",
"       </td>",
"       <td>",
"        19 (2)",
"       </td>",
"       <td>",
"        25 (2)",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder exstrophy",
"       </td>",
"       <td>",
"        10 (1)",
"       </td>",
"       <td>",
"        19 (2)",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndrome with chromosomal defect",
"       </td>",
"       <td>",
"        107 (12)",
"       </td>",
"       <td>",
"        128 (11)",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndrome without identified chromosomal defect",
"       </td>",
"       <td>",
"        54 (6)",
"       </td>",
"       <td>",
"        64 (6)",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple malformations&Delta;",
"       </td>",
"       <td>",
"        130 (14)",
"       </td>",
"       <td>",
"        176 (16)",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        924 (100)",
"       </td>",
"       <td>",
"        1130 (100)",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Total number of births included live births, stillbirths, and abortions.",
"     <br>",
"      &bull; Mean gestatational age of antenatal detection 24.3 weeks (range 18.5 to 28.3).",
"      <br>",
"       &Delta; Multiple malformations defined as at least one renal malformation and one or more major malformation of another system.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wiesel A, Queisser-Luft A, Clementi M, et al. Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 2005; 48:131.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_413=[""].join("\n");
var outline_f0_25_413=null;
var title_f0_25_414="Posterior subcapsular cataract";
var content_f0_25_414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior subcapsular cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slit lamp photo of a posterior subcapsular cataract reveals a \"frost-like\" haze just anterior to the posterior lens capsule (arrows), which is the back surface of the lens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_414=[""].join("\n");
var outline_f0_25_414=null;
var title_f0_25_415="MCP collateral ligaments";
var content_f0_25_415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Metacarpophalangeal joint collateral ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 205px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADNAcgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKxPEni3w/4Zi8zxBrNhp4IyFuJ1Vm/wB1ep/AVzEfxk8CyQPOusT/AGZGCNOdOuRGCRnl/L2/rQB6FRXOaJ458K65gaR4j0m7c/8ALOO6Qv8A985yPyrogQwyCCPUUALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFY3i7xFaeGNFk1C9WSVi6wwW0IzLczMcJFGO7Mfy5JwATQBpXt3bWFpLdX1xDbW0Q3STTOERB6ljwBXFf8J3ea0ceBvD9zrMH/QRupPsVmfdHZS8g90Qr/tUaX4NudcuIdY+ITRX96rCS30pDusrD0wvSWQZ5kfPP3Qo692AFACgADgAdqAOD/sf4hakN194q0rRRn/VaVpvnkf8AbSdiD/37H4VheIdG8R6Q4x4t8dalKUMm7T7GyZFwehBjGT7DmvWqKAPnNvEHjWDItvE/jvAP+qufAgmZR6ll2giqk7eM9ZYLqWs/Eu8iYH93Z6PBoidOjSvINo46nNe0ax8PtI1iQyahd67JMWZt6avcxgZ7BVcKB7AVzl78FfBCQvdXelalqrW6mRYJ9Rnm8wgZChWfBJxgA8UAc34Ok8P+GtQhWP8A4QnQ76U7p2k1E6rqL/3g7/KVJ9clRnpXuqMHRWQgqwyCO4rzz4SWmowR3clz4UsfDNlIqmGztoY4ihyeGK8ucYyx288BT94+iUAY+q+FvD+rknVdD0u9Oc5uLSOQ59eQa5g/CPwnC8j6TBqGiu45/srUZ7Vc+u1HC5/Cu/ooA4EeBtesCDoXj/XY8f8ALPU44b9D/wB9Kr/+PZqcRfEazLBbnwrqsaj5TJFPZO31wZQPwFdvRQBwp8Q+OoSBceBLaf1az1uNv0kRKlbxhrkI23PgHxAZOP8Aj3ns5V/Pzh+oFdrRQByEPizV5Tx4G8QqvQl5bMH8vPq4Ne1c4P8AwiWqgehubTP/AKOx+tdHRQBjafrdxd3SwTaFqtmx4LzrEUXj+8sjZ/CtmiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4LSIV8V/EC81ufEmmaA76fpyH7pusf6RN7kcRA9sSetdV4n1RND8OarqsoBSytZbggnGdilsfjiqHw80h9D8EaNYT5N0lur3BPVp3+eVj9XZj+NAHRUUUUAFFYuva6NM1TQ9PiiWa71S6MKKW2hUSNpJH/BV6dywraoAKKKKACsnWdRvrbUNLs9N05rpruU+dOxKxW0SgFmYgHLHICr3JPIAJrWooAKKxvC+kXelWcv8Aaeq3OqX9xIZZp5flQE9FjjyRGgHGByepJPNbNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUc80VvE0txIkUSjLO7BQB7k0ASUVwmqfFvwNp1z9mbxFa3V0TgQWAa7dj6ARBuazz8Rtc1X5fCfw/1+7ycCfVNmnQ4/vAuSzD6LQB6XRXnlu/xWnffLF4KsojyIi1zO4HoWG0Z9wDVfVfFvi/wbFHqHjPSdKvNB3Bbm90WSXfZgnHmPE4yyDjJVsjk4oA9LopkMiTQpLC6vE6hlZTkMDyCDVbWNUstF0241DVbqK1soF3SSyHAA/qSeABySQBzQBcqjqmr6bpMYk1TULSyQ9GuJljB+mSK5aFfEPi/97M934a0En5IFGy/uV/vO3PkKf7oHmepQ8VuaP4U0LR5zcWGl2yXbHLXTr5k7f70rZc/iaAKf/CdaDJJ5dnPd374zixsp7gY9cohH61j6l8VdE0lPN1nTfEmnWv8Az8XOjziP8wpx+Nd/XH+PtCS/snuZte8T6bswU/sZ3LKf9yNGLD6g/hQBnR/Gf4dyWhuV8WacIwM4Ysr/APfBG79Kqf8AC1ZNTA/4RDwb4m1xG5juWthZ2zj1EkxX/wBBrzHRtUkh8QvB/wALa0BpIWAA1/w+tvcxn0Jk8tieeu6vWNAiiutRspLz4iXOtXDzHy7eyeCGB2VdxXbEpYjAzhnPFAEkerfEm7XzI/Cvh6wX/nld6zI7/nHCV/WoX134l23EngrRb0jktba4UB9gHi613tjdLe2kVwkc0ayDISaNo3H1VsEfjU9AHmU3xJ13SQT4k+Heu2q9msLi3vePXCuD+lLZ/HDwLLgXuo3Wly949QsZocfU7dv613Wp6Bo+qS+Zqek6feSbdu+4tkkOPTLA8cmuS1X4QeCNQDFNETT5T0l02V7VlPriMgH8QRQBsad8QfB2ogfYvFOhzE/wrfR7vyzmt6K/s5tvlXdu+7kbZFOf1rx69+BYjC/2R4keRFzmHXNMttSV/YlkVvxzmqc3ws1OHd9p8FfDbWIV6C3gl06VvyWRc/kKAPdgcjI6UV4ZD4Jt7ZB/xaa4t5ANudL8QKnHpu8yM/hitNfDksUTjTvCvjq0buF8UbQc+mbpumPSgD2CivJbbRtWUKj6f8Q4cZ+ca7bS9v8Aam5/EVej07UoXRnufiCuG/inspAfqBnigD0yisDSdIvY/Inl1/W5E4c290tt067WKxA/XDfjW/QAUUUUAcb8X5Vi8B3ayLvSa6s4GX1D3USH9GNdlXIfF3S7jWPhtr9rY83i2/2mAf3pImEqr+JQD8a3fDWr2/iDw9pur2RzbX1vHcJnqAyg4PuM4oA0qKKKAOD1h1uvjHokcn+r0rRru9Ps0skUan/vlJKX4H3VzqHww0fUb6WSW5vzPeO0hJOZZnfHPYBgB7AVS8VRyQ/FFGhJL6h4YvYFC/eDRSxMp/8AIzVo/BBom+EPhEwFSn9mwgkf3guG/XNAGx4M8QjxPp93fw2/k2S3s1tayb932iOJthkxjgF1fA9AD3xW200SzpA0qCZ1LrGWG5lGASB1wMj8xXA/s/usnwe8NOmfmhctnu3mvuP4nNcf8LNfbxV8fvHl7csQunW66dp6EHHkLMyyMpPYyR5OPX2oA9yorxzwf8QNb8TfF7xFY2um6jceHtKn/s9HtxHHBG4JEksruQztkcIvRecE17HQAUVja74p0Dw+6Jrut6ZpzuNyrd3SRFh6gMQTWRH8TfBczMtr4k0+6df4baTzifoEBz+FAHYUU2J1kjR1ztYBhkEHB9jyKdQAUUUUAFFFFABRRRQAUUUUAFFFFAFTVNOt9UtDbXiyNETkiOV4z/30pB/WsgeEbJAVhvtbiQjG0arcMB9Nzkj8K6KigDmW8GWLIFfUfEDYOQf7ZulI/KQVVbwLGGzB4k8UwjJOBqbv/wChhjXYUUAcjb+DbmAvs8X+JyrZAV54X2/QmIn9ar6n4UuYbCWRvFvi5lQZK27wtIfoBDk121FAHhWoWRkWTZf/ABklIO39xiPOOeMqo/GsT/hB21CZbiT4eeK/EjK2Vm8V+IY4sf8AbNXb9Vr6QooA8u8LeCPEGAb+50vwrp+7I0rwxbJGWGQf3twy7ieMHYF+tek2tlbWslxJbQRxSXMnmzMi4Mj4A3H1OAB+FWKKACvKP2gNc1vR/DostMgsbu28Qg6GkMjmOaO4nVlR1OCHXBOVIHQHPJr1evLfi2sVx49+F1rcJmM6xJOCegeOFmX8d2PyoA7nTYrXwp4PtIby5WOy0mxSOS4lbAVIowCxP0XNc74ZtJ/GN5Z+K9cjeKwXE2jaZJ/yxUji5mHeZgcqOkanj5iTUPxGKeIdf0LwQCWt78tf6oq84s4SCEb0EkpRPoHFegABQAoAA4AHagBaKK4DxX8S7TTtb/4R7w1YT+I/E54ays2AS2/2riU/LEPzPTjkUAd/VLV9VsNGsZL3Vr22srSMZaa4kCKPxNcla+F/EusKs/i3xPcW5PP9n6CTawp7GY5lf65Qf7IqR/C/gbwzPHqGowafFcqcpeatcmaQH1WSZmIP0NAHRWZ0zxBY2mpLapPDIu+B7m2KvtPQhXAYZ69BWhBBFboUgijiUnJCKFGfXinRSJLEkkbBo3AZWHQg9DTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIyMHpXmnwPYabYeI/CrZU+H9XnghTOcW0h82H8NrkY9q9LryrxJN/whnxo0zXZv3eieJbZdJu5cYWK7jJaB3P+0pZB9KAPVaKKKAOD8TP5Hxg8DuTxPZalbDt82IJB9eEb8qq/A8fYNC1vw8QVOh6zd2iKevlM/nRn6FZRj6VZ+KIFvqvgTURw1vr8UJYDkLPFLDj6FnWjRB9g+NHii26JqemWd+vu8bSQufyEX6UARfBiRLDwJd2spKxaXqeo2xyuNqpdSkfoRXn3wis303xp4EvZkZZda8MXTuWPLM10tzuPqcTfr7V22s2N34X+H/xQuZF8tZnv7+1KnOVe2U568fvN9Q3+nDS9e+EM6ALb2qzaYT6eZZEqPxMAoAk/Zy2H4agnabo6lem6YdWl+0Pye+du3r7V6ZMhkhdA7RllKh0xlc9xnvXlXw5Q+GPi7438LHItNR2eIbEH/podk//AI+Fr1WcyCGQwKjShTsV2KqWxwCQDge+DQB57P8ADv4d+HopdW17T9OlkyHn1LW5vPeR8feZ5iRk47YHoKfpHxQ8DuRY+HJ575Ivl8vSdLuJ409sxxlR+dcf4o0Dw1pV9a3Xj2G98ceN7tTJb6XEGmRBnlYYOEjhBwN7jnBPJyKra34i8caVZxnVNV8FfDjSsfuLRiLu7RfQIMI2P9kUAezaHraax5hisNTtkT+K8tWg3fQNg/pWrXzRp3iex1ItIvjf4k+LpVf/AJgGmm2iJ7jAQf8AoWK6S2XUL1VeH4b+LtaH3gfEetJGo+sTyMoH0T8KAPckZXGUYMOnBzS153Y6j44soEh0/wCH+h2dqv8Ayxj1sIPwCwYFTLrnxEmGI/BWjWxxyZ9dLD/x2CgDvqK4qC7+Ijj99o/hSLjqNTuG/TyB/OtK0uPF2E+16boOf4vK1Cb9MwUAdHRSDOBuAB7gHNLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBneILyWx0uWW2msIrolUgN9KY4mkYgKpYc8ngYBOexrjIviU2kbovH2gal4dkTrdLG15ZOOxE8YO3PXDhcV22u2lvfaPeW17p8epW7xNus5FVlnwMhcN8vJA68VxHw+vvD8VxHZaZqWtaXKvTQdYZkePORhFlBdlGOPLcoO3FAHRaT468KavgaZ4l0a6Y/wR3kZb/vnOa4D49Xaaff8Aw78RI8b2lj4gijmkVs7UlUhjkdsA/pXo2s+EPDetsW1jQNKvnP8AFcWkbt+ZGa4/U/gV8ONRYtL4Zgibj/j3mlhH5IwH6UAUfhRe/wDCR/FH4ka8WDwW9zBo1qQchUgDb8H0LNu/GvSNf17SfD1kbzXdSs9PtugkuZVjBPoMnk+w5rhbD4G+ALBWW10e5jVzlwmpXSh/94CTmpZ9L+GPw6liuru30PTLwcxSXGJbkn/Y3bpD+FAFm7vdd8bp9l0Jb3QNAk/12rTIYru4T0to2+aPI/5auAQD8qn7w2dH0fwz8PdAn+xxWekaahM1xcTSYLt3eSRzlj7sSa58+LfFPiYlPBPh02dmeBq2vq0EZHrHbj96+R0LbBXL61pfhbRtWguPiLrt7418Tp89tpSQ+aEPXMVlHkLx/E+enWgCTxJ8S/FHilGsvg9oFxfK3Da5exeTaqPWISY3n36ezZpfBngLxpa3A1DWP+ESTVnCmTUrmCfUr1iB/fd0VB/sphR2Faz6h8UPEKf8SPR9H8J6f0jfVXNxdFexEUfyJ9GJxTIPBXiaNXvfG3xQ1LyE5K2EUOnxIPQtg5+vBoA9L0yG6gsYo7+6W7uhnfMsQiDHPZcnA7dTVqsfwrbWFvpKHSdQn1G2kJYXM1692ZD0OHZj6dBxWxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY3jDw7YeLPDV/omrRh7S7jKE45RuquvoynBHuK2aKAPNvhX4qvBPP4K8YTKvi3SVC+YxwNRt/4LiPP3sgYbuCDn0HpNcd8SPAVh42srcyTzafrNixl0/VLU7ZrWT1BGMqcDK9/Y4NcDJ4/8b/DcLF8S9F/tjRUO0eINIXOB6zRcbTyOflHpuoA6/45t9n8ANf4ybDUbC7Hr8l3FnH4Zq7qsbR/F3w7OgwJtJvoZG/vbZLZlH6sfzrkfid408LeMfgn4pn0LXbG5UWRkCiUJIjghkBQ4ZSSBgEda9J0N7fW9I0PWZYVad7ZLiJ+6eZGM4PuDQBQ+KKLL8NPFqOBtOk3Y5Gf+WLVzfi4yHwb4D1Jid1pqemTOw9JMQt+kxrtfF9r9u8J63aDrPYzxf8AfUbD+tcJqyNrX7OKTQHM39gQ3sRzn95FEsq/+PIKAHfEWL+zviv8ONahJVpri50qfHSRJIiyg/RkyKrfFTxrrlv4ntfCHhOOWLVLq1+0faVg3sxZiqpHuBRcYLPI2QqjgFiBUnxgv7a8+Hvh3xXC4FtYanpurpITwsbSKpJPpslOau+JvG765cHw38ObqG+1qVvLudQiHm2+lx/xSOw+VpOoWPOSevA5AOK0jSdVtbyTwb4G1ENr5Cy+KvF0y+dIjn/lihbrJ1wvRF/2iSOx8LfBTwdod0b68s5dd1ZzukvtYk+0uzeuD8uffGfeuy8IeG9P8KaFBpelI/lIS8ksrbpZ5GOWkkb+J2PJP8gAK2aAGxRpFGscSKkajCqowAPpTqKKACiiigAooooAKKKKACiiigAooqK6uYLSBp7uaKCFfvSSOFUfUmgCWisCTxn4Yjxv8R6MD6fbY/8A4qubh1/4fx6mb9fGFskpfeySeIJBEWznmNpduPbGKAPQ6K5HTdS8NXus/wBqaf4siu2bK+RFqyyQHjGBGGK8e3Oak1Xw5pF1aS3MqarqWB/q4dTnJbJ6AeaF/l0oA6qivKJrHSbEqyeEvHUQKnm1v5iAP91Lk8/hWVeX/gqNo477xJ448LXDNw1/eX9uoJ6AtPuiP5mgD2yivM9O0vXrpPtHg/4nJqlso+5fWtteoeeP3kPlsOPc1dsde8a6RqNpbeLdBsr2wncRnU9DeRxCx4BkgcbwuerKWA70Adnqlzc2lt5lnYy30u7HlRSIhx65cgfr3rlNS8V+HLqL7J4x02bTVLAFNZs/3GT/ANNvmh6/7ddXquowaZbCe5W4dS20LBbvM5OCcBUBPb0rhbn4xeErLU00/Xm1PRZJTtRtV06a3jf/AIEy4x7nAoA29K0DRbmxjm8O6repZnPltY6m8sP0UFmQAegFWpfDt47Er4n1yPPQL9nwPzhNVx4M8LX0y6nZafBDLOA/2vTZmtjKDyGLwsu7PqSanPhKzYnOoa7tP8I1e5H6h89vWgDG1HwRamOSfX/F3iaezUfOkupi1iA9zCsZx9TWboH/AAiWizuvw/8AC/8Aal8xIa9tIRsJ777yThup6M568V1sXg7QVu1uprAXlynKS30r3TIfVTKzY/CugAwMDpQBxsnh/wAQa8+fEmsmxss/8g7RXaPcPSS5OJG/4AI/xrc8O+G9G8N2zwaFplrYxud0hhjAaQ+rt1Y+5JNZvinxzonhy5SxuJpbzWJRmHS7CMz3Un0jX7o/2m2r71xniibWb7S5tU+IurQ+DfCSff06zuN11c/7Es69Mgf6uLJIJG40Aa/ifxtfajeS6D8OY7bUdXVil3qMh3WWmepkccNJ6RjJzy2AMHxzVfGXgXQtcELW+ofE/wAYhv3l3cDzbeN+NwiXDIijqBGjY6buK3YNN8R/Fyyt9K0S0l8F/CyNQqBIxHcahH6Kg+6h/LnJ39B7L4H8DeHfA+nCz8N6bFagjEk2N0sp9Xc8n6dB2AoA5fwH8TYNWljs9Ys5dLu5dq29omn3g+uWaFV9Olem0UUAFFFRXNxDaW8txdSxw28Sl5JZGCqigZJJPAAHegCWivPLn4kT6iGXwP4W1bxEOiXny2lk/qRNKQWA9VVgexNVoh8XNQcySP4P0WEkbYtk93Ko/wBpsqpP0oA9MorzpdD+JC5kn8c6LGinJ/4keRj3JmFa+m3Wq291GuseKvD86KcvHBZGF2H1M7Y/KgDrqKw0FxPrQng8QRNZtgrZJFGwIAGfm+8c/wBamubLVZtWjni1ZYLFGB+ypaqfMGOQzkk9c424wPXrQBrUUUUAFFFFABRRRQAUUUUANkkSKN5JXVI0BZmY4CgdSTXJT/EjwMJzazeK9B3OCCGvY9pHQjOcfhmsDU4P+E++ImoaVeq1x4X8OxRie03Yivr5xvCSf30jTadp43OMg4xWv4c8A6Yiy6j4j06x1DXLwZneeNZUgT+GCEMMLGgwvAG7GTkmgDlviJ8JvAHizwxqWrWGmWcd2trJLBe6U4QMyqSMhPkbJHOQTXafCSc3Pwt8IyswZm0m1yR6iJRXFePvghpmpabqT+Cry88MX91EyyQWEzRWl0SPuyxDgA4x8uPcGqfhbVL+w/ZYs9RtZJIL3T9PLq0ZyVEMpz9RtTkemaAPapo1mheKQZR1KsPY1xXweWO7+Efh23nQNGtiLSRG9EzGVP8A3yRXbROssaSRkMjAMpHcGuL+D6mHwhPaEkm11XUYPyvJsfoRQBwMELX/AOzh4v8ADtyfOufD8V9pjZ5J+zEtD/5DEVek/CrSdK0f4e6DBoNusFjLZxXAxgtIzoGLsR1Y55P9K5/wtBG/xM+Jmiyj/RLtLK72dj5sDRSfn5Q/OuA+FfxM13TtIPgqx8Ganruq+HGfTri4t5kihxG7ImWfhflUDB9DQB9FUV5/Y6p8SdVKt/wj2g+H4T1F9fPeSgf7sSqv/j9aGjeJ9Rg8TQ+HfFdhbWmoXMLzWV3aSl7e8CH51AYBkkUFSVORjJDHFAHYUUUUAFFFFABRRRQAUUUUAFFFFABTZI0kQpIiup6qwyDTqKAGRxRxgCNFQDjCjFNmtoJwRNDFICMHeoOalooA5zUPAvhLUWZr/wAMaHcOwwXksImb8yua524+Cvw+lleVPDkVtK/8VpcTQY+mxwBXotFAHm3/AAp3QYgBp+reKdPUdFttanUD82P+TVd/hn4hs8f2J8TPEsanhl1NIb8EemHUV6jRQB82+Jfhf4x09jfQaJ4W12SIlxdaQr6NqRJ6sGjIjJ9ju+lVPCHxe8R6VqkeiXPn394uFOk+IgtlfjjgR3OBHL3xvVGbgDNfTtcn8RPh94e+IGlfYvENmJHQHyLqP5ZoCe6t/Q5B7igDAHxCuNe02+fwwq2uq2EBe60fUdPlkvkkzgL5KumVOR84YjntXJat4/8AGWj6Gk3xX+HNrcaBMdt1LYyLcCBePmkhJcY57sB79M85LZat8MNWsE+I9rdeIfC9m4XTvE1mZEu9OXpslKHf5fONpJHpu+6PoqK7i1zQ1utDv7eSG6j3QXSKJoyD3xkZHtmgDzrwRoGlXOmLqnwm8WzWOkzkt9hKi7tI2PJHkuQ8TZOSoZfpXS4+IEDMAfC18oI2ki4tSR3z/rOa+fviL4J1vQtbuNT8L6brVjq4nX5tD02S3S8QtyVeGaVF65w6JxnPpXqc2ifGHRo1bR/FOia/EBnydXsvIlH+zui4Y9skigDsGm8evwtj4Xg4+8by4lwfp5S5/Oo7jw54l1gKmt+KmtLb+ODQ7b7Kz+xmdncD/c2H3ryfXfiz8UfD3ifSPD2reDtF/tPVH2WhiuGMcx3YJBDHaBkZz0HNdFrGjfG7WrC6K+IfDOiOyHy4LGJ3Y8fdMjqSv1GaANfxb4r8F/BnSRa2NjGdVvDuh060+e6vJCcBpHOWOTxvcknoMkYrB8JeAdf8d+Irbxj8WVjWOH59N8OjJhth2aVTwX7kdTxnGNo5D9nbSdP0Lx3q1r8R45k+I7Tb7WTUn8zzYSoG6GQkhnJ3AkEnAwP4hX0/QAAYGB0ooooAKKKKACvJPilqlpoOiS+JfiLsnsbeQLpvh+F90U02SUaUkfvH43YI2IAcBiAx9ZlkSGJ5JXVI0BZnY4CgdST2FeErBpvxz+Isd20b3XgbwzujQuCI9RvGxnHqigL9eOzUAZXgPxv448VsmtaRbXmtXk2dlqhFlo+nKeAryMN9zIOCQvAJ9q7Cb4deOPEoD+MviFeWsL8vYeH4Raxp/siU/Ow/3hXrUEMVvBHDbxpFDGoVERQqqB0AA6Cn0AeTxfs/+AmCHULPUdSlBy0l3qMzNIfVtrAfkBV6P4F/DaN9y+FrYn/ammYfkXr0qigDzmX4JfDmRNp8LWa/NuzHJIjA/UMDSD4MeD4tv2KLVrIr3t9Xulz78yGvR6KAPNz8JNPWMJb+KPGtuueRFrs3PtyTUsfwqs42DL4q8bbhnB/t2Y/1r0OigDi7PwRfafn7D428UDJHFzLBcj/yJET+tdPpVtd2tuUvr976TdkSPEsZA9MKAKu0UAFFFFABRRRQB518EwsmmeKbwkma88SahJJn1WXywPwVFr0Wvn3TNXufC/ijxPoKSyQ20XjKyu5HViAtve/Nt/3PMCg9vnr3/wA2PzjFvXzQu7ZnnHTOPSgB9eKeDbQ3n7NviDSzl5YYdXtSOB8wlnxj8xXtTsqIzuwVFGSScACvKPgSi6n8LdSu/mNtq2oajcR85zG8zjgfgaAO98DXv9o+CvD96XWQ3On28xdRgMWjU5x261ifCtiLTxLA2MweINQGR33ymQfpJimfA2f7R8IPCL5zjTok/wC+Rt/pUngoi38b+PLFAoj+2294AOxltow36xk/jQBj6VILX9onXrZm2m+8P2t0qn+Ly5nQkfTd+tQeBj/YHxq8c6DLhY9Vjg120GMZBHlTfjvAqHx5cDRvj38PL/B2anbXmlyEH0Cun/jxqx8TB/Y/xR+HPiFAVSa7m0W4YD74nQmJT9HXNAHfeKdbt/Dnh3UNYvFd4LOFpSifecjoq+5OAPc15T4i8a2HiC8+GV/BDPZaw/iGS2NlMuZIgiSQ3Kkj5eC6c55yPfHXfFxRqenaR4ZiZxca1qMCERnDpBE6zTSA9sKgGfVlHeuZ1Xw9pa+OfAfhjw3GzT+Hp5NWvrhpC7wxMpB8xj1kmkYH1O0ngUAexUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAI6q6MjqGRhggjIIrzeX4ZtoGoS6n8NtS/4R+5lbfPp0iGbT7o/7UWQYz23IRgdq9JooA4WDxP4vsV2674HnnKcNPo19DOje4SUxuPpg1y+mQadba+utR6Z8Q7jUBdzXTRSwMiuZBgRtnarIn8Izge+BXsVFAHkumaPrXi/4wWXinW9Bl0jRtDtJIbCK9dGnnnk6yFULBQFyOT1wfXHrVFFAHOeN/BPh/xtpws/Eenx3SpzFKPllhPqjjleg9jjnNcJFoHxG8BLjwzqkfjLRIx8um6tIIryNewjuOjf8C4HYV69RQB5dB8YrWywvi7wv4n8OsPvy3Fg01uD7SR5z+Qro9J+JXgnVolex8VaK+eQj3aRv/3yxDD8q66sPUvCHhrVJGk1Pw9o95I+CzXFlFITj1LKaAH/APCU6AyZTXtJ54B+1xkZ/wC+q4fRviFo3hjTntvF3jbSta1ZpmKjTl82VgeiiKLcR9McdyeTXRt8M/AzszHwf4fyev8AxL4h/wCy1uaRoOj6KrLo+lWGnqeotbdIs/8AfIFAHluv6f4p+Lsf2CSG+8JeCmP7/wC0IE1DUB/d2ZPlR/73J9COK9S8OaHp/hvRLTSdGtktrC1QJHGvp6k9yTySepNaVFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8x/tI2Mlj46uGtd6r4h8Pzo4THM9mwuEf6gIozXpXwq8Rx+KPGGtalvVmn0XSZUH90Os7MB9HYg+9Yvx/0433jb4dKq7jPLf2RHqJbcKR+Wa88/Znv5rTxv4aiLZt9U8MyKB6vDdygfXAVh9DQB778W578+CrzS9FieXVtZ/wCJbahQcIZQQ8jEfdVE3sT/ALI9awv2fLdrD4VRaPM6yyaVd3tg7hcBilxJzj3zXp9c74Y0CPw1p+sIJldLy/utRZtu0L5rlyD9M4z7UAcr+zXMZ/gj4XYsWKxSpz22zSDH6Vq+Gk8v4reNgRtMlrpso/2htnXP/juPwql+zzp76Z8GPC0Ev3ntjcD2EsjSD9HFXrciP403wHHnaBASP72y4lGfw3/rQB5X+1lfXthrfgC70uPzLqwnutSADYO2ARSN+GAc/Su2+PLHU/g+dc0nMsljLZ6vasnPCyI28fRGY0zx7psWtfG7wNZyxCaCHTdUkukPIEUkaRc+xLYrb+EekXUPwm0vRPEUIkeKGaxljkUjfCsjxqCD6oF4oAx/EusnwrP4o8d6/bHzYVGk6HaHl5RnPygd5ZfTnZGp7Vv/AAn8NXPh/wANfadZPm+I9WkN/qkx6tM/Oz2VBhQOgwcda8+8Kr/ws/4ryanhj4N8GyfZdNjJLJdXgGDKSTzswCD/ALh7mvdqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPLPi5Dv8ffC6TJwusSLge8JP/steZ/BuzNn4k+FcZAAis9btuO7JcyZ/D5hXqvxSAk8efDKLOHOrTSD6LbuT/SuY8AaFdaT4u8CW+oW8kE0FlrkoRwFKh7xGXI/3ZB+dAHuNRXlul3aT20ufLmRo2wcHBGDUtFAFfTbOHTtOtbG0XZb20SwxL6KoAA/IVUbRoW8TR63ub7Qlm1ntxwVZ1fP5r+tadFAGaujWY8Rvrm1jftaLZbieBGHL4A9y3P0HpXDftC+K5/C3w2vf7NZv7X1N106yVPvl5OCVxzkLuIPrivS68c16BvGP7ROkWDjdpnhGz/tCYEZDXU3EY+oAVh/umgDsfhB4SHgn4d6NojqouoovMuivOZnO5+e+CcA+gFdlRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5v8R9zfEv4YRg8G/u3Ix6Wr/wD167S70WG58SadrLO4nsree3RB91hKYySfp5Q/OuL+IIJ+Kvwu/u/a7/J/7dHr0igAooooAKKKKAK9xfWttdWttPcRR3F0zJBGzANKVUsQo74UE1538EUOoReKvFTlX/t3WJ3gcd7aE+TFz3+4x/Gk+KGvRabNrt2kEJudC8PT3cd0XYPDLOSkajnHzeUeozwMdees+Hmkf2B4D8P6UUCPaWEMUgAx84Qbj+LZNAHQ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcD8Tl8nXfAGoKDvg15YCQOizQTIf1K131ZHiPRE1tNOEkpi+xX0N6pC7txjOdvtn1rXoAKKKKACiiigDy3436bbPocNlDDi68T6vp2mzyEk5RZd/Q8YCo/Hua9Srzz4hKL34i/DjTZFJh+23WoN9Ybdgv8A49KK9DoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMLUtEkvPGGh6ysqLFp9vdQtGR8zGXysEfTyz+dbtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The collateral ligaments of the metacarpophalangeal joint are relaxed in extension but become taut in full flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff MP, Hatch RL, Calmbach WL. Fracture Management for Primary Care, 2nd ed., W.B. Saunders 2002. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_25_415=[""].join("\n");
var outline_f0_25_415=null;
